Synthetic cancer-specific promoters

[0001] This application claims the benefit of U.S. Provisional Application No. 63/834,389, filed on Jan. 22, 2025, and is a Continuation in-part of U.S. Nonprovisional Application No. 18/455,209, filed on Aug. 24, 2023, which is a Continuation of U.S. Nonprovisional Application No. 17/219,666, filed Mar. 31, 2021, now U.S. Pat. No. 12,060,613, issued Aug. 13, 2024, which is a Continuation in-part of International Application No. PCT/US2020/026758, filed Apr. 4, 2020, which claims benefit of U.S. patent application No. 62/955,925, filed Dec. 31, 2019, and U.S. Provisional Application No. 62/830,279, filed Apr. 5, 2019, each of which are incorporated by reference herein in their entirety.

[0002] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML format sequence listing, created on May 22, 2025, is named 53531-724_201_SL.xml, and is 704,717 bytes in size.

[0003] Endogenous cancer-activated promoters are controlled by a wide network of transcription factors (TFs), which can lead to non-ideal basal activity in non-target cells. It is also difficult to reliably predict the activity in a wide variety of cancer models.

[0004] There is a need to develop synthetic cancer-specific promoters with high specificity and sensitivity, for use in delivering polypeptides to cancer cells.

[0005] In some aspects, provided herein is a recombinant polynucleotide comprising: (a) a core promoter comprising a transcription start site (TSS), wherein the core promoter is derived from one or cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells and operably linked to an open reading frame (ORF) and (b) a plurality of binding sites for one or more transcription factors (TFs), wherein said one or more TFs are expressed at higher levels or more active in cancer cells compared to non-cancer cells. In some embodiments, the recombinant polynucleotide further comprises a plurality of enhancers. In some embodiments, said plurality of enhancers are derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells. In some embodiments, said plurality of enhancers are derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells, wherein one of said plurality of enhancers comprises: (i) a transcription regulatory element with at least 90% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes, and/or (ii) a sequence capable of binding a transcription associated protein as determined by chromatin immunoprecipitation (ChIP) or an in vitro transfection reporter assay.

[0006] In some aspects, provided herein is a recombinant polynucleotide comprising: (a) a core promoter comprising a transcription start site (TSS) and two or more promoter elements derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells and operably linked to an open reading frame (ORF) and (b) a plurality of binding sites for one or more transcription factors (TFs), wherein said one or more TFs are expressed at higher levels or more active in cancer cells compared to non-cancer cells. In some embodiments, the recombinant polynucleotide further comprises a plurality of enhancers. In some embodiments, said plurality of enhancers are derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells. In some embodiments, said plurality of enhancers are derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells, wherein one of said plurality of enhancers comprises: (i) a transcription regulatory element with at least 90% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes, and/or (ii) a sequence capable of binding a transcription associated protein as determined by chromatin immunoprecipitation (ChIP) or an in vitro transfection reporter assay.

[0007] In some aspects, provided herein is a recombinant polynucleotide comprising: (a) a core promoter comprising a transcription start site (TSS), wherein the core promoter is derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells and operably linked to an open reading frame (ORF) and (b) a plurality of enhancers. In some embodiments, said plurality of enhancers are derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells. In some embodiments, said plurality of enhancers are derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells, wherein one of said plurality of enhancers comprises: (i) a transcription regulatory element with at least 90% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes, and/or (ii) a sequence capable of binding a transcription associated protein as determined by chromatin immunoprecipitation (ChIP) or an in vitro transfection reporter assay.

[0008] In some aspects, provided herein, is a recombinant polynucleotide comprising: (a) a core promoter comprising a transcription start site (TSS), wherein the core promoter is derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells and operably linked to an open reading frame (ORF), (b) a plurality of binding sites for one or more transcription factors (TFs), wherein said one or more TFs are expressed at higher levels or more active in cancer cells compared to non-cancer cells, and (c) a plurality of enhancers. In some embodiments, said plurality of enhancers are derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells. In some embodiments, said plurality of enhancers are derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells, wherein one of said plurality of enhancers comprises: (i) a transcription regulatory element with at least 90% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes, and/or (ii) a sequence capable of binding a transcription associated protein as determined by chromatin immunoprecipitation (ChIP) or an in vitro transfection reporter assay.

[0009] In some aspects, provided herein is a recombinant polynucleotide comprising any of the sequences from Table 1A, Table 1B, or Table 1C. In some aspects, provided herein is a recombinant polynucleotide comprising a human alpha-fetoprotein (AFP) promoter sequence comprising a plurality of HNF-1A TF binding sites, wherein each HNF-1A binding site comprises the sequence 5′-GTTAATTATTAAC-3.′

[0010] In some aspects, provided herein is a vector comprising any of the recombinant polynucleotide described herein. In some aspects, provided herein is a pharmaceutical composition comprising any of the recombinant polynucleotide described herein or any the vector described herein and a pharmaceutically acceptable excipient, carrier, or diluents. In some aspects, provided herein is a lipid nanoparticle (LNP) comprising any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the pharmaceutical composition described herein. In some aspects, provided herein is a cell comprising any the recombinant polynucleotide described herein, any of the vector described herein, any of the pharmaceutical composition described herein, or any of the LNP described herein.

[0011] In some aspects, provided herein is a method of selectively expressing a reporter protein in a cancer or tumor cell, comprising contacting said tumor cell with any of the recombinant polynucleotide described herein, any of the vector described herein, any of the pharmaceutical composition described herein, or any of the LNP described herein, wherein the recombinant polynucleotide further comprises an open reading frame (ORF) encoding said reporter protein, wherein said ORF is operatively linked to said synthetic promoter.

[0012] In some aspects, provided herein is a method comprising: (a) administering to a subject any of the pharmaceutical composition described herein; or a composition any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the LNP described herein; wherein the recombinant polynucleotide further comprises an open reading frame (ORF) encoding a reporter protein, wherein said ORF is operatively linked to a synthetic promoter in said recombinant polynucleotide, and (b) detecting said reporter protein, wherein said pharmaceutical composition or said composition induces expression of said reporter protein preferentially in diseased cells in said subject compared to in non-disease cells, and wherein a relative ratio of said reporter protein expressed in said diseased cells over said non-diseased cells is greater than 1.0.

[0013] In some aspects, provided herein is a method for treating a subject having or suspected of having a disease, comprising administering to said subject any of the pharmaceutical composition described herein; or a composition any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the LNP described herein; wherein the recombinant polynucleotide further comprises an open reading frame (ORF) encoding a therapeutic protein, wherein said ORF is operatively linked to a synthetic promoter in said recombinant polynucleotide, wherein said pharmaceutical composition or said composition induces expression of said therapeutic protein preferentially in diseased cells in said subject compared to in non-disease cells, and wherein a relative ratio of said therapeutic protein expressed in said diseased cells over said non-diseased cells is greater than 1.0.

[0014] In some aspects, provided herein is a method comprising: (a) administering to a subject any of the pharmaceutical composition described herein; or a composition any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the LNP described herein; wherein the recombinant polynucleotide further comprises an open reading frame (ORF) encoding a reporter protein, wherein said ORF is operatively linked to a synthetic promoter in said recombinant polynucleotide, and (b) localizing a tumor or an absence thereof in a body of said subject via expression of said reporter protein using an imaging technique performed on said body of said subject.

[0015] In some aspects, provided herein is a method comprising: (a) introducing to a subject suspected of having a cancer via intravenous administration any of the pharmaceutical composition described herein; or a composition any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the LNP described herein; wherein said recombinant polynucleotide further comprises an open reading frame (ORF) encoding a reporter protein, wherein said ORF is operatively linked to a synthetic promoter in said recombinant polynucleotide, and (b) detecting said reporter protein from said subject.

[0016] In some aspects, provided herein is a method comprising: (a) introducing to a subject suspected of having a cancer via intravenous administration a plurality of recombinant polynucleotides, wherein: said plurality of recombinant polynucleotides comprises a plurality of different promoters of genes overexpressed in a tumor cell versus a normal tissue or functional fragments thereof operably linked to genes encoding reporter proteins, wherein said plurality of different promoters of genes overexpressed in said tumor cell versus said normal tissue drive expression of said corresponding reporter proteins in a cell affected by said cancer, wherein said DNA molecules are selected from the group consisting of nanoplasmids and linear double-stranded DNA molecules; and (b) detecting said reporter proteins from said subject.

[0017] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0099] The compositions and methods described herein contemplates a general strategy of identifying important elements of cancer-specific (or cancer-activated) promoters and designing and/or engineering cancer-specific promoters using elements of cancer-specific promoters identified. Cancer-specific promoters or cancer-activated promoters described herein can comprise promoters of genes that are preferentially expressed in cancer cells compared to non-cancer cells or expressed in higher level in cancer cells compared to non-cancer cells. Methods described herein can comprise identifying endogenous cancer-activated promoters by evaluating candidate promoter and/or enhancer sequences using bioinformatic analysis and designing/engineering a minimal cancer-activated promoter sequence (core promoter). For example, a candidate sequence (e.g., low-throughput or high-throughput screening) can be examined using a genome browser. The assessment range (e.g., sequence boundary) can be set based on the predicted transcriptional start site (TSS) of an endogenous promoter. For example, the assessment range can be from about −1000 bp to about +1000 bp relative to the predicted TSS. The assessment range can be adjusted based on chromatin immunoprecipitation (ChIP) data including, but not limited to, ChIP peaks of general transcription factors (TFs), indicators of active promoter regions, and TFs that may indicate cancer specificity by presence in cancer cells and absence in non-cancer cells; and abundance of predicted TF binding sequence (TFBS); and regions of high species conservation. In some embodiments, indicators of active promoter regions can include, but not limited to, RNA Polymerase II, DNAse I, H3K4me1, and H3K4me3. In some embodiments, TFBS abundance can be predicted using methods including, but not limited, to JASPAR or HOMER motif analysis. Methods described herein can also comprise testing highlight regulated TFs using Massively Parallel Reporter Assay (MPRA) to identify optimal sequences, optimal spacing between each sequence, and/or optimal combinations of different enhancer sequences to design synthetic tiled enhancers. Methods described herein can comprise a rationally designed (e.g., low-throughput) screening or a high-throughput screening to identify enhancer elements to increase transcription signal. In some embodiments, a synthetic tiled enhancer can comprise one or more copies of TFBS, or other highly conserved regulatory element repeats with spacing between repeats. One or more synthetic elements described herein can be placed upstream of core promoters. Synthetic elements described herein can also function as a promoter without a promoter or a core promoter.

[0100] A cancer-specific promoter described herein can comprise a recombinant polynucleotide comprising a core promoter sequence comprising a transcription start site (TSS). In some embodiments, a core promoter can be derived from a cancer-responsive gene and can be operably linked to an open reading frame (ORF). In some embodiments, a cancer-responsive gene can comprise a human cancer-responsive gene. In some embodiments, a core promoter can comprise a plurality of binding sites for a plurality of transcription factors (TFs) that are expressed in higher levels in cancer cells compared to non-cancer cells. In some embodiments, a core promoter can comprise a plurality of binding sites for a plurality of transcription factors (TFs) that are more active in cancer cells compared to non-cancer cells. In some embodiments, a core promoter can comprise a plurality of enhancers derived from two or more human cancer-response genes. In one embodiment, each of the plurality of enhancers can comprise a transcription regulatory element with at least 80% sequence homology to the enhancer consensus sequence of the two or more human cancer-response genes. In another embodiment, each of the plurality of enhancers can comprise a sequence capable of binding a transcription associated protein as assessed by ChIP.

[0101] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below.

[0102] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. The terms “and/or,” “a combination thereof,” and “any combination thereof” and their grammatical equivalents as used herein, can be used interchangeably. These terms can convey that any combination is specifically contemplated. Solely for illustrative purposes, the following phrases “A, B, and/or C,” “A, B, C, or a combination thereof,” or “A, B, C, or any combination thereof” can mean “A individually; B individually; C individually; A and B; B and C; A and C; and A, B, and C.” The term “or” can be used conjunctively or disjunctively, unless the context specifically refers to a disjunctive use. The term “about” or “approximately” can mean within an acceptable error range for the particular value, which may depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, within 5-fold, or within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.

[0103] Throughout this disclosure, numerical features are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of any embodiments. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range to the tenth of the unit of the lower limit unless the context clearly dictates otherwise. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual values within that range, for example, 1.1, 2, 2.3, 5, and 5.9. This applies regardless of the breadth of the range. The upper and lower limits of these intervening ranges may independently be included in the smaller ranges, and are also encompassed within the present disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the present disclosure, unless the context clearly dictates otherwise.

[0104] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the present disclosure, and vice versa. Furthermore, compositions of the present disclosure can be used to achieve methods of the present disclosure.

[0105] Reference in the specification to “embodiments,” “certain embodiments,” “preferred embodiments,” “specific embodiments,” “some embodiments,” “an embodiment,” “one embodiment” or “other embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily all embodiments, of the present disclosures. To facilitate an understanding of the present disclosure, a number of terms and phrases are defined below.

[0106] Certain specific details of this description are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the present disclosure may be practiced without these details. In other instances, well-known techniques or methods have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed disclosure.

[0107] The terms “nucleic acid sequence,” “polynucleic acid sequence,” and/or “nucleotide sequence” are used herein interchangeably and have the identical meaning herein and refer to DNA or RNA. In some embodiments, a nucleic acid sequence is a polymer comprising or consisting of nucleotide monomers, which are covalently linked to each other by phosphodiester-bonds of a sugar/phosphate-backbone. The terms “nucleic acid sequence,” “polynucleic acid sequence,” and “nucleotide sequence” may encompass unmodified nucleic acid sequences, i.e., comprise unmodified nucleotides, or natural nucleotides. In some embodiments, “natural nucleotide,” “unmodified nucleotide,” and/or “canonical nucleotide” are used herein interchangeably and have the identical meaning herein and refer to the naturally occurring nucleotide bases adenine (A), guanine (G), cytosine (C), uracil (U), and/or thymine (T). The terms “nucleic acid sequence,” “polynucleic acid sequence,” and “nucleotide sequence” may also encompass modified nucleic acid sequences, such as base-modified, sugar-modified or backbone-modified etc., DNA or RNA. The term “nucleic acid sequence” generally is understood to include, as applicable to the embodiment being described, single-stranded (such as sense or antisense) and double-stranded polynucleotides. The term “nucleic acid” generally is understood to include, as applicable to the embodiment being described, polymers containing a non-natural linkage or a non-natural nucleotide.

[0108] In some embodiments, a nucleic sequence acid as described herein comprises one or more non-natural linkages or one or more non-natural nucleotides. Non-natural nucleotides can include, but are not limited to, 2′-fluoro, 2′-O-methyl, 2′-O-methyl, 2′-O-methoxy-ethyl, 2′-O-methoxy-ethoxy, 5′-methyl, SNA, hGNA, hhGNA, mGNA, TNA, h′GNA, locked nucleic acids (LNAs), GNA-isoC, GNA-isoG, 5′-mUNA, 4′-mUNA, 3′-mUNA, 2′-mUNA, or an abasic nucleotide (e.g. DNA or RNA). Non-natural linkages can include, but are not limited to, phosphorothioate and methylphosphonate. In some embodiments, an oligonucleotide as described herein comprises a modified uracil. Example nucleobases and nucleosides having a modified uracil include pseudouridine (Ψ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s2U), 4-thio-uridine (s4U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho5U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5-bromo-uridine), 3-methyl-uridine (m3U), 5-methoxy-uridine (mo5U), uridine 5-oxyacetic acid (cmo5U), uridine 5-oxyacetic acid methyl ester (mcmo5U), 5-carboxymethyl-uridine (cm5U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm5U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm5U), 5-methoxycarbonylmethyl-uridine (mcm5U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm5s2U), 5-aminomethyl-2-thio-uridine (nm5s2U), 5-methylaminomethyl-uridine (mnm5U), 5-methylaminomethyl-2-thio-uridine (mnm5s2U), 5-methylaminomethyl-2-seleno-uridine (mnm5se2U), 5-carbamoylmethyl-uridine (ncm5U), 5-carboxymethylaminomethyl-uridine (cmnm5U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm5s2U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (τm5U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine (Σm5s2U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uridine (m5U, i.e., having the nucleobase deoxythymine), 1-methylpseudouridine (m1ψ), 5-methyl-2-thio-uridine (m5s2U), 1-methyl-4-thio-pseudouridine (m1s4ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m3ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m5D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine (aka 1-methylpseudouridine (m1ψ)), 3-(3-amino-3-carboxypropyl)uridine (acp3U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp3 ψ), 5-(isopentenylaminomethyl)uridine (inm5U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm5s2U), α-thio-uridine, 2′-O-methyl-uridine (Um), 5,2′-O-dimethyl-uridine (m5Um), 2′-O-methyl-pseudouridine (ψ m), 2-thio-2′-O-methyl-uridine (s2Um), 5-methoxycarbonylmethyl-2′-O-methyl-uridine (mcm5Um), 5-carbamoylmethyl-2′-O-methyl-uridine (ncm5Um), 5-carboxymethylaminomethyl-2′-O-methyl-uridine (cmnm5Um), 3,2′-O-dimethyl-uridine (m3Um), 5-(isopentenylaminomethyl)-2′-O-methyl-uridine (inm5Um), 1-thio-uridine, deoxythymidine, 2′-F-ara-uridine, 2′-F-uridine, 2′-OH-ara-uridine, 5-(2-carbomethoxyvinyl) uridine, and 5-[3-(1-E-propenylamino)uridine. In some embodiments, an oligonucleotide as described herein comprises a modified cytosine. Example nucleobases and nucleosides having a modified cytosine include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m3C), N4-acetyl-cytidine (ac4C), 5-formyl-cytidine (f5C), N4-methyl-cytidine (m4C), 5-methyl-cytidine (m5C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s2C), 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, lysidine (k2C), α-thio-cytidine, 2′-O-methyl-cytidine (Cm), 5,2′-O-dimethyl-cytidine (m5Cm), N4-acetyl-2′-O-methyl-cytidine (ac4Cm), N4,2′-O-dimethyl-cytidine (m4Cm), 5-formyl-2′-O-methyl-cytidine (f5Cm), N4,N4,2′-O-trimethyl-cytidine (m4 2Cm), 1-thio-cytidine, 2′-F-aracytidine, 2′-F-cytidine, and 2′-OH-aracytidine

[0109] The term “subject” can generally include human or non-human animals. Thus, the methods and compositions described herein are applicable to both human and veterinary disease and animal models. Preferred subjects are “patients,” i.e., living humans that are receiving medical care for a disease or condition (e.g., cancer). This includes persons with no defined illness who are being investigated for signs of pathology. Also included are persons suspected of possessing or being at-risk for a defined illness. In some embodiments, the subject has at least one risk factor for cancer.

[0110] A “vector” as used herein generally refers to a nucleic acid sequence capable of transferring other operably-linked heterologous or recombinant nucleic acid sequences to target cells. In some examples, a vector is a minicircle, plasmid, nanoplasmid, yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), cosmid, phagemid, bacteriophage genome, or baculovirus genome. Suitable vectors also include vectors derived from bacteriophages or plant, invertebrate, or animal (including human) viruses such as CELiD vectors, doggybone DNA (dbDNA) vectors, closed-end linear duplex DNA vectors (e.g., wherein each end is covalently closed by chemical modification), adeno-associated viral vectors (e.g., AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or pseudotyped combinations thereof such as AAV2/5, AAV2/2, AAV-DJ, or AAV-DJ8), retroviral vectors (e.g. MLV or self-inactivating or SIN versions thereof, or pseudotyped versions thereof), herpesviral (e.g. HSV- or EBV-based), lentiviral vectors (e.g., HIV-, FIV-, or EIAV-based, or pseudotyped versions thereof), or adenoviral vectors (e.g., AdS-based, including replication-deficient, replication-competent, or helper-dependent versions thereof). In some embodiments, a vector is a replication competent viral-derived vector. In some embodiments, a vector is a replication-incompetent viral-derived vector. In some cases, the vector may comprise an episomal maintenance element to facilitate replication in one or more target cell type, such as a Scaffold/Matrix Attachment Region (S/MAR). S/MAR elements are particularly useful to facilitate replication in the context of “naked” nucleic acid vectors such as minicircles.

[0111] Exemplary suitable S/MAR elements include, but are not limited to, EμMAR from the immunoglobulin heavy chain locus, the apoB MAR from the human apolipoprotein B locus, the Ch-LysMAR from the chicken lysozyme locus, and the huIFNβ MAR from the human IFNβ-locus. A vector may comprise a coding sequence capable of being expressed in a target cell. Accordingly, as used herein, the terms “vector construct,” “expression vector,” and “gene transfer vector,” may refer to any nucleic acid construct capable of directing the expression of a gene of interest and which is useful in transferring the gene of interest into target cells. Vectors as described herein may additionally comprise one or more cis-acting elements to stabilize or improve expression of mRNAs therefrom. Such cis-acting elements include, but are not limited to, any of the elements described e.g., in Johansen et al. The Journal of Gene Medicine. (5)12:1080-1089 (doi: 10.1002/jgm.444) or Vlasova-St. Louis and Sagarsky. Mammalian Cis-Acting RNA Sequence Elements (doi: 10.5772/intechopen.72124).

[0112] The term “promoter” generally can refer to a DNA sequence that directs the transcription of a polynucleotide. Typically, a promoter can be located in the 5′ region of a polynucleotide to be transcribed, proximal to the transcriptional start site of such polynucleotide. More typically, promoters can be defined as the region upstream of the first exon; more typically, as a region upstream of the first of multiple transcription start sites. Frequently promoters are capable of directing transcription of genes located on each of the complementary DNA strands that are 3′ to the promoter. Stated differently, many promoters can exhibit bidirectionality and can direct transcription of a downstream gene when present in either orientation (i.e., 5′ to 3′ or 3′ to 5′ relative to the coding region of the gene). Additionally, the promoter may also include at least one control element such as an upstream element. Such elements include upstream activator regions (UARs) and optionally, other DNA sequences that affect transcription of a polynucleotide such as a synthetic upstream element. Some promoters may be assembled from fragments of endogenous promoters (e.g., derived from the human genome).

[0113] The term “coding sequence,” and “encodes” when used in reference to a polypeptide herein generally refer to a nucleic acid molecule that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide, for example, when the nucleic acid is present in a living cell (in vivo) and placed under the control of appropriate regulatory sequences (or “control elements”). The boundaries of the coding sequence are typically determined by a start codon at the 5′ (amino) terminus and a translation stop codon at the 3′ (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from viral, prokaryotic or eukaryotic mRNA, genomic DNA sequences from viral, eukaryotic, or prokaryotic DNA, and synthetic DNA sequences. A transcription termination sequence may be located 3′ to the coding sequence, and a promoter may be located 5′ to the coding sequence; along with additional control sequences if desired, such as enhancers, introns, poly adenylation site, etc. A DNA sequence encoding a polypeptide may be optimized for expression in a selected cell by using the codons preferred by the selected cell to represent the DNA copy of the desired polypeptide coding sequence.

[0114] The term “operably linked” as used herein generally can refer to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, a given promoter that is operably linked to a coding sequence (e.g., a reporter expression cassette) is capable of effecting the expression of the coding sequence when the proper enzymes are present. The promoter or other control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. For example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.

[0115] The term “sequence identity” or “percent identity” in the context of two or more nucleic acids or polypeptide sequences, generally refers to two (e.g., in a pairwise alignment) or more (e.g., in a multiple sequence alignment) sequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a local or global comparison window, as measured using a sequence comparison algorithm. Suitable sequence comparison algorithms for polypeptide sequences include, e.g., BLASTP using parameters of a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix setting gap costs at existence of 11, extension of 1, and using a conditional compositional score matrix adjustment for polypeptide sequences longer than 30 residues; BLASTP using parameters of a wordlength (W) of 2, an expectation (E) of 1000000, and the PAM30 scoring matrix setting gap costs at 9 to open gaps and 1 to extend gaps for sequences of less than 30 residues (these are the default parameters for BLASTP in the BLAST suite available at blast.ncbi.nlm.nih.gov); CLUSTALW with parameters of; the Smith-Waterman homology search algorithm with parameters of a match of 2, a mismatch of −1, and a gap of −1; MUSCLE with default parameters; MAFFT with parameters retree of 2 and maxiterations of 1000; Novafold with default parameters; HMMER hmmalign with default parameters.

[0116] The term “lipid particle” generally includes a lipid formulation that can be used to deliver an active agent or therapeutic agent, such as a nucleic acid to a target site of interest (e.g., cell, tissue, organ, and the like). In preferred embodiments, the lipid particle of the invention is a nucleic acid-lipid particle (e.g. a particle that has only nucleic acids and lipids), which is typically formed from a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that prevents aggregation of the particle. In other preferred embodiments, the active agent or therapeutic agent, such as a nucleic acid, may be encapsulated in the lipid portion of the particle, thereby protecting it from enzymatic degradation. In some cases, a “lipid particle” is a lipid nanoparticle (LNP). The lipid particles can be prepared by any suitable method, including but not limited to microfluidic assembly or extrusion. In some embodiments, for a lipid particle (e.g. LNP composition), a particle has a particular composition. In some embodiments, for a lipid particle (e.g. LNP composition), each particle has a particular composition. In some embodiments, for a lipid particle (e.g. LNP composition), at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.9% of the particles have a particular composition.

[0117] When nucleic acid sequences are referred to herein, the current disclosure is generally understood to include nucleic acid sequences with at least about 80-100% identity to the sequences described herein, or to reverse complements of the sequences described herein.

In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of the sequences listed in Table 1A, or to reverse complements of any of the sequences listed in Table 1A. In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of SEQ ID NOs: 1-343, or to reverse complements of any of SEQ ID NOs: 1-343. In some embodiments, the disclosure provides for a promoter comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of SEQ ID NOs: 1-343, or to reverse complements of any of SEQ ID NOs: 1-343. In some embodiments, the nucleic acid can be a double-stranded nucleic acid.

[0118] In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of the sequences listed in Table 1B, or to reverse complements of any of the sequences listed in Table 1B. In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of SEQ ID NOs: 377-397, or to reverse complements of any of SEQ ID NOs: 377-397. In some embodiments, the disclosure provides for a promoter comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of SEQ ID NOs: 377-397, or to reverse complements of any of SEQ ID NOs: 377-397. In some embodiments, the disclosure provides for an enhancer comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of SEQ ID NOs: 377-397, or to reverse complements of any of SEQ ID NOs: 377-397. In some embodiments, the nucleic acid can be a double-stranded nucleic acid.

[0119] In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of the sequences listed in Table 1C, or to reverse complements of any of the sequences listed in Table 1C. In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of SEQ ID NOs: 398-488, or to reverse complements to any of SEQ ID NOs: 398-488. In some embodiments, the disclosure provides for a promoter having a sequence having at least 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of the sequences listed in Table 1C, or to reverse complements of any of the sequences listed in Table 1C. In some embodiments, the disclosure provides for a promoter comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any of SEQ ID NOs: 398-486 and SEQ ID NOs: 556-557, or to reverse complements to any of SEQ ID NOs: 398-486 and SEQ ID NOs: 556-557. In some embodiments, the nucleic acid can be a double-stranded nucleic acid.

[0120] In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any one of the of the sequences listed in Table 1J, or to reverse complements of any one of the sequences listed in Table 1J. In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any SEQ ID NOs: 558-587, or to any reverse complements of any SEQ ID NOs: 558-587. In some embodiments, the disclosure provides for a core promoter comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any one of the of the sequences listed in Table 1J, or to reverse complements of any one of the sequences listed in Table 1J. In some embodiments, the disclosure provides for the core promoter comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to any SEQ ID NOs: 558-587, or to any reverse complements of any SEQ ID NOs: 558-587. In some embodiments, the nucleic acid can be a double-stranded nucleic acid.

[0121] In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to SEQ ID NO: 556, listed in Table 1C, or to a reverse complement thereof. In some embodiments, the nucleic acid can be a double-stranded nucleic acid.

[0122] In some embodiments, the disclosure provides for a nucleic acid comprising a sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to SEQ ID NO: 557, listed in Table 1C, or to a reverse complement thereof. In some embodiments, the nucleic acid can be a double-stranded nucleic acid.

[0123] In some embodiments, any of the nucleic acids disclosed herein can have at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, at least about 200, at least about 220, at least about 240, at least about 260, at least about 280, at least about 300, at least about 320, at least about 340, at least about 360, at least about 380, at least about 400, at least about 420, at least about 440, at least about 460, at least about 480, at least about 500, at least about 520, at least about 540, at least about 560, at least about 580, at least about 600, at least about 620, at least about 640, at least about 680, at least about 700, at least about 720, at least about 740, at least about 760, at least about 780, at least about 800, at least about 820, at least about 840, at least about 860, at least about 880, at least about 900, at least about 920, at least about 940, at least about 960, at least about 980, at least about 1000, at least about 1020, at least about 1040, at least about 1060, at least about 1080, at least about 1100, at least about 1120, at least about 1140, at least about 1160, at least about 1180, at least about 1200, at least about 1220, at least about 1240, at least about 1260, at least about 1280, at least about 1300, at least about 1320, at least about 1340, at least about 1360, at least about 1380, at least about 1400, at least about 1420, at least about 1440, at least about 1460, at least about 1480, at least about 1500, at least about 1520, at least about 1540, at least about 1560, at least about 1580, at least about 1600, at least about 1620, at least about 1640, at least about 1660, at least about 1680, at least about 1700, at least about 1720, at least about 1740, at least about 1760, at least about 1780, at least about 1800, at least about 1820, at least about 1840, at least about 1860, at least about 1880, at least about 2000, at least about 2020, at least about 2040, at least about 2060, at least about 2080, at least about 2100, at least about 2120, at least about 2140, at least about 2160, at least about 2180, at least about 2200, at least about 2220, at least about 2240, at least about 2260, at least about 2280, at least about 2300, at least about 2320, at least about 2340, at least about 2360, at least about 2380, at least about 2400, at least about 2420, at least about 2440, at least about 2460, at least about 2480, at least about 2500, at least about 2520, at least about 2540, at least about 2560, at least about 2580, at least about 2600, at least about 2620, at least about 2640, at least about 2660, at least about 2680, at least about 2700, at least about 2720, at least about 2740, at least about 2760, at least about 2780, at least about 2800, at least about 2820, at least about 2840, at least about 2860, at least about 2880, at least about 2900, at least about 2920, at least about 2940, at least about 2960, at least about 2980, at least about 3000, at least about 3020, at least about 3040, at least about 3060, at least about 3080, at least about 3100, at least about 3120, at least about 3140, at least about 3160, at least about 3180, at least about 3200, at least about 3220, or at least about 3240 consecutive nucleotides of any of the nucleic acid sequences disclosed herein, or of any reverse complements of any of the nucleic acid sequences disclosed herein.

[0124] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods, and materials are described below.

Synthetic Promoter Strategy and Design

[0125] Provided herein are synthetic promoters that can be activated in target cells with high sensitivity and specificity. These promoters can be modular and engineerable. In some embodiments, synthetic promoters described herein can be designed to drive specificity and sensitivity. For example, synthetic promoters can be designed to specifically respond to dysregulated pathways in cancer. In one embodiment, synthetic promoters described herein can comprise an endogenous promoter of a gene that is expressed specifically or preferentially in cancer cells compared to non-cancer cells. In another embodiment, synthetic promoters described herein can comprise a core promoter. A core promoter described herein can comprise a minimal promoter sequence of an endogenous promoter of a gene expressed specifically or preferentially in cancer cells compared to non-cancer cells. A minimal promoter can refer to a short DNA sequence that can allow for the formation of a transcription initiation complex or a DNA sequence comprising a minimal number of nucleotides sufficient to allow for the formation of a transcription initiation complex. In some embodiments, synthetic promoters described herein can comprise a structure comprising three major components (1) a cancer-specific promoter or core promoter, (2) cancer-activated response elements (e.g., binding sites of one or more transcription factors specific for cancer cells), and optionally (3) an enhancer to boost signal strength (e.g., see FIG. 1 or FIG. 72). In some embodiments, synthetic promoters described herein can comprise only (1) a cancer-specific promoter or core promoter. In some embodiments, synthetic promoters described herein can comprise only (1) a cancer-specific promoter or core promoter and (3) an enhancer to boost signal strength. In some embodiments, an enhancer or a transcription binding site can be referred to as a Synthetic Response Element (SRE). In some embodiments, a synthetic promoter comprising a promoter or core promoter and one or more SREs can be referred to as a Synthetic Response Sensor (SRS). In some embodiments, cancer-activated response elements can be designed and constructed to respond to specific dysregulated transcription factors. In some embodiments, cancer-activated response elements described herein can demonstrate predictable activity based on transcriptomic and proteomic data when applied in new cancer models.

[0126] In some embodiments, bioinformatics can be used to identify endogenous cancer-activated core promoter sequences. In some embodiments, multi-omic approaches can be used to identify transcription factors (TFs) and their binding sites that are master-regulated. In some embodiments, such TF binding sites can be tiled and tested using high-throughput sequencing (HTS) to optimize promoter sequences, spacing, and combinations thereof. In some embodiments, one or more rationally designed enhancer elements that increase transcription and boost reporter signal can be used. An exemplary workflow and synthetic promoter are described in FIGS. 10-13.

[0127] In some embodiments, candidate TF binding site sequences can be identified using Multi-Omics Factor Analysis (MOFA). In some embodiments, candidate TF binding site sequences can be highly dysregulated. In some embodiments, Multi-Omics Factor Analysis (MOFA) can be used to identify TFs specific for a cancer. In some embodiments, a cancer can comprise lung cancer, breast cancer, liver cancer, and/or colorectal cancer. In some embodiments, a lung cancer can comprise non-small cell lung cancer (NSCLC).

[0128] In some embodiments, a synthetic promoter can comprise a core promoter sequence. In some embodiments, a core promoter can be identified by analyzing one or more endogenous promoters that can drive cancer specific expression in vitro and/or in vivo, that is the one or more endogenous promoters can preferentially activate gene expression of a gene that is functionally or operatively linked to said one or more promotors in cancer cells (e.g., either in a subject or cancer cell lines) compared to corresponding healthy or normal cells. In some embodiments, one or more endogenous promoters can be analyzed and annotated using UCSC genome browser to build and test core promoters. In some embodiments, core promoters identified can be combined with other elements described herein. In some embodiments, a core promoter sequence can comprise a minimal cancer-activated core promoters. For example, a core promoter sequence can comprise a promoter sequence comprising a minimal number of nucleotides sufficient to drive expression (e.g., recruit transcription initiation complex) of a gene that is functionally or operatively linked to the core promoter in cancer cells. Examples of a minimal cancer-activated cores can include, but are not limited to, coreBIRC5, coreCST1, coreAGR2, coreFAM111B, CEACAM5, CEP55, UBE2C, FAM111B, KIF20A, FOXA1, MYC, or TP53 (e.g., FIGS. 2-5 and FIG. 11). In some embodiments, a core promoter sequence can provide specificity. In some embodiments, a synthetic promoter can comprise a response element. In some embodiments, a response element can comprise a binding site for a master regulated transcription factor (TF). Examples of a master regulated TF can include, but are not limited to, tiled TFBS for FOS, CREB, MYC, HOXC10, TCF7, or combinations thereof. In some embodiments, a response element can provide specificity and/or sensitivity. In some embodiments, a synthetic promoter can comprise a signal strength enhancer. In some embodiments, a signal strength enhancer can comprise a synthetic enhancer (also referred herein as a Synthetic Response Element or SRE). Examples of a synthetic enhancer can include, but are not limited to enhancers of SP1, ETS, CEBP, NF-KB, or combinations thereof. In some embodiments, a synthetic enhancer can provide signal strength. Table A shows a table comparing different synthetic promoters. In some embodiments, synthetic promoters (FOS-AGR2, FOS-CST1, and HIGH-FAM111B) can drive high expression of the reporter gene and have improved signal-to-noise ratio (SNR) compared to BIRC5 variant promoters.

[0129]

TABLE A
Exemplary Synthetic Promoters
				H1299	H1299
			H1299	SubQ	SubQ
	In	In	SubQ	Tumor	Tumor
	Vitro	Vitro	Tumor	SNR	SNR
Promoter	Signal	Noise	Signal	Lung	Liver
CAG	+++	−−−	38/11	10/3	<<1
FOS-TATA	+++	−−−	9	3.6	<<1
BIRC5	+	−−		n/a at 1.4 mpk
FOSL-	++	−−		n/a at 1.4 mpk
coreBIRC5
HIGH-	+++	−−	3.6	3.2	1.8
coreBIRC5
FOS-	+++	−−	9.3/3	10/3.3	3.2
coreAGR2			3.8	5	2.5
FOS-	+++	−−	3.7	4.1	1
coreCST1
HIGH-	+++	−−	7.5	3.4	1.33
coreFAM111B

[0130] In some embodiments, synthetic promoters described herein that can drive expression in a broad range of cancer cells or cancer tissues including, but not limited to, lung cancer cells, can be identified using methods described herein. In one example, promoters identified using methods described herein can include promoters or binding sites/motifs of TCF7, one of TCFs that can be activated by Wnt/B-cat pathway, known for functioning in development pathways. In some embodiments, cancer cell lines based on Wnt/B-cat pathway can be used for further analysis. For example, a principal component analysis (PCA) of PDX database and CCLE focused on the B-cat/Wnt pathway can be used to choose cell lines for further analysis (e.g., 163 genes involved in Wnt/B-cat pathway, 50 CCLE lung cell lines, and 91 PDX lung cell lines). In some embodiments, a PCA including all lung-related PDXs from CRL as well as the CCLE transcriptome database can be used. Examples of cell lines include, but are not limited to, PC2, H520, LK2, or PDX430. In some embodiments, these cell lines can have similar level of expressions of Wnt7B, CCND1, FZD3, AXIN2 or NKD1. In another example, promoters identified using methods described herein can include promoters of TP53, a tumor suppressor that can activate or repress expression depending on location of the binding site. In some embodiments, TP53 binding sequence or motifs can be included in a promoter or a core promoter.

[0131] In some embodiments, synthetic promoters that can integrate multiple signaling can be engineered using methods described herein. For example, binding sequences or motifs of TCF, TP53, FOS, MNX1, HOXC10, of CREB can be combined with core promoters described herein to engineer synthetic promoters. In some embodiments, synthetic promoters can comprise promoters or binding sequences/motifs/sites TFs of genes in multiple regulatory pathways. In some embodiments, synthetic promoters comprising two or more endogenous or core promoters can result in gene expression with greater signal and coverage. Details of synthetic promoter design and construction are described in Example 1 and Example 2.

Synthetic Response Sensor (SRSs or synthetic promoter) and Synthetic Response Elements (SREs)

[0132] In some aspects, provided herein is a recombinant polynucleotide comprising a Synthetic Response Sensor (SRS) that can drive expression of a gene or an ORF operatively linked to the SRS in tissue- or cell-specific manner. In some embodiments, an SRS described herein can drive cancer specific or cancer-activated expression of a gene or an ORF operatively linked to the SRS. For example, an SRS described herein can drive expression of a gene or an ORF operatively linked to the SRS preferentially or specifically in cancer cells or cancer tissues compared to non-cancer cells or non-cancer tissues. In some embodiments, the expression level of a gene or an ORF operatively linked to an SRS is higher in cancer cells or cancer tissues compared to non-cancer cells or non-cancer tissues. In some embodiments, an SRS can comprise a promoter or a core promoter and one or more Synthetic Response Elements (SREs). In some embodiments, the promoter or the core promoter can provide tissue- or cell-specificity for gene expression. In some embodiments, an SRE can provide tissue- or cell-specificity for gene expression and/or enhance the tissue- or cell-specificity of gene expression. In some embodiments, an SRE can comprise a plurality of binding sites for one or more transcription factors or a plurality of enhancers. For example, an SRE can comprise a plurality of binding sites for one or more transcription factors that are activated in cancer cells or cancer pathways or are dysregulated (e.g., expressed in aberrantly higher levels, etc.) in cancer cells or cancer pathways. In some embodiments, an SRS can drive expression of an ORF operatively linked to the SRS in cancer cells or cancer tissues but not in normal cells or tissues (including normal tissues or cells adjacent to cancer cells or cancer tissues) and/or benign lesions.

[0133] In some embodiments, an SRS can comprise a promoter and one or more SREs comprising a plurality of binding sites for one or more transcription factors and a plurality of enhancers. In some embodiments, an SRS can comprise a promoter and one or more SREs comprising a plurality of binding sites for one or more transcription factors. In some embodiments, an SRS can comprise a core promoter and one or more SREs comprising a plurality of binding sites for one or more transcription factors. In some embodiments, an SRS can comprise a promoter and one or more SREs comprising a plurality of enhancers. In some embodiments, an SRS can comprise a core promoter and one or more SREs comprising a plurality of enhancers. In some embodiments, an SRS can comprise a core promoter and one or more SREs comprising a plurality of binding sites for one or more transcription factors and a plurality of enhancers. An exemplary SRS is shown in FIG. 72. In one embodiment, an SRE can comprise a plurality of binding sites for one or more transcription factors, wherein each of the plurality of transcription binding sites can comprise the same binding site sequences or motifs (FIG. 72, left). In another embodiment, an SRE can comprise a plurality of binding sites for one or more transcription factors, wherein each of the plurality of transcription binding sites can comprise different binding site sequences or motifs. In yet another embodiment, an SRE can comprise a plurality of binding sites for one or more transcription factors, wherein the plurality of transcription binding sites can comprise a mixture of the same binding site sequences and different binding site sequences (FIG. 72, middle). In some embodiments, an SRS comprising an SRE that comprises a mixture of different transcription factor binding sequences or motifs can drive stronger or higher expression of an ORF operatively linked to the SRS in cancer cells or cancer tissues compared to a corresponding SRS comprising an SRE that that comprises a plurality of the same transcription binding sequences or motifs.

[0134] In some embodiments, an SRS can comprise one or more SREs comprising a plurality of binding sites for one or more transcription factors at the 5′ or upstream of a promoter or a core promoter. In some embodiments, an SRS can comprise one or more SREs comprising a plurality of enhancers at the 5′ or upstream of a promoter or a core promoter. In some embodiments, an SRS can comprise a plurality of enhancers at the 5′ or upstream of a plurality of binding sites for one or more transcription factors, wherein the plurality of binding sites for one or more transcription factors are at the 5′ or upstream of a promoter or a core promoter. For example, an SRS can comprise (i) a plurality of enhancers, (ii) a plurality of binding sites for one or more transcription factors, and (iii) a promoter or a core promotor in 5′ to 3′ direction. In some embodiments, an SRS can comprise a plurality of enhancers at the 5′ or upstream of a promoter or a core promoter and at the 3′ or downstream of a plurality of binding sites for one or more transcription factors. For example, an SRS can comprise (i) a plurality of binding sites for one or more transcription factors, (ii) a plurality of enhancers, and (ii) a promoter or a core promoter in 5′ to 3′ direction.

[0135] In some embodiments, an SRS described herein can drive the expression of an ORF operably linked to the SRS in one specific type of cancer cells. In some embodiments, an SRS described herein can drive the expression of an ORF operably linked to the SRS in two or more types of cancer cells.

[0136] In some embodiments, a recombinant polynucleotide comprising an SRS describe herein can drive the expression of an ORF operably linked to the SRS at a higher level compared to a corresponding recombinant polynucleotide comprising a constitutive promoter and an ORF operatively linked to the constitutive promoter. For example, a recombinant polynucleotide comprising an SRS describe herein can drive the expression of an ORF operably linked to the SRS at a level that is at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% higher compared to a corresponding recombinant polynucleotide comprising a constitutive promoter and an ORF operatively linked to the constitutive promoter. In some embodiments, an ORF can comprise an ORF of a natural gene or a synthetic gene. In some embodiments, a natural gene or a synthetic can comprise a gene encoding a reporter protein, a biomarker protein, or a therapeutic protein.

[0137] In some embodiments, a recombinant polynucleotide comprising an SRS describe herein can drive the expression of an ORF operably linked to the SRS at a higher level in cancer cells compared to a corresponding recombinant polynucleotide comprising a constitutive promoter and an ORF operatively linked to the constitutive promoter. For example, a recombinant polynucleotide comprising an SRS describe herein can drive the expression of an ORF operably linked to the SRS in cancer cells at a level that is at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% higher compared to a corresponding recombinant polynucleotide comprising a constitutive promoter and an ORF operatively linked to the constitutive promoter.

Promoter/Core Promoter

[0138] A core promoter described herein can comprise a minimal promoter that can comprise a transcription start site or a transcription start site sequence that is derived from a promoter of one or more genes expressed in cancer cells or cancer tissues (also referred to as a cancer-responsive gene herein). In some embodiments, a core promoter described herein can comprise a minimal promoter that can comprise a transcription start site or a transcription start site sequence that is derived from a promoter of one or more genes expressed at a higher level in cancer cells or cancer tissues compared to non-cancer cells or non-cancer tissues. For example, a core promoter described herein can comprise a minimal promoter that can comprise a transcription start site or a transcription start site sequence that is derived from a promoter of one or more genes expressed at a level that is at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% higher in cancer cells or cancer tissues compared to non-cancer cells or non-cancer tissues.

[0139] In some embodiments, a core promoter can further comprise one or more promoter elements that are derived from a promoter of one or more genes expressed in cancer cells or cancer tissues. In some embodiments, a core promoter can further comprise one or more promoter elements that are derived from a promoter of one or more genes expressed at a level that is at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% higher in cancer cells or cancer tissues compared to non-cancer cells or non-cancer tissues. In some embodiments, promoter elements can include, but are not limited to, elements specific for tissue, elements specific for development or development stage, elements specific for cancer (e.g., transcription factor binding sites specific for cancer or oncogenic transcription factor binding sites), elements important for transcription (e.g., general promoter elements). In some embodiments, a core promoter can comprise two or more promoter elements that are derived from a promoter of two or more genes expressed in cancer cells or cancer tissues. For example, a core promoter can comprise two or more promoter elements that are derived from a promoter of at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 genes expressed in cancer cells or cancer tissues. Non-limiting examples of cancer-responsive genes can include TCF7, MNX1, HOXC10, TPS3, CEACAM5, CEP55, FAM111B, CST1, BIRC5, AGR2, FOXA1, cMYC, FOS, TWIST1, E2F2, UBE2C, KIF20A, or ETV4.

[0140] In some embodiments, a core promoter can comprise a minimal promoter derived from one or more genes expressed in cancer cells or cancer tissues. In one example, a core promoter can comprise a minimal promoter derived from one or more cancer-responsive genes comprising TCF7, MNX1, HOXC10, TPS3, CEACAM5, CEP55, FAM111B, CST1, BIRC5, AGR2, FOXA1, cMYC, FOS, TWIST1, E2F2, UBE2C, KIF20A, or ETV4. In another example, a core promoter can comprise a hybrid minimal promoter derived from two or more cancer-responsive genes comprising TCF7, MNX1, HOXC10, TPS3, CEACAM5, CEP55, FAM111B, CST1, BIRC5, AGR2, FOXA1, cMYC, FOS, TWIST1, E2F2, UBE2C, KIF20A, or ETV4. In some embodiments, a core promoter can comprise a minimal promoter and one or more promoter elements described herein derived from two or more cancer-responsive genes comprising TCF7, MNX1, HOXC10, TPS3, CEACAM5, CEP55, FAM111B, CST1, BIRC5, AGR2, FOXA1, cMYC, FOS, TWIST1, E2F2, UBE2C, KIF20A, or ETV4. In some embodiments, a core promoter can comprise a minimal promoter and two or more promoter elements described herein derived from TCF7 and HOXC10. In some embodiments, a core promoter can comprise a minimal promoter and two or more promoter elements described herein derived from TP53 and CEP55.

[0141] In some embodiments, a core promoter can comprise a minimal promoter and two or more promoter elements described herein derived from FAM111B and KIF20A. In some embodiments, a core promoter can comprise a minimal promoter and two or more promoter elements described herein derived from BIRC5 and E2F2. In some embodiments, a core promoter can comprise a minimal promoter and two or more promoter elements described herein derived from CEACAM5 and TWIST1. In some embodiments, a core promoter can comprise a hybrid promoter comprising two or more promoter elements described herein derived from two or more cancer-responsive genes comprising TCF7, MNX1, HOXC10, TP53, CEACAM5, CEP55, FAM111B, CST1, BIRC5, AGR2, FOXA1, cMYC, FOS, TWIST1, E2F2, UBE2C, KIF20A, or ETV4. In some embodiments, a core promoter can comprise a hybrid promoter comprising two or more promoter elements described herein derived from TCF7 and HOXC10. In some embodiments, a core promoter can comprise a hybrid promoter comprising two or more promoter elements described herein derived from TP53 and CEP55. In some embodiments, a core promoter can comprise a hybrid promoter comprising two or more promoter elements described herein derived from FAM111B and KIF20A. In some embodiments, a core promoter can comprise a hybrid promoter comprising two or more promoter elements described herein derived from BIRC5 and E2F2. In some embodiments, a core promoter can comprise a hybrid promoter comprising two or more promoter elements described herein derived from CEACAM5 and TWIST1. In some embodiments, a core promoter can comprise a hybrid promoter comprising a minimal promoter and two or more promoter elements described herein derived from two or more cancer-responsive genes comprising TCF7, MNX1, HOXC10, TP53, CEACAM5, CEP55, FAM111B, CST1, BIRC5, AGR2, FOXA1, cMYC, FOS, TWIST1, E2F2, UBE2C, KIF20A, or ETV4. In some embodiments, a core promoter can comprise a hybrid promoter comprising a minimal promoter and two or more promoter elements described herein derived from TCF7 and HOXC10. In some embodiments, a core promoter can comprise a hybrid promoter comprising a minimal promoter and two or more promoter elements described herein derived from TP53 and CEP55.

[0142] In some embodiments, a core promoter can comprise a hybrid promoter comprising a minimal promoter and two or more promoter elements described herein derived from FAM111B and KIF20A. In some embodiments, a core promoter can comprise a hybrid promoter comprising a minimal promoter and two or more promoter elements described herein derived from BIRC5 and E2F2. In some embodiments, a core promoter can comprise a hybrid promoter comprising a minimal promoter and two or more promoter elements described herein derived from CEACAM5 and TWIST1.

[0143] In some embodiments, a core promoter can comprise a hybrid promoter comprising a chimeric sequence of two or more promoter elements from two or more cancer-responsive genes comprising TCF7, MNX1, HOXC10, TP53, CEACAM5, CEP55, FAM111B, CST1, BIRC5, AGR2, FOXA1, cMYC, FOS, TWIST1, E2F2, UBE2C, KIF20A, or ETV4. In some embodiments, a core promoter can comprise a hybrid promoter comprising a chimeric sequence of two or more promoter elements derived from TCF7 and HOXC10. In some embodiments, a core promoter can comprise a hybrid promoter comprising a chimeric sequence of two or more promoter elements derived from TPS3 and CEP55. In some embodiments, a core promoter can comprise a hybrid promoter comprising a chimeric sequence of two or more promoter elements derived from FAM111B and KIF20A. In some embodiments, a core promoter can comprise a hybrid promoter comprising a chimeric sequence of two or more promoter elements derived from BIRC5 and E2F2. In some embodiments, a core promoter can comprise a hybrid promoter comprising a chimeric sequence of two or more promoter elements derived from CEACAM5 and TWIST1.

[0144] In some embodiments, a core promoter can comprise a TATA box or a TATA box sequence. In some embodiments, a core promoter can comprise a sequence of a region from about −300 bp to about +100 bp, from about −250 bp to about +100 bp, from about −200 bp to about +100 bp, from about −150 bp to about +100 bp, from about −100 bp to about +100 bp, from about −90 bp to about +100 bp, from about −80 bp to about +100 bp, from about −70 bp to about +100 bp, from about −60 bp to about +100 bp, from about −50 bp to about +100 bp, from about −40 bp to about +100 bp, or from about −30 bp to about +100 bp relative to a transcription start site (TSS) of a cancer-responsive gene. In some embodiments, a core promoter can comprise a sequence of a region from about 300 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 250 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 200 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 150 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 100 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 90 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 80 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 70 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 60 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 50 bp upstream of a TSS to about 100 bp downstream of a TSS, from about 40 bp upstream of a TSS to about 100 bp downstream of a TSS, or from about 30 bp upstream of a TSS to about 100 bp downstream of a TSS of a cancer-responsive gene. In some embodiments, a cancer-responsive gene can comprise a human cancer-responsive gene.

[0145] In some embodiments, the sequence of a region from about −300 bp to about +100 bp relative to a TSS (or from about 300 bp upstream of a TSS to about 100 bp downstream of a TSS) can comprise elements that are important for transcription, elements that are tissue specific, elements that are specific for certain development stage, and/or one or more binding sites for transcription factors specific for cancer (e.g., oncogenic transcription factors). In some embodiments, a promoter or a core promoter can comprise one or more elements or sequences binding to NKX2-1, NANOG, GATA3, TRPS1, SOX9, KSLF14, Sp5, ZEB1, ZEB2, TGIF, PITX, NKX6-1, THRb, ERRa, COUP-TFII, PR, Asc12, Slug, E2A, PITX1, or NKX3.2.

[0146] In some embodiments, a promoter or a core promoter can be operably linked to an open reading frame (ORF) of a gene of interest. A gene of interest can be any gene for which expression is desired specifically in cancer cells. Non-limiting examples of a gene of interest can include a gene encoding a therapeutic protein, a gene encoding a synthetic protein, a gene encoding a marker protein (e.g., biomarker for diagnostics, etc.), or a gene encoding a reporter protein.

[0147] In some embodiments, the core promoter can be derived from a promoter of one or more genes that are expressed at a higher level in cancer cells compared to non-cancer cells. For example, the core promoter can be derived from a promoter of one or more genes that are expressed at a level that is at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% higher in cancer cells compared to non-cancer cells. In some embodiments, the core promoter can be derived from a promoter of one or more genes that are more active in cancer cells compared to non-cancer cells. For example, the core promoter can be derived from a promoter of one or more genes that are at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% more active in cancer cells compared to non-cancer cells.

[0148] In some embodiments, a phosphorylation assay can be used to measure activation or activity levels of cancer-responsive genes described herein.

[0149] In some embodiments, the core promoter can be derived from one or more cancer-responsive genes that are expressed at a higher level in cancer cells compared to non-cancer cells. For example, the core promoter can be derived from one or more cancer-responsive genes that are either expressed at a level that is at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% higher in cancer cells compared to non-cancer cells. In some embodiments, the core promoter can be derived from one or more cancer-responsive genes that are more active in cancer cells compared to non-cancer cells. For example, the core promoter can be derived from one or more cancer-responsive genes that are at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% more active in cancer cells compared to non-cancer cells. In some embodiments, a phosphorylation assay can be used to measure activation or activity levels of cancer-responsive genes described herein.

Synthetic Response Elements—Transcription Factors (TFs)

[0150] In some embodiments, an SRS can comprise one or more SREs, wherein the one or more SREs can comprise a plurality of binding sites for one or more transcription factors. In some embodiments, a plurality of binding sites (e.g., binding site DNA sequence) for one or more transcription factors can be identified from a multi-omics approach, including but not limited to, transcriptomics, proteomics, and/or phospho-proteomics to be upregulated in cancer cells or tissues compared to normal (e.g., non-cancer) cells or tissues. In some embodiments, the one or more SREs can comprise a plurality of binding sites for one or more transcription factors that are expressed in higher levels in cancer cells compared to non-cancer cells. In some embodiments, ChIP assay can be used to measure expression levels of transcription factors described herein. In some embodiments, the one or more SREs can comprise a plurality of binding sites for one or more transcription factors that are more active in cancer cells compared to non-cancer cells. For example, the one or more SREs can comprise a plurality of binding sites for one or more transcription factors that have higher level of phosphorylation in cancer cells compared to non-cancer cells. In some embodiments, a phosphorylation assay can be used to measure activation or activity levels of transcription factors described herein.

[0151] In some embodiments, an SRS comprising a promoter (or a core promoter) and a plurality of binding sites for one or more transcription factors can drive the expression of an ORF operably linked to the promoter (or the core promoter) at least 1.1-fold, at least 1.2-fold, at least 1.3-fold, at least 1.4-fold, at least 1.5-fold, at least 1.6-fold, at least 1.7-fold, at least 1.8-fold, at least 1.9-fold, at least 2-fold, at least 2.1-fold, at least 2.2-fold, at least 2.3-fold, at least 2.4-fold, at least 2.5-fold, at least 2.6-fold, at least 2.7-fold, at least 2.8-fold, at least 2.9-fold, at least 3-fold, at least 3.1-fold, at least 3.2-fold, at least 3.3-fold, at least 3.4-fold, at least 3.5-fold, at least 3.6-fold, at least 3.7-fold, at least 3.8-fold, at least 3.9-fold, at least 4-fold, at least 4.1-fold, at least 4.2-fold, at least 4.3-fold, at least 4.4-fold, at least 4.5-fold, at least 4.6-fold, at least 4.7-fold, at least 4.8-fold, at least 4.9-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold, at least 70-fold, at least 80-fold, at least 90-fold, or at least 100-fold higher than the expression of a corresponding ORF driven by a promoter (or a core promoter) without the plurality of binding sites for one or more transcription factors.

[0152] In some embodiments, an SRS comprising a promoter described herein (or a core promoter described herein, e.g., a cancer-specific core promoter comprising a TATA-TSS and other elements in−300 bp to about +100 bp relative to a TSS) and a plurality of binding sites for one or more transcription factors can drive the expression of an ORF operably linked to the promoter (or the core promoter) at least 1.1-fold, at least 1.2-fold, at least 1.3-fold, at least 1.4-fold, at least 1.5-fold, at least 1.6-fold, at least 1.7-fold, at least 1.8-fold, at least 1.9-fold, at least 2-fold, at least 2.1-fold, at least 2.2-fold, at least 2.3-fold, at least 2.4-fold, at least 2.5-fold, at least 2.6-fold, at least 2.7-fold, at least 2.8-fold, at least 2.9-fold, at least 3-fold, at least 3.1-fold, at least 3.2-fold, at least 3.3-fold, at least 3.4-fold, at least 3.5-fold, at least 3.6-fold, at least 3.7-fold, at least 3.8-fold, at least 3.9-fold, at least 4-fold, at least 4.1-fold, at least 4.2-fold, at least 4.3-fold, at least 4.4-fold, at least 4.5-fold, at least 4.6-fold, at least 4.7-fold, at least 4.8-fold, at least 4.9-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, at least 15-fold, at least 16-fold, at least 17-fold, at least 18-fold, at least 19-fold, at least 20-fold, at least 21-fold, at least 22-fold, at least 23-fold, at least 24-fold, at least 25-fold, at least 26-fold, at least 27-fold, at least 28-fold, at least 29-fold, at least 30-fold, at least 31-fold, at least 32-fold, at least 33-fold, at least 34-fold, at least 35-fold, at least 36-fold, at least 37-fold, at least 38-fold, at least 39-fold, at least 40-fold, at least 41-fold, at least 42-fold, at least 43-fold, at least 44-fold, at least 45-fold, at least 46-fold, at least 47-fold, at least 48-fold, at least 49-fold, at least 50-fold, at least 55-fold, at least 60-fold, at least 65-fold, at least 70-fold, at least 75-fold, at least 80-fold, at least 85-fold, at least 90-fold, at least 95-fold, or at least 100-fold higher than the expression of a corresponding ORF driven by a non-cancer specific promoter (e.g., TATA-TSS promoter only) and the plurality of binding sites for one or more transcription factors.

[0153] Non-limiting examples of transcription factors can include TRPS1, MNX1, TWIST1, ETV4, FOSL2, NFIC, EN2, TFDP1, PITX2, TCF7L1, VENTX, HOXB9, DLX1, MYCN, SIX4, TP63, SOX11, E2F8, TFDP1, SURV, TOXE, EN1, ZBTB7B, SP3, SIX2, XBP1, HIF-1A, CREB3L1, HSF-1, MTF1, NFE2L2, USF2, TP73, POU2F2, HOXA1, FOXO1, TFAP4, BACH1, E2F4, HOXC10, KLF11, FOXM1, E2F2, E2F3, E2F1, GLIS3, GATA1, DLX3, LHX2, BARX1, HOXC9, FOXK1, RUNX2, RUNX1, SOX4, RREB1, HES6, ASCL1, FOXA3, HOXB2, DLX4, GRHL1, FOXA, HIF, E2F6, FOSL1, JUN, JUNB, FOSB, AP-1, NF-1, RFX6, EL4, TCF3, TCF12, SNAI2, REST, DMRTA2, RFX7, NRF1, ZNF148, ZNF652, PRDM1, HIF1A, TGIF1, STAT2, ESRRA, RELB, HSF1, MAFB, TFAP2C, YBX1, YY1, PITX1, SATB1, ARID3A, POU3F1, SP4, MGA, SALL4, AHR, MLXIP, PRDM4, NFIL3, TFAP2A, ZBTB17, ZFP91, ARID5A, IRF6, ZFX, POU2F1, NKX2-1, NKX2-8, FOXA1, NFKB1, HNF4G, ARID1A, NFATC2, SMAD2, ARID3B, TPS3, FOS, FOS-CREB, ELK3, FOXO1::ELK3, TCF7, E2F2, CREB3L1, SHOX2, TCF7L1, HOXA1, MYBL2, NR2C2, MYCN, FOXN1, PITX2, EN2, NFIC, MYC, DLX4, SP3, FOXE1, VENTX, TPS3, GLIS3, CUX1, MGA, DLX1, DLX6, GATA1, RUNX2, E2F7, GRHL1, ZBTB7B, HNF1A, FOXA3, NPAS2, TP63, RREB1, SOX4, ZIC2, TCF7, EN1, DMBX1, E2F8, FOSL2, PBX3, NKX3-2, DLX3, HOXB7, TRPS1, SOX11, PAX8, HES6, HOXC10, MNX1, SIX2, ZNF281, ETV4, ZNF384, ASCL1, BARX1, PAX7, LHX2, OTX1, RUNX1, ETV6, FOXK1, HOXB9, E2F4, NR2F6, TWIST1 HOXC9, IRF6, NR2E1, RORB, E2F1, E2F3, TFDP1, FOXJ3, SIX4, MAX::MYC, ONECUT1, or NFκB.

[0154] In some embodiments, transcription factors enriched in lung adenocarcinoma (LUAD) can comprise E2F2, CREB3L1, SHOX2, TCF7L1, HOXA1, MYBL2, NR2C2, MYCN, FOXN1, PITX2, EN2, NFIC, MYC, DLX4, SP3, FOXE1, VENTX, TP53, GLIS3, CUX1, MGA, DLX1, DLX6, GATA1, RUNX2, E2F7, GRHL1, ZBTB7B, HNF1A, FOXA3, NPAS2, TP63, RREB1, SOX4, ZIC2, TCF7, EN1, DMBX1, E2F8, FOSL2, PBX3, NKX3-2, DLX3, HOXB7, TRPS1, SOX11, PAX8, HES6, HOXC10, MNX1, SIX2, ZNF281, ETV4, ZNF384, ASCL1, BARX1, PAX7, LHX2, OTX1, RUNX1, ETV6, FOXK1, HOXB9, E2F4, NR2F6, TWIST1, HOXC9, IRF6, NR2E1, RORB, E2F1, E2F3, TFDP1, FOXJ3, SIX4, MAX::MYC, or ONECUT1.

[0155] In some embodiments, transcription factors can comprise E2F4, E2F3, E2F1, GLIS3, GATA1, DLX1, DLX3, LHX2, BARX1, PBX3, HOXC9, FOXK1, FOXA3, TRPS1, RUNX2, HOXA1, NFE2L2, TCF3, TCF12, SNAI2, REST, DMRTA2, RFX7, NRF1, ZNF148, ZNF652, PRDM1, HIF1A, TGIF1, STAT2, ESRRA, RELB, HSF1, MAFB, TFAP2C, YBX1, YY1, PITX1, SATB1, ARID3A, USF2, POU3F1, SP4, MGA, SALL4, AHR, MLXIP, MTF1, PRDM4, ZBTB7B, NFIL3, TFAP2A, ZBTB17, ZFP91, BACH1, MLXIP, ARID5A, IRF6, ZFX, POU2F1, NKX2-1, NKX2-8, FOXA1, NFKB1, MGA, HNF4G, ARID1A, NFATC2, POU2F2, SMAD2, PRDM4, MLXIP, or ARID3B. In some embodiments, control TF tiles can comprise TCF7_v2, TCF7L1_v19, TP53_v5, TP53_v22, Control-1-FOSL1_v1, HOXC10_v24, HOXC10_v14, CREB3L1_v6, CREB3L1_v14, Control-Filler_v1, Control-Filler_v2, Control-Filler_v3, Control-Filler_v4, or Control-Filler_v5. In some embodiments, TF tiles can comprise homotypic TF-tiles or heterotypic TF tiles. For examples, TF-tiles comprising mixed binding sequences/sites/motifs from the same TF can be referred to as homotypic TF-tiles. For example, TF-tiles comprising mixed binding sequences/sites/motifs from different TF can be referred to as heterotypic TF-tiles. In some embodiments, SREs can comprise binding sequences, sites, or motifs of TFs of dysregulated genes that are involved in the EGFR, KRAS or p53 pathways in NSCLC.

[0156] In some embodiments, a binding site for a transcription factor can comprise a known transcription factor binding site (TFBS) sequence element or DNA binding site sequence element. In some embodiments, a transcription factor can bind to TFBS sequence element or DNA binding site sequence element and can recruit additional transcriptional machinery and co-factors (e.g., RNA polymerase, etc.) to the promoter or the core promoter. In some embodiments, a transcription factor can comprise a transcription co-factor.

[0157] In one embodiment, transcription factors that bind to the plurality of transcription binding sites can drive the expression of an ORF operably linked to the promoter in one specific type of cancer cells. In another embodiment, transcription factors that bind to the plurality of transcription binding sites can drive the expression of an ORF operably linked to the promoter in two or more types of cancer cells.

[0158] In some embodiments, an SRE can comprise at least about one, at least about two, at least about three, at least about four, at least about five, at least about six, at least about seven, at least about eight, at least about nine, or at least about ten binding sites for one or more transcription factors. In some embodiments, an SRE can comprise at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, or at least about 50 binding sites for one or more transcription factors. In some embodiments, an SRE can comprise at most about 50, at most about 45, at most about 40, at most about 35, at most about 30, at most about 25, at most about 24, at most about 23, at most about 22, at most about 21, at most about 20, at most about 19, at most about 18, at most about 17, at most about 16, at most about 15, at most about 14, at most about 13, at most about 12, at most about 11, at most about 10, at most about 9, at most about 8, at most about 7, at most about 6, or at most about 5 binding sites for one or more transcription factors.

[0159] In some embodiments, an SRE can comprise a plurality of binding sites for at least about one, at least about two, at least about three, at least about four, at least about five, at least about six, at least about seven, at least about eight, at least about nine, or at least about ten transcription factors. In some embodiments, an SRE can comprise a plurality of binding sites for at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, or at least about 50 transcription factors. In some embodiments, an SRE can comprise a plurality of binding sites for at most about 50, at most about 45, at most about 40, at most about 35, at most about 30, at most about 25, at most about 24, at most about 23, at most about 22, at most about 21, at most about 20, at most about 19, at most about 18, at most about 17, at most about 16, at most about 15, at most about 14, at most about 13, at most about 12, at most about 11, at most about 10, at most about 9, at most about 8, at most about 7, at most about 6, or at most about 5 transcription factors.

[0160] In some embodiments, an SRE can comprise two or more transcription factor binding sites for one transcription factor, wherein each of the two or more transcription factor binding sites can be sequentially arranged or tiled in a sequential manner. For example, an SRE can comprise two or more transcription factor binding site sequences for one transcription factor and each of the two or more transcription factor binding sites can be sequentially arranged or tiled in a sequential manner (e.g., arranged side by side). In some embodiments, an SRE can comprise two or more transcription factor binding sites for one transcription factor, wherein each of two or more transcription factor binding sites can be sequentially arranged or tiled in a sequential manner at 5′ to a core promoter in the recombinant polynucleotide comprising the SRE and the core promoter.

[0161] In some embodiments, an SRE can comprise two or more transcription factor binding sites for two or more transcription factors, wherein each of two or more transcription factor binding sites can be non-sequentially arranged or tiled in a non-sequential manner. For example, an SRE can comprise two or more transcription factor binding site sequences for two or more transcription factors and the two or more transcription factor binding site sequences may be (i) the same, (ii) different, or (iii) a combination of (i) and (ii). In this example, the two or more transcription binding sites can comprise (ii) different transcription factor binding site sequences that are non-sequentially arranged or tiled in a non-sequential manner (e.g., shuffled) in the recombinant polynucleotide. In another example, the two or more transcription factor binding sites can comprise (iii) a combination of the same and different transcription factor binding site sequences, wherein all of the two or more transcription factor binding sites are non-sequentially arranged or tiled in a non-sequential manner in the recombinant polynucleotide. In yet another example, the two or more transcription factor binding sites can comprise (iii) a combination of the same and different transcription factor binding site sequences, wherein some of the two or more transcription factor binding sites are sequentially arranged or tiled in a sequential manner and the some of the two or more transcription factor binding sites are non-sequentially arranged or tiled in a non-sequential manner in the recombinant polynucleotide. In some embodiments, an SRE can comprise two or more transcription factor binding sites for two or more transcription factors, wherein each of two or more transcription factor binding sites can be non-sequentially arranged or tiled in a non-sequential manner at 5′ to a core promoter in the recombinant polynucleotide comprising the SRE and the core promoter.

[0162] In some embodiments, an SRE comprising a plurality of binding sites for one or more transcription factors can further comprise a spacer element between each of the plurality of binding sites for one or more transcription factors. In some embodiments, a spacer element can comprise a nucleotide sequence of from about 1 to about 10 nucleotides or base pairs. For example, a spacer element can comprise a nucleotide sequence of from about 1 to about 10 nucleotides, from about 2 to about 15 nucleotides, from about 3 to about 20 nucleotides, from about 4 to about 25 nucleotides, from about 4 to about 30 nucleotides, from about 5 to about 35 nucleotides, from about 6 to about 40 nucleotides, from about 7 to about 50 nucleotides, from about 8 to about 55 nucleotides, from about 9 to about 60 nucleotides, from about 10 to about 65 nucleotides, from about 15 to about 70 nucleotides, from about 20 to about 75 nucleotides, from about 25 to about 80 nucleotides, from about 30 to about 85 nucleotides, from about 35 to about 90 nucleotides, from about 40 to about 95 nucleotides, or from about 45 to about 100 nucleotides. In some embodiments, a spacer element can comprise a nucleotide sequence of at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, or at least about 100 nucleotides. In some embodiments, a spacer element can comprise a nucleotide sequence of at most about 100, at most about 95, at most about 90, at most about 85, at most about 80, at most about 75, at most about 70, at most about 65, at most about 60, at most about 55, at most about 50, at most about 45, at most about 40, at most about 35, at most about 30, at most about 25, at most about 24, at most about 23, at most about 22, at most about 21, at most about 20, at most about 19, at most about 18, at most about 17, at most about 16, at most about 15, at most about 14, at most about 13, at most about 12, at most about 11, or at most about 10 nucleotides. In some embodiments, a spacer element can comprise a nucleotide sequence of 0, 3, 7, or 10 nucleotides or base pairs.

[0163] In some embodiments, an SRS can comprise a plurality of binding sites for one or more transcription factors (TFs), wherein said one or more TFs are expressed at higher levels in cancer cells compared to non-cancer cells. For example, the one or more TFs core promoter may be expressed at a level that is at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% higher in cancer cells compared to non-cancer cells.

[0164] In some embodiments, an SRS can comprise a plurality of binding sites for one or more transcription factors (TFs), wherein said one or more TFs are more active in cancer cells compared to non-cancer cells. For example, the one or more TFs may be at least 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500%, 510%, 520%, 530%, 540%, 550%, 560%, 570%, 580%, 590%, 600%, 610%, 620%, 630%, 640%, 650%, 660%, 670%, 680%, 690%, 700%, 710%, 720%, 730%, 740%, 750%, 760%, 770%, 780%, 790%, 800%, 810%, 820%, 830%, 840%, 850%, 860%, 870%, 880%, 890%, 900%, 110%, 920%, 930%, 940%, 950%, 960%, 970%, 980%, 990%, or at least 1000% more active in cancer cells compared to non-cancer cells. In some embodiments, a phosphorylation assay can be used to measure activation or activity levels of TFs described herein.

Synthetic Response Elements—Enhancers

[0165] In some embodiments, an SRE can comprise a plurality of enhancers. For example, an SRE can comprise a plurality of any known enhancers that can increase the level of transcription of a gene. In some embodiments, an SRE can comprise a plurality of endogenous enhancer sequences. In some embodiments, an SRE can comprise a plurality of enhancers derived from a cancer-responsive gene described herein. In some embodiments, a cancer-responsive gene can comprise a human cancer-responsive gene. In some embodiments, an SRE can comprise at least about one, at least about two, at least about three, at least about four, at least about five, at least about six, at least about seven, at least about eight, at least about nine, or at least about ten enhancers derived from a cancer-responsive gene. In some embodiments, an SRE can comprise at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, or at least about 50 enhancers derived from a cancer-responsive gene. In some embodiments, an SRE can comprise at most about 50, at most about 45, at most about 40, at most about 35, at most about 30, at most about 25, at most about 24, at most about 23, at most about 22, at most about 21, at most about 20, at most about 19, at most about 18, at most about 17, at most about 16, at most about 15, at most about 14, at most about 13, at most about 12, at most about 11, at most about 10, at most about 9, at most about 8, at most about 7, at most about 6, or at most about 5 enhancers derived from a cancer-responsive gene.

[0166] In some embodiments, an SRE can comprise a plurality of enhancers derived from two or more cancer-responsive genes described herein. In some embodiments, a cancer-responsive gene can refer to a gene specifically or preferentially expressed in cancer cells or cancer tissues compared to non-cancer cells or non-cancer tissues. In some embodiments, a cancer-responsive gene can comprise a human cancer-responsive gene. In some embodiments, an SRE can comprise a plurality of enhancers derived from at least about two, at least about three, at least about four, at least about five, at least about six, at least about seven, at least about eight, at least about nine, or at least about ten cancer-responsive genes. In some embodiments, an SRE can comprise a plurality of enhancers derived from at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, or at least about 100 cancer-responsive genes. In some embodiments, an SRE can comprise a plurality of enhancers derived from at most about 100, at most about 95, at most about 90, at most about 85, at most about 80, at most about 75, at most about 70, at most about 65, at most about 60, at most about 55, at most about 50, at most about 45, at most about 40, at most about 35, at most about 30, at most about 25, at most about 24, at most about 23, at most about 22, at most about 21, at most about 20, at most about 19, at most about 18, at most about 17, at most about 16, at most about 15, at most about 14, at most about 13, at most about 12, at most about 11, at most about 10, at most about 9, at most about 8, at most about 7, at most about 6, or at most about 5 cancer-responsive genes.

[0167] In some embodiments, a plurality of enhancers described herein can comprise a transcription regulatory element (TRE). A TRE can refer to a region of DNA that can regulate transcription of a gene.

[0168] In some embodiments, a TRE can increase the transcription of a gene. In some embodiments, a TRE can decrease the transcription of a gene. In some embodiments, a TRE can comprise a transcription binding site. In some embodiments, a plurality of enhancers can comprise a transcription regulatory element that has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes. In some embodiments, a plurality of enhancers can comprise a transcription regulatory element that has 90% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes.

[0169] In some embodiments, a plurality of enhancers can comprise an enhancer consensus sequence of two or more homologous cancer-responsive genes. In some embodiments, an enhancer consensus sequence of two or more homologous cancer-responsive genes can comprise a consensus sequence of an enhancer sequence derived from two or more cancer-responsive genes that has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity between the two or more cancer-responsive genes. In some embodiments, an enhancer consensus sequence of two or more homologous cancer-responsive genes can comprise a consensus sequence of an enhancer sequence derived from two or more cancer-responsive genes that has at least 90% sequence identity between the two or more cancer-responsive genes.

[0170] In some embodiments, an SRE can comprise a plurality of enhancers comprising at least two enhancer sequences, wherein each of the at least two enhancer sequences can comprise (i) the same enhancer sequences, (ii) different enhancer sequences, or (iii) a combination of (i) and (ii). In some embodiments, each of the at least two enhancer sequences can be sequentially arranged or tiled in a sequential manner in a recombinant polynucleotide. In some embodiments, each of the at least two enhancer sequences can be sequentially arranged or tiled in a sequential manner at 5′ to a core promoter in the recombinant polynucleotide comprising the core promoter and an SRE comprising the plurality of enhancers. In some embodiments, each of said at least two enhancer sequences can be sequentially arranged or tiled in a sequential manner at 5′ to a core promoter and/or at 3′ to a plurality of binding sites for one or more TFs, if present, in the recombinant polynucleotide comprising the core promoter, an SRE comprising the plurality of enhancers, and/or the plurality of transcription factor binding sites.

[0171] In some embodiments, an SRE can comprise a plurality of enhancers comprising at least two enhancer sequences, wherein each of the at least two enhancer sequences can comprise (ii) different enhancer sequences. In this embodiment, each of said plurality of enhancers comprising different enhancer sequences can be non-sequentially arranged or tiled in a non-sequential manner. In some embodiments, each of said plurality of enhancers comprising different enhancer sequences can be non-sequentially arranged or tiled in a non-sequential manner at 5′ to a core promoter in the recombinant polynucleotide comprising the core promoter and an SRE comprising the plurality of enhancers. In some embodiments, each of said plurality of enhancers comprising different enhancer sequences can be non-sequentially arranged or tiled in a non-sequential manner at 5′ to a core promoter and/or at 3′ to a plurality of binding sites for one or more TFs, if present, in the recombinant polynucleotide comprising the core promoter, an SRE comprising the plurality of enhancers, and/or the plurality of transcription factor binding sites.

[0172] In some embodiments, an SRE can comprise a plurality of enhancers comprising at least two enhancer sequences, wherein each of the at least two enhancer sequences can comprise (iii) a combination of the same and different enhancer sequences. In this embodiment, each of said plurality of enhancers comprising a combination of the same and different enhancer sequences can be non-sequentially arranged or tiled in a non-sequential manner. In some embodiments, each of said plurality of enhancers comprising a combination of the same and different enhancer sequences can be non-sequentially arranged or tiled in a non-sequential manner at 5′ to a core promoter in the recombinant polynucleotide comprising the core promoter and an SRE comprising the plurality of enhancers. In some embodiments, each of said plurality of enhancers comprising a combination of the same and different enhancer sequences can be non-sequentially arranged or tiled in a non-sequential manner at 5′ to a core promoter and/or at 3′ to a plurality of binding sites for one or more TFs, if present, in the recombinant polynucleotide comprising the core promoter, an SRE comprising the plurality of enhancers, and/or the plurality of transcription factor binding sites.

[0173] In some embodiments, a plurality of enhancers described herein can comprise a sequence capable of binding to a transcription associated protein. A transcription associated protein as described herein can comprise any protein that is involved in transcription of a DNA sequence to an RNA sequence. In some embodiments, a transcription associated protein can bind to an enhancer sequence. In some embodiments, an assay can be used to determine if a transcription associated protein can bind to a sequence comprised in a plurality of enhancers. For example, chromatin immunoprecipitation (ChIP) assay, an in vitro transfection reporter assay, or any other suitable assays or methods can be used to determine if a transcription associated protein can bind to a sequence comprised in a plurality of enhancers. In some embodiments, a plurality of enhancers described herein can comprise a sequence capable of binding to a transcription associated protein determined by chromatin immunoprecipitation (ChIP) or an in vitro transfection reporter assay.

[0174] In some embodiments, a plurality of enhancers can comprise a CpG island. For example, at least one enhancer of the plurality of enhancers can comprise a CpG island. In some embodiments, a plurality of enhancers may not comprise a CpG island. For example, at least one enhancer of the plurality of enhancers may not comprise a CpG island.

[0175] In some embodiments, an SRS can comprise a core promoter and a plurality of binding sites for one or more transcription factors derived from two or more cancer-responsive genes, wherein the core promoter and the plurality of binding sites for one or more transcription factors are not derived from the same cancer-responsive gene. In some embodiments, an SRS can comprise a core promoter and a plurality of enhancers derived from two or more cancer-responsive genes, wherein the core promoter and the plurality of enhancers are not derived from the same cancer-responsive gene. In some embodiments, an SRS can comprise a core promoter, a plurality of binding sites for one or more transcription factors, and a plurality of enhancer derived from two or more cancer-responsive genes, wherein the core promoter, the plurality of binding sites for one or more transcription factors, and the plurality of enhancer are not derived from the same cancer-responsive gene. In some embodiments, a cancer-responsive gene can comprise a human cancer-responsive gene.

[0176] In some embodiments, a plurality of enhancers can comprise an enhancer sequence that can bind to SP1, ETS, CEBP, NF-KB, EBS, C/EBP, ARE, DRE, NFκB, GC-box, UN5CL, BOP1, RTN4RL2, ARNTL2, AGR2, LHX2, TRNP1, MU5AC, or DOK4. In some embodiments, a plurality of enhancers can comprise at least two, at least about three, at least about four, at least about five, at least about six, at least about seven, at least about eight, at least about nine, or at least about ten enhancer sequences. In some embodiments, a plurality of enhancers can comprise at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, or at least about 100 enhancer sequences. In some embodiments, a plurality of enhancers can comprise at least two SP1, ETS, CEBP, NF-KB, EBS, C/EBP, ARE, DRE, NFκB, GC-box, UN5CL, BOP1, RTN4RL2, ARNTL2, AGR2, LHX2, TRNP1, MU5AC, or DOK4 enhancer sequences.

[0177] In some embodiments, core promoter, plurality of binding sites for one or more transcription factors, or plurality of enhancers derived from two or more cancer-responsive genes can comprise a sequence listed in Table 1A, Table 1B, or Table 1C. In some embodiments, an SRS described herein can comprise a sequence listed in Table 1A, Table 1B, or Table 1C.

[0178] In some embodiments, an SRS can comprise a sequence comprising a human alpha-fetoprotein (AFP) promoter sequence comprising a plurality of HNF-1A transcription binding sites. AFP level is elevated in liver cancer including, but not limited to, hepatic carcinomas. In some embodiments, an HNF-1A transcription binding site can comprise a sequence of 5′-GTTAATTATTAAC-3′ (SEQ ID NO: 128).

Cancer Cells or Cell Lines

[0179] Described herein is a method of selectively expressing a protein in cancer or tumor cells. In some embodiments, the method can comprise contacting cancer or tumor cells with a recombinant polynucleotide comprising any SRS described herein that comprises a promoter or a core promoter, one or more SREs, and an open reading frame (ORF) encoding a protein. In some embodiments, the ORF can be operatively linked to the SRS or the promoter (or the core promoter) in the SRS. In some embodiments, cancer or tumor cells described herein can comprise malignant cancer cells. Examples of cancer or tumor cells include, but are not limited to, colorectal cancer (CRC) cells, hepatocellular carcinoma cells, breast cancer cells, or lung cancer cells. In some embodiments, cancer or tumor cells can comprise cancer or tumor cells associated with colorectal cancer (CRC), hepatocellular carcinoma, lung cancer, liver cancer, breast cancer, prostate cancer, cervix cancer, uterus cancer, pancreas cancer, kidney cancer, stomach cancer, bladder cancer, ovary cancer, brain cancer, head and neck cancer, eye cancer, mouth cancer, throat cancer, esophagus cancer, chest cancer, bone cancer, rectum or other gastrointestinal tract organ cancer, spleen cancer, skeletal muscle cancer, subcutaneous tissue cancer, testicles or other reproductive organ cancer, skin cancer, thyroid cancer, blood cancer, or lymph nodes cancer. In some embodiments, adenocarcinoma (LUAD) cells can comprise LXFA586, LXFA629, LXFA2184, or A549.

[0180] In some embodiments, large cell carcinoma cells can comprise H1299, LXFL430, LXFL1121, or LXFL529. In some embodiments, squamous cell carcinoma (LUSC) cells can comprise LK2, H520, H1703, SK-MES-1, or Calu-1. In some embodiments, hepatocellular carcinoma (HCC) cells can comprise HUH7.

[0181] In some embodiments, promoters active in LXFA586 cell lines can comprise promoters of TP53, HES6, FOS, FOS-CREB, FOXO1::ELK3, or MTF1. In some embodiments, promoters active in LXFA629 cell lines can comprise promoters of FOS, CREB3L1, or HES6. In some embodiments, promoters active in LXFA2184 cell lines can comprise promoters of FOS or MNX. In some embodiments, promoters active in H1299 cell lines can comprise promoters of FOS, CREB3L1, HES6, FOS-CREB, NFE2L2, FOXO1::ELK3, or XBP1. In some embodiments, promoters active in LXFL430 cell lines can comprise promoters of TCF7, ETV4, HOXC10, FOS-CREB, FOXO1::ELK3, or XBP1. In some embodiments, promoters active in LXFL1121 cell lines can comprise promoters of FOS, CREB3L1, or ETV4. In some embodiments, promoters active in LXFL529 cell lines can comprise promoters of FOS.

[0182] In some embodiments, expression of the protein encoded by the ORF may be increased in cancer cells compared to non-cancer cells. In some embodiments, expression of the protein encoded by the ORF may be increased when the recombinant polynucleotide comprising the SRS and the ORF is introduced to cancer cells compared to non-cancer cells. For example, expression of the protein encoded by the ORF may be increased at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, at least about 200%, or at least about 250% in cancer cells compared to non-cancer cells. In some embodiments, the ORF can comprise a sequence encoding a therapeutic protein, marker protein (e.g., for diagnostic imaging, etc.), or a reporter protein (e.g., luciferase). In some embodiments, the ORF can comprise a sequence encoding a recombinant, synthetic, or engineered protein.

[0183] In some embodiments, expression of the protein encoded by the ORF may be increased in a first plurality of cancer cells when said recombinant polynucleotide is introduced to the first plurality of cancer cells compared to a second plurality of cancer cells, wherein the first plurality of cancer cells and the second plurality of cancer cells are different types of cancer cells. In some embodiments, expression of the protein encoded by the ORF may be increased in a first plurality of cancer cells when the recombinant polynucleotide comprising the SRS and the ORF is introduced to the first plurality of cancer cells compared to a second plurality of cancer cells, wherein the first plurality of cancer cells and the second plurality of cancer cells are different types of cancer cells. For example, expression of the protein encoded by the ORF operatively linked to a first type of SRS in the recombinant polynucleotide may be increased in cells of one type of cancer in which the first type of SRS can drive expression of the ORF compared to in cells of another type of cancer in which the first type of SRS cannot drive expression of the ORF. For example, expression of the protein encoded by the ORF operatively linked to an SRS that is specific for lung cancer may be increased in lung cancer cells compared to in liver cancer cells.

[0184] In some embodiments, expression of the protein encoded by the ORF may be increased in a first plurality of cancer cells comprising two or more types of cancer cells when the recombinant polynucleotide comprising the SRS and the ORF is introduced to the first plurality of cancer cells compared to a second plurality of cancer cells. For example, expression of the protein encoded by the ORF operatively linked to a first type of SRS in the recombinant polynucleotide may be increased in cells of two or more types of cancer in which the first type of SRS can drive expression of the ORF compared to in cells of another type of cancer in which the first type of SRS cannot drive expression of the ORF. For example, expression of the protein encoded by the ORF operatively linked to an SRS that is specific for lung and liver cancer may be increased in lung cancer cells and liver cancer cells compared to in non-lung cancer cells and non-liver cancer cells (e.g., breast cancer cells, etc.). In some embodiments, the first plurality of cancer cells comprising two or more types of cancer cells can comprise cells associated with two or more cancers comprising colorectal cancer, hepatocellular carcinoma, lung cancer, liver cancer, breast cancer, prostate cancer, cervix cancer, uterus cancer, pancreas cancer, kidney cancer, stomach cancer, bladder cancer, ovary cancer, brain cancer, head and neck cancer, eye cancer, mouth cancer, throat cancer, esophagus cancer, chest cancer, bone cancer, rectum or other gastrointestinal tract organ cancer, spleen cancer, skeletal muscle cancer, subcutaneous tissue cancer, testicles or other reproductive organ cancer, skin cancer, thyroid cancer, blood cancer, or lymph nodes cancer.

Therapeutic or Diagnostic Applications

[0185] Provided herein are recombinant polynucleotides (or any vector, pharmaceutical composition, or lipid nanoparticle comprising any recombinant polynucleotides described herein) useful for the diagnosis or the treatment of a disease or condition. In some aspects, recombinant polynucleotides described herein (or any vector, pharmaceutical composition, or lipid nanoparticle comprising any recombinant polynucleotides described herein) are present or administered in an amount for sufficient expression of a protein (e.g., a reporter protein or a biomarker) useful for a diagnosis of a disease or condition. In some embodiments, the disease or condition comprise a cancer. In some aspects, provided herein is a method of selectively expressing a reporter protein or a biomarker in a cancer or tumor cell. In some aspects, the method comprises contacting a tumor cell with any of recombinant polynucleotides described herein, any of vectors comprising recombinant polynucleotide described herein, any of pharmaceutical composition comprising recombinant polynucleotide described herein, or any of lipid nanoparticle (LNP) comprising the recombinant polynucleotide, the vector, or the pharmaceutical composition described herein, wherein recombinant polynucleotides can comprise an open reading frame (ORF) encoding the reporter protein or the biomarker operatively linked to a synthetic promoter described herein (e.g., a synthetic promoter that can drive expression of the ORF preferentially or specifically in cancer cells).

[0186] In some aspects, provided herein is a method for diagnosing a disease or a condition. In some embodiments, the method can comprise administering to any of recombinant polynucleotide described herein, a vector comprising the recombinant polynucleotide described herein, the pharmaceutical composition comprising the recombinant polynucleotide described herein, or a lipid nanoparticle (LNP) comprising the recombinant polynucleotide, the vector, or the pharmaceutical composition described herein to a subject. In some embodiments, the recombinant polynucleotide can further comprise an open reading frame (ORF) encoding a reporter protein or a biomarker, wherein the ORF is operatively linked to a synthetic promoter in the recombinant polynucleotide that can drive expression of the ORF selectively, preferentially, or specifically in diseased cells compared to non-disease cells. In some embodiments, the method can further comprise detecting the reporter protein or a biomarker of which expression can be induced by a synthetic promoter in the recombinant polynucleotide described herein selectively, preferentially, or specifically in diseased cells compared to non-disease cells. In some embodiments, a relative ratio of the reporter protein or the biomarker expressed in the diseased cells over the non-diseased cells can be greater than 1.0. For example, a relative ratio of the reporter protein or the biomarker expressed in the diseased cells over the non-diseased cells can be greater than about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, 90.0, 95.0, or about 100.0. In some embodiments, the disease or condition can comprise a cancer.

[0187] In some aspects, recombinant polynucleotides (or any vector, pharmaceutical composition, or lipid nanoparticle comprising any recombinant polynucleotides described herein) are present or administered in an amount sufficient to treat or prevent a disease or condition. In some aspects, provided herein, is a method of treating a disease or condition comprising administering to a subject in need thereof the recombinant polynucleotide described herein, a vector comprising the recombinant polynucleotide described herein, a pharmaceutical composition comprising the recombinant polynucleotide described herein, or a lipid nanoparticle (LNP) comprising the vector, the pharmaceutical composition or the recombinant polynucleotide described herein. In some aspects, provided herein, is recombinant polynucleotide described herein, a vector comprising the recombinant polynucleotide described herein, the pharmaceutical composition comprising the recombinant polynucleotide described herein, or a lipid nanoparticle (LNP) comprising the recombinant polynucleotide, the vector, or the pharmaceutical composition described herein for use in a method of treating a disease or a condition in a subject in need thereof. In some aspects, provided herein, is the use of recombinant polynucleotide described herein, a vector comprising the recombinant polynucleotide described herein, the pharmaceutical composition comprising the recombinant polynucleotide described herein, or a lipid nanoparticle (LNP) comprising the recombinant polynucleotide, the vector, or the pharmaceutical composition described herein for the manufacture of a medicament for treating a disease or a condition in a subject in need thereof.

[0188] In some aspects, provided herein is a method for treating a subject having or suspected of having a disease or a condition. In some embodiments, the method can comprise administering any of recombinant polynucleotide described herein, a vector comprising the recombinant polynucleotide described herein, the pharmaceutical composition comprising the recombinant polynucleotide described herein, or a lipid nanoparticle (LNP) comprising the recombinant polynucleotide, the vector, or the pharmaceutical composition described herein to a subject. In some embodiments, the recombinant polynucleotide can further comprise an open reading frame (ORF) encoding a therapeutic protein, wherein the ORF is operatively linked to a synthetic promoter in the recombinant polynucleotide that can drive expression of the ORF selectively, preferentially, or specifically in diseased cells compared to non-disease cells. In some embodiments, a relative ratio of the therapeutic protein expressed in the diseased cells over the non-diseased cells can be greater than 1.0. For example, a relative ratio of the therapeutic protein expressed in the diseased cells over the non-diseased cells can be greater than about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, or about 15.0.

[0189] In some embodiments, the disease or disorder can comprise a cancer. Examples of cancer can include, but are not limited to, colorectal cancer (CRC), hepatocellular carcinoma, breast cancer, lung cancer, liver cancer, prostate cancer, cervix cancer, uterus cancer, pancreas cancer, kidney cancer, stomach cancer, bladder cancer, ovary cancer, brain cancer, head and neck cancer, eye cancer, mouth cancer, throat cancer, esophagus cancer, chest cancer, bone cancer, rectum or other gastrointestinal tract organ cancer, spleen cancer, skeletal muscle cancer, subcutaneous tissue cancer, testicles or other reproductive organ cancer, skin cancer, thyroid cancer, blood cancer, or lymph nodes cancer.

[0190] Also provided herein are pharmaceutical compositions comprising any recombinant polynucleotide described herein or any vector comprising the recombinant polynucleotide described herein and a pharmaceutically acceptable excipient, carrier, or diluent. A pharmaceutical composition can denote a mixture or solution comprising a therapeutically effective amount of an active pharmaceutical ingredient together with one or more pharmaceutically acceptable excipients to be administered to a subject in need thereof. The term “pharmaceutically acceptable” can denote an attribute of a material which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and is acceptable for veterinary as well as human pharmaceutical use. The term “Pharmaceutically acceptable” can refer to a material, such as a excipient, carrier, or diluent, which does not abrogate the biological activity or properties of the recombinant polynucleotide or the compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained. A pharmaceutically acceptable excipient can denote any pharmaceutically acceptable ingredient in a pharmaceutical composition having no therapeutic activity and being non-toxic to the subject administered, such as disintegrators, binders, fillers, solvents, buffers, tonicity agents, stabilizers, antioxidants, surfactants, carriers, diluents, excipients, preservatives, or lubricants used in formulating pharmaceutical products. Pharmaceutical compositions can facilitate administration of a recombinant polynucleotide, a vector comprising recombinant polynucleotide, or a compound to an organism and can be formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. A proper formulation is dependent upon the route of administration chosen and a summary of pharmaceutical compositions can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), herein incorporated by reference. In some embodiments, pharmaceutical compositions can be formulated by dissolving active substances (e.g., recombinant polynucleotides or vectors comprising the recombinant polynucleotides described herein) in aqueous solution for administration into a cell, a tissue or a subject (e.g., a disease cell, disease tissue, or a subject in need thereof). In some embodiments, pharmaceutical compositions can be formulated by dissolving active substances (e.g., recombinant polynucleotides or vectors comprising the recombinant polynucleotides described herein) in aqueous solution for administration into a cell, a tissue or a subject (e.g., a disease cell, disease tissue, or a subject in need thereof).

[0191] Also provided herein are methods of treating a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any recombinant polynucleotide described herein, any vector comprising recombinant polynucleotide described herein, or pharmaceutical compositions described herein. The terms “effective amount” or “therapeutically effective amount,” as used herein, can refer to a sufficient amount of an agent, a compound, any recombinant polynucleotide described herein, any vector comprising recombinant polynucleotide described herein, or pharmaceutical compositions described herein being administered which will relieve to some extent one or more of the symptoms of the disease or the condition being treated; for example a reduction and/or alleviation of one or more signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses can be an amount of an agent that provides a clinically significant decrease in one or more disease symptoms. An appropriate “effective” amount may be determined using techniques, such as a dose escalation study, in individual cases. In some embodiments, an “effective amount” can comprise an amount for sufficient expression of a protein (e.g., a reporter protein or a biomarker) useful for diagnosing a disease or condition in a subject.

[0192] The terms “treat,” “treating” or “treatment,” as used herein, can include alleviating, abating or ameliorating at least one symptom of a disease or a condition, preventing additional symptoms, inhibiting the disease or the condition, e.g., arresting the development of the disease or the condition, relieving the disease or the condition, causing regression of the disease or the condition, relieving a condition caused by the disease or the condition, or stopping the symptoms of the disease or the condition either prophylactically and/or therapeutically. In some embodiments, treating a disease or condition comprises reducing the size of disease tissues or diseased cells. In some embodiments, treating a disease or a condition in a subject comprises increasing the survival of a subject. In some embodiments, treating a disease or condition comprises reducing or ameliorating the severity of a disease, delaying onset of a disease, inhibiting the progression of a disease, reducing hospitalization of or hospitalization length for a subject, improving the quality of life of a subject, reducing the number of symptoms associated with a disease, reducing or ameliorating the severity of a symptom associated with a disease, reducing the duration of a symptom associated with a disease, preventing the recurrence of a symptom associated with a disease, inhibiting the development or onset of a symptom of a disease, or inhibiting of the progression of a symptom associated with a disease. In some embodiments, treating a cancer comprises reducing the size of tumor or increasing survival of a patient with a cancer.

[0193] In some cases, a subject can encompass mammals. Examples of mammals include, but are not limited to, any member of the mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. In some cases, the mammal is a human. In some cases, the subject may be an animal. In some cases, an animal may comprise human beings and non-human animals. In one embodiment, a non-human animal may be a mammal, for example a rodent such as rat or a mouse. In another embodiment, a non-human animal may be a mouse. In some instances, the subject is a mammal. In some instances, the subject is a human. In some instances, the subject is an adult, a child, or an infant. In some instances, the subject is a companion animal. In some instances, the subject is a feline, a canine, or a rodent. In some instances, the subject is a dog or a cat.

[0194] Recombinant polynucleotides, vectors, or pharmaceutical compositions described herein can be administered to a subject using any suitable methods known in the art. Suitable formulations for use in the present invention and methods of delivery are generally well known in the art. For example, compositions described herein can be administered to the subject in a variety of ways, including parenterally, intravenously, intradermally, intramuscularly, colonically, rectally, or intraperitoneally. In some embodiments, compositions described herein is administered by intraperitoneal injection, intramuscular injection, subcutaneous injection, or intravenous injection of the subject. In some embodiments, compositions described herein can be administered parenterally, intravenously, intramuscularly or orally. In some embodiments, compositions described herein can be administered via injection into disease tissues or cells.

[0195] In some embodiments, compositions or pharmaceutical compositions comprising any recombinant polynucleotide described herein can be delivered to a cell via direct DNA transfer (Wolff et al. (1990) Science 247, 1465-1468). In some embodiments, recombinant polynucleotides can be delivered to cells following mild mechanical disruption of the cell membrane, temporarily permeabilizing the cells. Such a mild mechanical disruption of the membrane can be accomplished by gently forcing cells through a small aperture (Sharei et al. PLOS ONE (2015) 10(4), e0118803). In another embodiment, compositions or pharmaceutical compositions comprising any recombinant polynucleotide described herein can be delivered to via liposome or lipid nanoparticle (LNP) (e.g., Gao & Huang (1991) Biochem. Ciophys. Res. Comm. 179, 280-285, Crystal (1995) Nature Med. 1, 15-17, Caplen et al. (1995) Nature Med. 3, 39-46). A liposome or LNP can encompass a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Recombinant polynucleotides can be encapsulated in the aqueous interior of a liposome or LNP, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, or complexed with a liposome.

[0196] In some aspects, provided herein is a method comprising: (a) administering to a subject any of the pharmaceutical composition described herein; or a composition any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the LNP described herein; wherein the recombinant polynucleotide further comprises an open reading frame (ORF) encoding a reporter protein, wherein said ORF is operatively linked to a synthetic promoter in said recombinant polynucleotide, and (b) localizing a tumor or an absence thereof in a body of said subject via expression of said reporter protein using an imaging technique performed on said body of said subject. In some embodiments, the imaging technique comprises photoacoustic imaging, Magnetic resonance imaging (MRI) imaging, positron emission tomography (PET) imaging, or single-photon emission computed tomography (SPECT) imaging.

[0197] In some aspects, provided herein is a recombinant polynucleotide comprising: (a) a core promoter comprising a transcription start site (TSS), wherein the core promoter is derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells and operably linked to an open reading frame (ORF) and (b) a plurality of binding sites for one or more transcription factors (TFs), wherein said one or more TFs are expressed at higher levels or more active in cancer cells compared to non-cancer cells. In some embodiments, the recombinant polynucleotide further comprises a plurality of enhancers.

[0198] In some aspects, provided herein is a recombinant polynucleotide comprising: (a) a core promoter comprising a transcription start site (TSS) and two or more promoter elements derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells and operably linked to an open reading frame (ORF) and (b) a plurality of binding sites for one or more transcription factors (TFs), wherein said one or more TFs are expressed at higher levels or more active in cancer cells compared to non-cancer cells. In some embodiments, the recombinant polynucleotide further comprises a plurality of enhancers.

[0199] In some embodiments, said plurality of enhancers are derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells. In some embodiments, said plurality of enhancers are derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells, wherein one of said plurality of enhancers comprises: (i) a transcription regulatory element with at least 90% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes, and/or (ii) a sequence capable of binding a transcription associated protein as determined by chromatin immunoprecipitation (ChIP) or an in vitro transfection reporter assay.

[0200] In some aspects, provided herein is a recombinant polynucleotide comprising: (a) a core promoter comprising a transcription start site (TSS), wherein the core promoter is derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells and operably linked to an open reading frame (ORF) and (b) a plurality of enhancers. In some embodiments, said plurality of enhancers are derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells. In some embodiments, said plurality of enhancers are derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells, wherein one of said plurality of enhancers comprises: (i) a transcription regulatory element with at least 90% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes, and/or (ii) a sequence capable of binding a transcription associated protein as determined by chromatin immunoprecipitation (ChIP) or an in vitro transfection reporter assay.

[0201] In some aspects, provided herein, is a recombinant polynucleotide comprising: (a) a core promoter comprising a transcription start site (TSS), wherein the core promoter is derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells and operably linked to an open reading frame (ORF), (b) a plurality of binding sites for one or more transcription factors (TFs), wherein said one or more TFs are expressed at higher levels or more active in cancer cells compared to non-cancer cells, and (c) a plurality of enhancers. In some embodiments, said plurality of enhancers are derived from one or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells. In some embodiments, said plurality of enhancers are derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells, wherein one of said plurality of enhancers comprises: (i) a transcription regulatory element with at least 90% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes, and/or (ii) a sequence capable of binding a transcription associated protein as determined by chromatin immunoprecipitation (ChIP) or an in vitro transfection reporter assay.

[0202] In some embodiments, said core promoter further comprises two or more promoter elements derived from two or more cancer-responsive genes that are either expressed at a higher level or are more active in cancer cells compared to non-cancer cells and operably linked to an open reading frame (ORF). In some embodiments, said one or more cancer-responsive genes are derived from a human subject. In some embodiments, (a) said core promoter, and (b) said plurality of binding sites for one or more TFs or said plurality of enhancers derived from one or more cancer-responsive genes are not derived from a same cancer-responsive gene. In some embodiments, said enhancer consensus sequence of two or more homologous cancer-responsive genes is a consensus sequence of an enhancer sequence derived from two or more cancer-responsive genes that has at least 90% sequence identity between two or more human cancer-responsive genes.

[0203] In some embodiments, the recombinant polynucleotide comprises (a) a plurality of binding sites for one or more transcription factors (TFs), wherein one or more TFs are expressed in higher levels or more active in cancer cells compared to non-cancer cells and (b) a plurality of enhancers derived from two or more cancer-responsive genes, wherein each of said plurality of enhancers comprising: (i) a transcription regulatory element with at least 90% sequence homology to an enhancer consensus sequence of two or more homologous cancer-responsive genes, and/or (ii) a sequence capable of binding a transcription associated protein as determined by chromatin immunoprecipitation (ChIP) or an in vitro transfection reporter assay.

[0204] In some embodiments, at least one of the plurality of enhancers comprises a CpG island. In some embodiments, at least one of the plurality of enhancers does not comprise a CpG island. In some embodiments, said higher levels of TF expression in cancer cells compared to non-cancer cells is determined by chromatin immunoprecipitation (ChIP).

[0205] In some embodiments, the recombinant polynucleotide further comprises an open reading frame (ORF), wherein said core promoter is operably linked to said ORF. In some embodiments, said plurality of binding sites for one or more TFs are 5′ to said core promoter. In some embodiments, said plurality of enhancers are 5′ to said core promoter and 3′ to said plurality of binding sites for one or more TFs, if present. In some embodiments, said plurality of binding sites for one or more TFs comprises two or more binding sites for one TF, wherein each of the plurality of binding sites for one or more TFs is sequentially arranged at 5′ to said core promoter in the recombinant polynucleotide. In some embodiments, said plurality of binding sites for one or more TFs comprises two or more binding sites for two or more TFs, wherein each of the plurality of binding sites for one or more TFs is non-sequentially arranged at 5′ to said core promoter in the recombinant polynucleotide.

[0206] In some embodiments, said plurality of binding sites for one or more TFs comprise a plurality of TRPS1, MNX1, TWIST1, ETV4, FOSL2, NFIC, EN2, TFDP1, PITX2, TCF7L1, VENTX, HOXB9, DLX1, MYCN, SIX4, TP63, SOX11, E2F8, TFDP1, SURV, TOXE1, EN1, ZBTB7B, SP3, SIX2, XBP1, HIF-1A, CREB3L1, HSF-1, MTF1, NFE2L2, USF2, TP73, USF2, POU2F2, HOXA1, FOXO1, TFAP4, BACH1, E2F4, HOXC10, KLF11, FOXM1, E2F2, RUNX1, SOX4, RREB1, ETV4, HES6, ASCL1, TWIST1, FOXA3, PITX2, HOXB2, EN2, DLX4, GRHL1, FOXA, HIF, E2F6, FOSL1, NF-1, RFX6, EL4, or NFκB TF binding sites.

[0207] In some embodiments, the recombinant polynucleotide further comprises a spacer element comprising 1-10 nucleotides between each of plurality of binding sites for one or more TFs. In some embodiments, said one or more cancer-responsive genes from which said core promoter is derived comprises TCF7, MNX1, HOXC10, TP53, CEACAM5, CEP55, FAM111B, CST1, BIRC5, FOS, TWIST1, E2F2, KIF20A, or ETV4. In some embodiments, said one or more cancer-responsive genes from which said core promoter is derived comprise two or more of TCF7, MNX1, HOXC10, TP53, CEACAM5, CEP55, FAM111B, CST1, BIRC5, FOS, TWIST1, E2F2, KIF20A, or ETV4. In some embodiments, said one or more cancer-responsive genes from which said core promoter is derived comprise TCF7 and HOXC10. In some embodiments, said one or more cancer-responsive genes from which said core promoter is derived comprise TP53 and CEP55. In some embodiments, said one or more cancer-responsive genes from which said core promoter is derived comprise FAM111B and KIF20A. In some embodiments, said one or more cancer-responsive genes from which said core promoter is derived comprise BIRC5 and E2F2. In some embodiments, said one or more cancer-responsive genes from which said core promoter is derived comprise CEACAM5 and TWIST1. In some embodiments, said core promoter comprises a region from about −300 bp to +100 bp relative to said TSS.

[0208] In some embodiments, said plurality of enhancers comprises at least two enhancer sequences, wherein each of said at least two enhancer sequences comprises (i) the same enhancer sequences, (ii) different enhancer sequences, or (iii) a combination thereof. In some embodiments, each of said at least two enhancer sequences is sequentially arranged at 5′ to said core promoter in the recombinant polynucleotide. In some embodiments, each of said at least two enhancer sequences is sequentially arranged at 5′ to said core promoter and at 3′ to said plurality of binding sites for one or more TFs, if present, in the recombinant polynucleotide. In some embodiments, each of said at least two enhancer sequences comprises (ii), wherein each of said plurality of enhancers comprising different enhancer sequences is non-sequentially arranged at 5′ to said core promoter in the recombinant polynucleotide. In some embodiments, each of said at least two enhancer sequences comprises (ii), wherein each of said plurality of enhancers is non-sequentially arranged at 5′ to said core promoter and at 3′ to said plurality of binding sites of one or more TF binding sites, if present, in the recombinant polynucleotide. In some embodiments, each of said at least two enhancer sequences comprises (iii), wherein each of said plurality of enhancers comprising a combination of the same and different enhancer sequences is non-sequentially arranged at 5′ to said core promoter in the recombinant polynucleotide. In some embodiments, each of said at least two enhancer sequences comprises (iii), wherein each of said plurality of enhancers comprising a combination of the same and different enhancer sequences is non-sequentially arranged at 5′ to said core promoter and at 3′ to said plurality of binding sites for one or more TFs, if present, in the recombinant polynucleotide. In some embodiments, said plurality of enhancers comprises at least two EBS, C/EBP, ARE, DRE, NFκB, GC-box, UN5CL, BOP1, RTN4RL2, ARNTL2, AGR2, LHX2, TRNP1, MU5AC, or DOK4 enhancer sequences.

[0209] In some embodiments, expression of said ORF is increased when said recombinant polynucleotide is introduced to cancer cells compared to non-cancer cells. In some embodiments, expression of said ORF is increased in a first plurality of cancer cells when said recombinant polynucleotide is introduced to said first plurality of cancer cells compared to a second plurality of cancer cells, wherein said first plurality of cancer cells and said second plurality of cancer cells are different types of cancer cells. In some embodiments, said cancer cells comprise malignant cancer cells. In some embodiments, said cancer cells comprise lung cancer cells, colorectal cancer cells, breast cancer cells, or hepatocellular carcinoma cells. In some embodiments, said cancer cells comprise cells associated with colorectal cancer, hepatocellular carcinoma, lung cancer, liver cancer, breast cancer, prostate cancer, cervix cancer, uterus cancer, pancreas cancer, kidney cancer, stomach cancer, bladder cancer, ovary cancer, brain cancer, head and neck cancer, eye cancer, mouth cancer, throat cancer, esophagus cancer, chest cancer, bone cancer, rectum or other gastrointestinal tract organ cancer, spleen cancer, skeletal muscle cancer, subcutaneous tissue cancer, testicles or other reproductive organ cancer, skin cancer, thyroid cancer, blood cancer, or lymph nodes cancer. In some embodiments, said cancer cells comprise cells associated with two or more cancers comprising colorectal cancer, hepatocellular carcinoma, lung cancer, liver cancer, breast cancer, prostate cancer, cervix cancer, uterus cancer, pancreas cancer, kidney cancer, stomach cancer, bladder cancer, ovary cancer, brain cancer, head and neck cancer, eye cancer, mouth cancer, throat cancer, esophagus cancer, chest cancer, bone cancer, rectum or other gastrointestinal tract organ cancer, spleen cancer, skeletal muscle cancer, subcutaneous tissue cancer, testicles or other reproductive organ cancer, skin cancer, thyroid cancer, blood cancer, or lymph nodes cancer.

[0210] In some embodiments, said core promoter, said plurality of binding sites for one or more transcription factors (TFs), said plurality of enhancers, or said recombinant polynucleotide comprises a sequence from Table 1A, Table 1B, or Table 1C.

[0211] In some aspects, provided herein is a recombinant polynucleotide comprising any of the sequences from Table 1A, Table 1B, or Table 1C.

[0212] In some aspects, provided herein is a recombinant polynucleotide comprising a human alpha-fetoprotein (AFP) promoter sequence comprising a plurality of HNF-1A TF binding sites, wherein each HNF-1A binding site comprises the sequence 5′-GTTAATTATTAAC-3′ (SEQ ID NO: 128).

[0213] In some aspects, provided herein is a vector comprising any of the recombinant polynucleotide described herein. In some aspects, provided herein is a pharmaceutical composition comprising any of the recombinant polynucleotide described herein or any the vector described herein and a pharmaceutically acceptable excipient, carrier, or diluents. In some aspects, provided herein is a lipid nanoparticle (LNP) comprising any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the pharmaceutical composition described herein. In some aspects, provided herein is a cell comprising any the recombinant polynucleotide described herein, any of the vector described herein, any of the pharmaceutical composition described herein, or any of the LNP described herein.

[0214] In some aspects, provided herein is a method of selectively expressing a reporter protein in a cancer or tumor cell, comprising contacting said tumor cell with any of the recombinant polynucleotide described herein, any of the vector described herein, any of the pharmaceutical composition described herein, or any of the LNP described herein, wherein the recombinant polynucleotide further comprises an open reading frame (ORF) encoding said reporter protein, wherein said ORF is operatively linked to said synthetic promoter.

[0215] In some aspects, provided herein is a method comprising: (a) administering to a subject any of the pharmaceutical composition described herein; or a composition any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the LNP described herein; wherein the recombinant polynucleotide further comprises an open reading frame (ORF) encoding a reporter protein, wherein said ORF is operatively linked to a synthetic promoter in said recombinant polynucleotide, and (b) detecting said reporter protein, wherein said pharmaceutical composition or said composition induces expression of said reporter protein preferentially in diseased cells in said subject compared to in non-disease cells, and wherein a relative ratio of said reporter protein expressed in said diseased cells over said non-diseased cells is greater than 1.0. In some embodiments, said relative ratio of said reporter protein expressed in said diseased cells over said non-diseased cells is greater than 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, or about 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, 90.0, 95.0, or about 100.0.

[0216] In some aspects, provided herein is a method for treating a subject having or suspected of having a disease, comprising administering to said subject any of the pharmaceutical composition described herein; or a composition any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the LNP described herein; wherein the recombinant polynucleotide further comprises an open reading frame (ORF) encoding a therapeutic protein, wherein said ORF is operatively linked to a synthetic promoter in said recombinant polynucleotide, wherein said pharmaceutical composition or said composition induces expression of said therapeutic protein preferentially in diseased cells in said subject compared to in non-disease cells, and wherein a relative ratio of said therapeutic protein expressed in said diseased cells over said non-diseased cells is greater than 1.0.

[0217] In some embodiments, said diseased cells comprise a cancer or tumor cell. In some embodiments, said cancer or tumor cell is associated with colorectal cancer (CRC), hepatocellular carcinoma, lung cancer, liver cancer, breast cancer, prostate cancer, cervix cancer, uterus cancer, pancreas cancer, kidney cancer, stomach cancer, bladder cancer, ovary cancer, brain cancer, head and neck cancer, eye cancer, mouth cancer, throat cancer, esophagus cancer, chest cancer, bone cancer, rectum or other gastrointestinal tract organ cancer, spleen cancer, skeletal muscle cancer, subcutaneous tissue cancer, testicles or other reproductive organ cancer, skin cancer, thyroid cancer, blood cancer, or lymph nodes cancer.

[0218] In some aspects, provided herein is a method comprising: (a) administering to a subject any of the pharmaceutical composition described herein; or a composition any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the LNP described herein; wherein the recombinant polynucleotide further comprises an open reading frame (ORF) encoding a reporter protein, wherein said ORF is operatively linked to a synthetic promoter in said recombinant polynucleotide, and (b) localizing a tumor or an absence thereof in a body of said subject via expression of said reporter protein using an imaging technique performed on said body of said subject.

[0219] In some aspects, provided herein is a method comprising: (a) introducing to a subject suspected of having a cancer via intravenous administration any of the pharmaceutical composition described herein; or a composition any of the recombinant polynucleotide described herein, any of the vector described herein, or any of the LNP described herein; wherein said recombinant polynucleotide further comprises an open reading frame (ORF) encoding a reporter protein, wherein said ORF is operatively linked to a synthetic promoter in said recombinant polynucleotide, and (b) detecting said reporter protein from said subject.

[0220] In some aspects, provided herein is a method comprising: (a) introducing to a subject suspected of having a cancer via intravenous administration a plurality of recombinant polynucleotides, wherein: said plurality of recombinant polynucleotides comprises a plurality of different promoters of genes overexpressed in a tumor cell versus a normal tissue or functional fragments thereof operably linked to genes encoding reporter proteins, wherein said plurality of different promoters of genes overexpressed in said tumor cell versus said normal tissue drive expression of said corresponding reporter proteins in a cell affected by said cancer, wherein said DNA molecules are selected from the group consisting of nanoplasmids and linear double-stranded DNA molecules; and (b) detecting said reporter proteins from said subject.

[0221]

TABLE 1A
Sequences of engineered promoters according to the disclosure
SEQ	EA
ID	RLI.
NO:	ID	Name	Regulatory element sequence (nucleotide)
1	PL1	1-	ggcctaactggccggtaccacatcggctatgctgctgctatgcgagcgtcagtattt
	009	TRPS1_	tatctttgatcagctattttatctttagtatcgtattttatctttctcatcgtattt
		v22-	tatctttatccgattattttatctttcagcagttattttatctttggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
2	PL1	2-	ggcctaactggccggtaccagctcatgcctatccgattagcttatcttttgaccaga
	010	TRPS1_	gctagcttatctttctaactcgcatagcttatcttttgcaagctactagcttatctt
		v9-	tcgatgctcattagcttatctttagacgtactctagcttatctttggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
3	PL1	3-	ggcctaactggccggtaccatcactgctgaggtacagatgcacgatgtagctgagcg
	011	MNX1_v	acagtatagtgcacagtgagtcattatgatacgtgtcattatcaccattgtcattat
		18-	tagacgtgtcattatctgctatgtcattatgctacaggtcattatggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
4	PL1	4-	ggcctaactggccggtacccagcagtcattatacgtcgcctaaatcgagatgctgta
	012	TWIST1_	ctgatctatattccagatgttttcaattccagatgttttacattccagatgttttac
		v3-	attccagatgtttctcattccagatgttttgaattccagatgtttggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
5	PL1	5-	ggcctaactggccggtaccctgagcgacagtatagtgcacagtgacattacagatgt
	013	TWIST1_	ttacgacgaattacagatgtttctcatcgattacagatgtttcagctcaattacaga
		v18-	tgtttgctgctgattacagatgtttaccagagattacagatgtttggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
6	PL1	6-	ggcctaactggccggtacccgatgtagctgagcgacagtatagtgcacagtgactgc
	014	HOXA1_	agcagtcattatacgtcgcctaaatcgagatgctgtactgatctataaggatcggta
		v8-	atgacgtaatgacgtaatgacgtaatgacgtaatgacgtaatgacggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
7	PL1	7-	ggcctaactggccggtaccagctgagcgacagtatagtgcacagtgactgcagcagt
	015	HOXC10_	cattatacgtcgcctaaatcgagatgctgtactgatctataagtcgtaaactgtcgt
		v24-	aaactgtcgtaaactgtcgtaaactgtcgtaaactgtcgtaaactggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
8	PL1	8-	ggcctaactggccggtacctgtagctgagcgacagtatagtgcacagtgactgcagc
	016	HOXC10_	agtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcgtaaattagcgac
		v14-	agtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaattggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
9	PL1	9-	ggcctaactggccggtaccatccgatgtgcctgacgaactcatttctaatctatcga
	017	GATA1_	tgtagctttctaatctatgcagtcattattctaatctattcgcaatctattctaatc
		v1-	tatcttctaactcttctaatctattgctacagctttctaatctatggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
10	PL1	10-	ggcctaactggccggtaccgcacagtgactgcagcagtcattatacgtcgcctaaat
	018	NFIC_v1	cgagatgctgtactgatctatttcttggcagatgattcttggcagatcgttcttggc
		5-	agagcattcttggcagaggtttcttggcagactcttcttggcagaggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
11	PL1	11-	ggcctaactggccggtaccgtgcaccattagtacctgatcagcgatgctcatctcga
	019	EN2_v7-	cctgatcggtacaacttctcacggaggcttctaactcgccgcaattataacgcaatt
		coreBIR	attccgcaattactacgcaattacctcgcaattaactcgcaattaggtacctgcgct
			cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
12	PL1	12-	ggcctaactggccggtaccacatcggctatgctgctgctaatgccacgtcaccacat
	020	CREB3L	cgacatgccacgtcaccatcatgccatgccacgtcaccactgcaagatgccacgtca
		1_v6-	ccacagtataatgccacgtcaccaagttactatgccacgtcaccaggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
13	PL1	13-	ggcctaactggccggtaccccccaaatcaccccccccccaccgtaaagtccccaaat
	021	RREB1_	caccccccccccaaggtaagacccccaaatcacccccccccccgtcgcctaacccca
		v17-	aatcacccccccccctactctgctcccccaaatcaccccccccccggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
14	PL1	14-	ggcctaactggccggtaccgaccgtaaagtggtgtgcaccattgaaacttgagctta
	022	SIX4_v9	caccatcgaaacttgagcgtatcgcatcgaaacttgagcggtacagatggaaacttg
		coreBIR	agcaccattagtagaaacttgagcagcgacagtagaaacttgagcggtacctgcgct
		C5-	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		FLUC	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
			aatccggtactgttggtaaagccacc
15	PL1	15-	ggcctaactggccggtacctgcacagtgactgcagcagtcgggcgtgcgctcccgac
	023	SURV_v	tagcccagggcgtgcgctcccgactagccccgggcgtgcgctcccgactagccctgg
		11-	gcgtgcgctcccgactagccccgggcgtgcgctcccgactagcccggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
16	PL1	16-	ggcctaactggccggtaccaggatcgactagaagtcgcagattagacgacgatacgt
	024	TCF7_v3	actactctgctcctagacgtatcctttgatgtaaatcctttgatgtcaatcctttga
		coreBIR	tgttaatcctttgatgttagtcctttgatgtctgtcctttgatgtggtacctgcgct
		C5-	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		FLUC	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
			aatccggtactgttggtaaagccacc
17	PL1	17-	ggcctaactggccggtacctgagcgacagtatagtgcacagtgactgcagcagtcat
	025	TCF7L1_	tatacgtcgcctaaaagacatcaaaggtccagacatcaaaggtacagacatcaaagg
		v19-	ggaagacatcaaagggacagacatcaaaggtgcagacatcaaaggggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
18	PL1	18-	ggcctaactggccggtaccatgcacgatgtagctgagaaacatcaaaggacgcaacg
	026	TCF7L1_	ccaaacatcaaaggagcctacacgaaacatcaaagggacgctgctaaaacatcaaag
		v5-	gctacacgaccaaacatcaaagggccttacaccaaacatcaaaggggtacctgcgct
		coreBIR	cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
		C5-	gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
		FLUC	aatccggtactgttggtaaagccacc
19	PL1	CREB3L	GAATTCTAGTGCACAGTGACTGCAGCAATGCCACGTCAACATCATGCCATGCCACGT
	030	1_v14	CAACACCTACACATGCCACGTCAACAACCAGAGATGCCACGTCAACACTAGCATATG
			CCACGTCAACATAAGGATATGCCACGTCAACAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
20	PL1	EN2_v7	GAATTCGTGCACCATTAGTACCTGATCAGCGATGCTCATCTCGACCTGATCGGTACA
	031		ACTTCTCACGGAGGCTTCTAACTCGCCGCAATTATAACGCAATTATTCCGCAATTAC
			TACGCAATTACCTCGCAATTAACTCGCAATTAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
21	PL1	ETV4_v	ggcctaacgaattcgacgctgctacagctcagcctacacgaccgtaaagtggtgtgc
	032	14	acaccggaaatgagtatagaccggaaatggccttacaccggaaatgcagctcaaccg
			gaaatgactgcagaccggaaatgcgctgctaccggaaatgggtacctgcgctcccga
			catgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcaga
			ggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatcc
			ggtactgttggtaaagccaccatggtggcc
22	PL1	ETV4_v	ggcctaactggccgaattctgagcgacagtatagtgcacagtgactgcagcagtcat
	033	2	tatacgtaccggaagtgtgtgcctaccggaagtgctatgcgaccggaagtgtagacg
			aaccggaagtgcagattaaccggaagtggctgctaaccggaagtgggtacctgcgct
			cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
			gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
			aatccggtactgttggtaaagccacc
23	PL1	MYCN	GAATTCGTGCACCATTAGTACCTGATCAGCGATGCTCATCTCGACCTGATCGGTACA
	034	v22	ACTTCTCACGGAGGCTTCTAACTCGCCGCAATTATAACGCAATTATTCCGCAATTAC
			TACGCAATTACCTCGCAATTAACTCGCAATTAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
24	PL1	PAX8_v	GAATTCGTCATTATACGTCGCGTCATGCATGACTGCCTGAGCGGTCATGCATGACTG
	035	18	CTACTCAAGTCATGCATGACTGCGACCAGAGTCATGCATGACTGCCGCCTAAGTCAT
			GCATGACTGCCTCTGCTGTCATGCATGACTGCGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
25	PL1	PITX2_v	GAATTCAAGTCGCAGATTAGACGACGATACGTACTACTCTGCTCCTAGACGTACTCA
	036	22	AGTATATTAATCCAGTGACCATTAATCCACTCATGCTTAATCCAATAACTGTTAATC
			CAGTATCGCTTAATCCACTACAGCTTAATCCAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
26	PL1	SIX2_v7	ggcctaactggccgaattccagatgcacgatgtagctgagcgacagtaaactgtaac
	037		ctgatacagcaactgtaacctgataccctaactgtaacctgatacgataactgtaac
			ctgatacaaaaactgtaacctgatacggcaactgtaacctgatacggtacctgcgct
			cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
			gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
			aatccggtactgttggtaaagccacc
27	PL1	SOX11_	ggcctaactggccgaattcgactgcagcagtcattatacgtcgcctaaatcggagaa
	038	v2	caaaggatggtgtggagaacaaaggataactgagagaacaaaggaaggatcggagaa
			caaaggaactgctggagaacaaaggatatagtggagaacaaaggaggtacctgcgct
			cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
			gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
			aatccggtactgttggtaaagccacc
28	PL1	TCF7_v2	ggcctaactggccgaattcctgagcgacagtatagtgcacagtgactgcagcagtca
	039		ttcctttgatgtacgcaactcctttgatgtctatgcgtcctttgatgttaaggattc
			ctttgatgtaggtacatcctttgatgtccgtaaatcctttgatgtggtacctgcgct
			cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
			gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
			aatccggtactgttggtaaagccacc
29	PL1	TCF7_v3	GAATTCAGGATCGACTAGAAGTCGCAGATTAGACGACGATACGTACTACTCTGCTCC
	040		TAGACGTATCCTTTGATGTAAATCCTTTGATGTCAATCCTTTGATGTTAATCCTTTG
			ATGTTAGTCCTTTGATGTCTGTCCTTTGATGTGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
30	PL1	TFDP1_	ggcctaactggccgaattccaagactgcaagctacgtgtgaccagagccgataactg
	041	v6	agggcgggaacgcgcaacggggcgggaacgatgctgtggggggaacgacagctcgg
			gcgggaacgctctgctggggggaacggctcctagggcgggaacgggtacctgcgct
			cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
			gcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
			aatccggtactgttggtaaagccacc
31	PL1	E2F7_v1	GAATTCAGGATCGACTAGAAGTCGCAGATTAGACGACGATACGTACTACTCTGCTCC
	042	1	TAGACGTATCCTTTGATGTAAATCCTTTGATGTCAATCCTTTGATGTTAATCCTTTG
			ATGTTAGTCCTTTGATGTCTGTCCTTTGATGTGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
32	PL1	E2F7_v1	GAATTCAGGTAAGTTTCCCGCCAAAATGTGACCAGAGTTTCCCGCCAAAATGACGAA
	043	3	CTCGTTTCCCGCCAAAAATGTAGCTGAGTTTCCCGCCAAAACATAGTTACTGTTTCC
			CGCCAAAACCTAAATCGAGTTTCCCGCCAAAAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
33	PL1	FOXA3_	GAATTCTGCTATGCGAGCGTCAGCTCATGCCTATCCGATGTGCCTATGTAAACATAA
	044	v2	GAGCCGATGTAAACATATAAGGATATGTAAACATATAGACGAATGTAAACATAGAGG
			TACATGTAAACATAACACGACATGTAAACATAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
34	PL1	GLIS3_v	GAATTCTACAGCTCAGCCTACACGACCGTAAAGTGGTGTGCACCATTGACCCCCCAC
	045	7	AAAGCAGGACCCCCCACAAAGCGAGACCCCCCACAAAGGACGACCCCCCACAAAGCC
			TGACCCCCCACAAAGAGTGACCCCCCACAAAGGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
35	PL1	GLIS3_v	GAATTCAAGGTAGACCCCCCACTAAGCTCAAGTATAGACCCCCCACTAAGATAGTGC
	046	9	ACAGACCCCCCACTAAGTATCCGATGTGACCCCCCACTAAGCGCAACGCCTGACCCC
			CCACTAAGTCCTAGACGTGACCCCCCACTAAGGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
36	PL1	HOXC9_	GAATTCAACTGAGTATCGCATCGCTCAAGATCAGTGGTCATAAATTAGCAGTCATTG
	047	v21	TCATAAATTCCTGATCGGTGTCATAAATTGCCTAAATCGGTCATAAATTCAGCTCAT
			GCGTCATAAATTACGCTGCTACGTCATAAATTGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
37	PL1	NR2F6_	GAATTCAGTATAGTGCACAGTGACTGCAGCAGTCATTATACGTCGCCGGGGTCAAAG
	048	v11	GTCACCAGGGGTCAAAGGTCATCTGGGGTCAAAGGTCATTAGGGGTCAAAGGTCATA
			GGGGGTCAAAGGTCACGAGGGGTCAAAGGTCAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
38	PL1	NR2F6_	AATTCACATCGGCTATGCTGCTGCTACAGGTCAAAGGTCATTAGACGCAGGTCAAAG
	049	v18	GTCACACAGTGCAGGTCAAAGGTCAAGGTACACAGGTCAAAGGTCACTGACGACAGG
			TCAAAGGTCACTCATCTCAGGTCAAAGGTCAGGTACCTGCGCTCCCGACATGCCCCG
			CGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCTA
			GCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGTT
			GGTAAAGCCACC
39	PL1	E2F3_v1	GAATTCTGCACCATTAGTACCTGATCAGCGATGCTATTTTGGCGCCCAAATCATATT
	050	1	TTGGCGCCCAAATGACATTTTGGCGCCCAAATACAATTTTGGCGCCCAAATACGATT
			TTGGCGCCCAAATAGCATTTTGGCGCCCAAATGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
40	PL1	E2F4_v2	GAATTCGGTACAACTTCTCACGGAGGCTTTTGGCGCCATTTCGACGATTTTTGGCGC
	051		CATTTACTCAAGTTTTGGCGCCATTTTAGTGCATTTTGGCGCCATTTCGCAATCTTT
			TGGCGCCATTTGGAGGCTTTTTGGCGCCATTTGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
41	PL1	EN2_v6	GAATTCACGATACGTACTACTCTGCTCCTAGACGTACTCAAGTATAAGGTAAGACAT
	052		AGTTACCGCAATTATAAGACACGCAATTACTAGAAGCGCAATTAACGTCGCCGCAAT
			TAGACTGCACGCAATTAGAATCTCCGCAATTAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
42	PL1	FOXK1_	GAATTCAAGTATAATGTAAACACGGCAGCATCGTCCAATGTAAACACGGCAAGACAT
	053	v9	AGTAATGTAAACACGGCTCTCACGGAGAATGTAAACACGGCCTAGCATCGTAATGTA
			AACACGGCGATGCTCATCAATGTAAACACGGCGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
43	PL1	GRHL1_	GAATTCAAGTCGCAGATTAGACGAAAAACCGGTTATGACGTACTCAAAAACCGGTTA
	054	v5	TGAGATGCTGTAAAACCGGTTATTCCGACGCAAAAAACCGGTTATACGAACTCATAA
			AACCGGTTATAGCTCAGCCTAAAACCGGTTATGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
44	PL1	HOXB9_	GAATTCTGACTGCAGCAGTCATTATACGTCGCCTAAATCGAGATGCTGTACGTCGTA
	055	v6	AATTCACGACCGTCGTAAATTCGATAACGTCGTAAATTCTAGCATGTCGTAAATTTG
			CAGCAGTCGTAAATTAGATTAGGTCGTAAATTGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
45	PL1	MNX1_v	GAATTCATTAGACGACGATACGTACTACTCTGCTCCTAGACGTACTCAAGTATAAGG
	056	10	TAAGACGCAATTATTGCACAGGCAATTATTCAGCCTGCAATTATCTACAGCGCAATT
			ATCTGATCAGCAATTATGATACGTGCAATTATGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
46	PL1	MYC_v2	GAATTCACTCTGCTCCTAGACGTACTCAAGTATAAGGTAGGACACGTGCCCGATGCA
	057	2	CGGACACGTGCCCCCGTAAAGGACACGTGCCCTAAATCGGGACACGTGCCCTAGACG
			TGGACACGTGCCCGACTAGAGGACACGTGCCCGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
47	PL1	OTX1_v	GAATTCCACAGTGACTGCAGCAGTCATTATACGTCGCCTAAATCGAGATGCTGTACT
	058	14	GATCTATTAAGCCGCGTACTCTTAAGCCGGTCATTATTAAGCCGCTATAAGTTAAGC
			CGCAACGCCTTAAGCCGACGACCGTTAAGCCGGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
48	PL1	PITX2_v	GAATTCTCGGCTATGCTGCTGCTATGCGAGCGTCAGCTCATGCCTATCCGATGTGCC
	059	19	TGACGAACTCATCGACGCTGCTACAGCTAATCCTATGCTAATCCTAACCTAATCCTA
			CCCTAATCCTAGCCTAATCCTTGCCTAATCCTGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
49	PL1	RUNX1_	GAATTCTGTACTGATCTATAAGGATCGACTAGAAGTCGCAGATTAGTATGTGGTTTA
	060	v22	GTACCTGTATGTGGTTTTCGCAATGTATGTGGTTTATGCTGCGTATGTGGTTTAGCA
			GTCGTATGTGGTTTGAGCGTCGTATGTGGTTTGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
50	PL1	RUNX1_	GAATTCCTGCAGCAGTCATTATACGTCGCCTAAATCGAGATGCTGTACTGATCTATA
	061	v23	AGGATCGAGTATGTGGTTTATCGTATGTGGTTTGTAGTATGTGGTTTCTGGTATGTG
			GTTTTGTGTATGTGGTTTCCAGTATGTGGTTTGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
51	PL1	SHOX2_	GAATTCCACGATGTAGCTGAGCGACAGTATAGTGCACAGTGACTGCAGCCAATTAAC
	062	v5	TGACGAACTCCAATTAAATCAGTGATCCCAATTAATGCAAGCTACCCAATTAATATG
			CTGCTGCCAATTAACATCGGCTATCCAATTAAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
52	PL1	SHOX2_	GAATTCTTAGTACCTGATCAGCGATGCTCATCTCGACCTGATCGGTACTCAATTAAT
	063	v21	GTACTGATCTCAATTAAGTCGCCTAAATCAATTAACGTACTACTCTCAATTAAGATC
			GGTACATCAATTAAAAGTCGCAGATCAATTAAGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
53	PL1	SIX4_v2	GAATTCCTACGTGTGACCAGAGCCGATAACTGAGTATCGCATCGCTCAAGATCAGTG
	064	3	ATCACTGCGAAATTTGAGCCCTGAAATTTGAGCCGAGAAATTTGAGCGCTGAAATTT
			GAGCCACGAAATTTGAGCTTAGAAATTTGAGCGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
54	PL1	TCF7_v1	GAATTCGACCTGATCGGTACAACTTCTCACGGAGGCTTCTAACTCTCCTTTGATATA
	065	0	ACTCGCTCCTTTGATATAGCAGTCTCCTTTGATATCTCATCTTCCTTTGATATCTGT
			ACTTCCTTTGATATTGCTATGTCCTTTGATATGGTACCTGCGCTCCCGACATGCCCC
			GCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGGCAGAGGTGGGCT
			AGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGT
			TGGTAAAGCCACC
55	PL1	PL-	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	068	3XFOSL	ggtgatcatgctagcctcgaggatatcaagatcggtaccacctcttaacaatacgtt
		1-	tcacaaatagttaaaaacatgcatactgaaaagcatacttttgcaatgttattttta
		coreAGR	aaaacaaggaactctttaacccagggaagataatcacttggggaaaggaaggttcgt
		2_2	ttctgagttagcaacaagtaaatgcagcactagtgggtgggattgaggtgtgccctg
			gtgcataaatagagactcagctgtgctggcacactcagaagcttggaccgcatccta
			gccgccgactcacacaaggcaggtgggtgaggaaatccaggtaaggctcctgacagc
			agctttagaagggtacttgctggagtgaattcgggcctctgattaccggtgctagcc
			tcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggt
			aaagccacc
56	PL1	PL-	ggcctaactggccggtaccgatcttgatatcctcgaggctagcatgatcaccatgag
	069	revFOSL	tcacccatgagtcacccatgagtcacccatgagtcacccatgagtcacccatgagtc
		1-	acccatgagtcacccatgagtcacccatgagtcaccactagtggtaccacctcttaa
		coreAGR	caatacgtttcacaaatagttaaaaacatgcatactgaaaagcatacttttgcaatg
		2_2	ttatttttaaaaacaaggaactctttaacccagggaagataatcacttggggaaagg
			aaggttcgtttctgagttagcaacaagtaaatgcagcactagtgggtgggattgagg
			tgtgccctggtgcataaatagagactcagctgtgctggcacactcagaagcttggac
			cgcatcctagccgccgactcacacaaggcaggtgggtgaggaaatccaggtaaggct
			cctgacagcagctttagaagggtacttgctggagtgaattcgggcctctgattaccg
			gtgctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggt
			actgttggtaaagccacc
57	PL1	PL-	ggcctaactggccggtaccgattcttgatatcctcgaggctagcatgatcaccatga
	070	revFOSL	gtcacccatgagtcacccatgagtcacccatgagtcacccatgagtcacccatgagt
		1-	cacccatgagtcacccatgagtcacccatgagtcaccactagtggtaccgatcttga
		coreCST	tatcctcgaggctagcatgatcaccatgagtcacccatgagtcacccatgagtcacc
		1	catgagtcacccatgagtcacccatgagtcacccatgagtcacccatgagtcaccca
			tgagtcaccactagtggtaccagtggtgggggagtgaaaagagagatggagaaagag
			gggatgggcagaaagaggaggaggagtcaggggcagggcatggaggtgggtggggct
			gggctgccaaagcaggataaatgcacacctgcctgctggtctgggctccctgcctcg
			ggctctcaccctcctctcctgcagctccagctttgtgcttctaccggtgctagcctc
			gaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaa
			agccacc
58	PL1	PL-	ggcctaactggccggtaccactagtgacgtcaccggaagtaagaaccggaagtatcg
	071	ETV4-	accggaagtagacaccggaagtactaaccggaagtaactaccggaagtatgcaccgg
		coreCST	aagtagacgtctacgtaagtggtgggggagtgaaaagagagatggagaaagagggga
			tgggcagaaagaggaggaggagtcaggggcagggcatggaggtgggtggggctgggc
			tgccaaagcaggataaatgcacacctgcctgctggtctgggctccctgcctcgggct
			ctcaccctcctctcctgcagctccagctttgtgctctaccggtgctagcctcgagga
			tatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagcca
			CC
59	PL1	PL-	ggcctaactggccggtaccactagtgacgtcaccggaagtaagaaccggaagtatcg
	072	ETV4-	accggaagtagacaccggaagtactaaccggaagtaactaccggaagtatgcaccgg
		coreKIF	aagtagacgtctacgtaggcccgccccctttccttacgcggattggtagctgcaggc
			ttccctatctgattggccgaacgaacgcagcgcgtaatttaaaatattgtatctgta
			acaaagctgcacctcgtgggcggagttgtgctctgcggctgcgaaagtccagcttcg
			gcgactaggtgtgagtaagccagtatcccaggaggagcaagtggcacgtcttcgggt
			gagtgtgcggctgtgctggagcccgggttaccagctctttaccggtgctagcctcga
			ggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaag
			ccacc
60	PL1	PL-	ggcctaactggccggtacactagtgacgtcaccggaagtaagaaccggaagtatcga
	073	ETV4-	ccggaagtagacaccggaagtactaaccggaagtaactaccggaagtatgcaccgga
		coreAGR	agtagacgtctacgtacatactgaaaagcatacttttgcaatgttatttttaaaaac
		2	aaggaactctttaacccagggaagataatcacttggggaaaggaaggttcgtttctg
			agttagcaacaagtaaatgcagcactagtgggtgggattgaggtgtgccctggtgca
			taaatagagactcagctgtgctggcacactcagaagcttggaccgcatcctagccgc
			cgactcacacaaggcaggtgggtgaggaaatccaggtaaggctcctgacagcagctt
			tagaagggtacttgctggagtgaattcgggcctctgattactagcctcgaggatatc
			aagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
61	PL1	PL-	ggcctaactggccggtaccactagtgacgtcaccggaagtaagaaccggaagtatcg
	074	ETV4-	accggaagtagacaccggaagtactaaccggaagtaactaccggaagtatgcaccgg
		coreCEA	aagtagacgtctacgtaacccacgtgatgctgagaagtactcctgccctaggaagag
		CAM	actcagggcagagggaggaaggacagcagaccagacagtcacagcagccttgacaaa
			acgttcctggaactaccggtgctagcctcgaggatatcaagatctggcctcggcggc
			caagcttggcaatccggtactgttggtaaagccacc
62	PL1	PL-	GGCCTAACTGGCCGGTACCACTAGTGACGTCACCGGAAGTAAGAACCGGAAGTATCG
	075	ETV4-	ACCGGAAGTAGACACCGGAAGTACTAACCGGAAGTAACTACCGGAAGTATGCACCGG
		coreFA	AAGTAGACGTCTACGTACGGGAAAAGTTCAGCTGAGAGATATAAAAGAGCAGTCTTT
		M111B	CCAGCACCTGCAAATCCAGAGCGGCGGGCACTGACGGGCACTTGCACCGTGTGGACA
			GACTCTCCGGTTCTGTGAGTGGTTTTTCTTTTCCCGGGTCGGACCTGGAGTTCTTAG
			GGGGATGGCTGAACCGGTGCTAGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCA
			AGCTTGGCAATCCGGTACTGTTGGTAAAGCCACC
63	PL1	PL-	ggcctaactggccggtaccactagtgacgtcaccggaagtaagaaccggaagtatcg
	076	ETV4-	accggaagtagacaccggaagtactaaccggaagtaactaccggaagtatgcaccgg
		Twist_v1	aagtagacgtctacgtactgagcgacagtatagtgcacagtgacattacagatgttt
		8-	acgacgaattacagatgtttctcatcgattacagatgtttcagctcaattacagatg
		coreCST	tttgctgctgattacagatgtttaccagagattacagatgttttacgtaagtggtgg
			gggagtgaaaagagagatggagaaagaggggatgggcagaaagaggaggaggagtca
			ggggcagggcatggaggtgggtggggctgggctgccaaagcaggataaatgcacacc
			tgcctgctggtctgggctccctgcctcgggctctcaccctcctctcctgcagctcca
			gctttgtgctctaccggtgctagcctcgaggatatcaagatctggcctcggcggcca
			agcttggcaatccggtactgttggtaaagccacc
64	PL1	PL-	ACTAGTGACGTCACCGGAAGTAAGAACCGGAAGTATCGACCGGAAGTAGACACCGGA
	077	ETV4-	AGTACTAACCGGAAGTAACTACCGGAAGTATGCACCGGAAGTAGACGTCTACGTACT
		Twist_v1	GAGCGACAGTATAGTGCACAGTGACATTACAGATGTTTACGACGAATTACAGATGTT
		8-	TCTCATCGATTACAGATGTTTCAGCTCAATTACAGATGTTTGCTGCTGATTACAGAT
		coreKIF	GTTTACCAGAGATTACAGATGTTTTACGTAGGCCCGCCCCCTTTCCTTACGCGGATT
			GGTAGCTGCAGGCTTCCCTATCTGATTGGCCGAACGAACGCAGCGCGTAATTTAAAA
			TATTGTATCTGTAACAAAGCTGCACCTCGTGGGCGGAGTTGTGCTCTGCGGCTGCGA
			AAGTCCAGCTTCGGCGACTAGGTGTGAGTAAGCCAGTATCCCAGGAGGAGCAAGTGG
			CACGTCTTCGGGTGAGTGTGCGGCTGTGCTGGAGCCCGGGTTACCAGCTCTTtaccg
			gtgctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggt
			actgttggtaaagccacc
65	PL1	PL-	ggcctaactggccggtacactagtgacgtcaccggaagtaagaaccggaagtatcga
	078	ETV4-	ccggaagtagacaccggaagtactaaccggaagtaactaccggaagtatgcaccgga
		Twist_v1	agtagacgtctacgtactgagcgacagtatagtgcacagtgacattacagatgttta
		8-	cgacgaattacagatgtttctcatcgattacagatgtttcagctcaattacagatgt
		coreAGR	ttgctgctgattacagatgtttaccagagattacagatgttttacgtacatactgaa
		2	aagcatacttttgcaatgttatttttaaaaacaaggaactctttaacccagggaaga
			taatcacttggggaaaggaaggttcgtttctgagttagcaacaagtaaatgcagcac
			tagtgggtgggattgaggtgtgccctggtgcataaatagagactcagctgtgctggc
			acactcagaagcttggaccgcatcctagccgccgactcacacaaggcaggtgggtga
			ggaaatccaggtaaggctcctgacagcagctttagaagggtacttgctggagtgaat
			tcgggcctctgattactagcctcgaggatatcaagatctggcctcggcggccaagct
			tggcaatccggtactgttggtaaagccacc
66	PL1	PL-	ggcctaactggccggtaccactagtgacgtcaccggaagtaagaaccggaagtatcg
	079	ETV4-	accggaagtagacaccggaagtactaaccggaagtaactaccggaagtatgcaccgg
		Twist_v1	aagtagacgtctacgtactgagcgacagtatagtgcacagtgacattacagatgttt
		8-	acgacgaattacagatgtttctcatcgattacagatgtttcagctcaattacagatg
		coreFA	tttgctgctgattacagatgtttaccagagattacagatgttttacgtacgggaaaa
		M111B	gttcagctgagagatataaaagagcagtctttccagcacctgcaaatccagagcggc
			gggcactgacgggcacttgcaccgtgtggacagactctccggttctgtgagtggttt
			ttcttttcccgggtcggacctggagttcttagggggatggctgaaccggtgctagcc
			tcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggt
			aaagccacc
67	PL1	PL-	ggcctaactggccggtaccactagtgacgtcaccggaagtaagaaccggaagtatcg
	080	ETV4-	accggaagtagacaccggaagtactaaccggaagtaactaccggaagtatgcaccgg
		Twist_v1	aagtagacgtctacgtactgagcgacagtatagtgcacagtgacattacagatgttt
		8-	acgacgaattacagatgtttctcatcgattacagatgtttcagctcaattacagatg
		coreCEA	tttgctgctgattacagatgtttaccagagattacagatgttttacgtaacccacgt
		CAM	gatgctgagaagtactcctgccctaggaagagactcagggcagagggaggaaggaca
			gcagaccagacagtcacagcagccttgacaaaacgttcctggaactaccggtgctag
			cctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttg
			gtaaagccacc
68	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgagcgacagtatagtgca
	081	Twist_v1	cagtgacattacagatgtttacgacgaattacagatgtttctcatcgattacagatg
		8-	tttcagctcaattacagatgtttgctgctgattacagatgtttaccagagattacag
		coreCST	atgttttacgtaagtggtgggggagtgaaaagagagatggagaaagaggggatgggc
			agaaagaggaggaggagtcaggggcagggcatggaggtgggtggggctgggctgcca
			aagcaggataaatgcacacctgcctgctggtctgggctccctgcctcgggctctcac
			cctcctctcctgcagctccagctttgtgctctaccggtgctagcctcgaggatatca
			agatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
69	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgagcgacagtatagtgca
	082	Twist_v1	cagtgacattacagatgtttacgacgaattacagatgtttctcatcgattacagatg
		8-	tttcagctcaattacagatgtttgctgctgattacagatgtttaccagagattacag
		coreKIF	atgttttacgtaggcccgccccctttccttacgcggattggtagctgcaggcttccc
			tatctgattggccgaacgaacgcagcgcgtaatttaaaatattgtatctgtaacaaa
			gctgcacctcgtgggcggagttgtgctctgcggctgcgaaagtccagcttcggcgac
			taggtgtgagtaagccagtatcccaggaggagcaagtggcacgtcttcgggtgagtg
			tgcggctgtgctggagcccgggttaccagctctttaccggtgctagcctcgaggata
			tcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
70	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgagcgacagtatagtgca
	083	Twist_v1	cagtgacattacagatgtttacgacgaattacagatgtttctcatcgattacagatg
		8-	tttcagctcaattacagatgtttgctgctgattacagatgtttaccagagattacag
		coreAGR	atgttttacgtacatactgaaaagcatacttttgcaatgttatttttaaaaacaagg
		2	aactctttaacccagggaagataatcacttggggaaaggaaggttcgtttctgagtt
			agcaacaagtaaatgcagcactagtgggtgggattgaggtgtgccctggtgcataaa
			tagagactcagctgtgctggcacactcagaagcttggaccgcatcctagccgccgac
			tcacacaaggcaggtgggtgaggaaatccaggtaaggctcctgacagcagctttaga
			agggtacttgctggagtgaattcgggcctctgattagctagcctcgaggatatcaag
			atctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
71	PL1	PL-	ggcctaactggccggtaccactagtgacgtcctgagcgacagtatagtgcacagtga
	084	Twist_v1	cattacagatgtttacgacgaattacagatgtttctcatcgattacagatgtttcag
		8.2-	ctcaattacagatgtttgctgctgattacagatgtttaccagagattacagatgttt
		coreKIF	gacgtctacgtaggcccgccccctttccttacgcggattggtagctgcaggcttccc
			tatctgattggccgaacgaacgcagcgcgtaatttaaaatattgtatctgtaacaaa
			gctgcacctcgtgggcggagttgtgctctgcggctgcgaaagtccagcttcggcgac
			taggtgtgagtaagccagtatcccaggaggagcaagtggcacgtcttcgggtgagtg
			tgcggctgtgctggagcccgggttaccagctctttaccggtgctagcctcgaggata
			tcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
72	PL1	PL-	ggcctaactggccggtaccactagtgacgtcctgagcgacagtatagtgcacagtga
	085	Twist_v1	cattacagatgtttacgacgaattacagatgtttctcatcgattacagatgtttcag
		8.2-	ctcaattacagatgtttgctgctgattacagatgtttaccagagattacagatgttt
		coreCST	gacgtctacgtactgatcagcgatgctcatctcgacctgatcggtacaacttctcac
			ggaggcttctaagtcattacatacgtagtcattactatacgtgtcattacagatgct
			gtcattacacgaactgtcattacgtactcagtcattactacgtaagtggtgggggag
			tgaaaagagagatggagaaagaggggatgggcagaaagaggaggaggagtcaggggc
			agggcatggaggtgggtggggctgggctgccaaagcaggataaatgcacacctgcct
			gctggtctgggctccctgcctcgggctctcaccctcctctcctgcagctccagcttt
			gtgctctaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagctt
			ggcaatccggtactgttggtaaagccacc
73	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgagcgacagtatagtgca
	086	Twist_v1	cagtgacattacagatgtttacgacgaattacagatgtttctcatcgattacagatg
		8-	tttcagctcaattacagatgtttgctgctgattacagatgtttaccagagattacag
		coreFA	atgttttacgtacgggaaaagttcagctgagagatataaaagagcagtctttccagc
		M111B	acctgcaaatccagagcggcgggcactgacgggcacttgcaccgtgtggacagactc
			tccggttctgtgagtggtttttcttttcccgggtcggacctggagttcttaggggga
			tggctgaaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagctt
			ggcaatccggtactgttggtaaagccacc
74	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgagcgacagtatagtgca
	087	Twist_v1	cagtgacattacagatgtttacgacgaattacagatgtttctcatcgattacagatg
		8-	tttcagctcaattacagatgtttgctgctgattacagatgtttaccagagattacag
		coreCEA	atgttttacgtaacccacgtgatgctgagaagtactcctgccctaggaagagactca
		CAM	gggcagagggaggaaggacagcagaccagacagtcacagcagccttgacaaaacgtt
			cctggaactaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
75	PL1	PL-	ggcctaactggccggtaccactagtgacgtcctgagcgacagtatagtgcacagtga
	088	Twist_v1	cattacagatgtttacgacgaattacagatgtttctcatcgattacagatgtttcag
		8.2-	ctcaattacagatgtttgctgctgattacagatgtttaccagagattacagatgttt
		coreAGR	gacgtctacgtacatactgaaaagcatacttttgcaatgttatttttaaaaacaagg
		2	aactctttaacccagggaagataatcacttggggaaaggaaggttcgtttctgagtt
			agcaacaagtaaatgcagcactagtgggtgggattgaggtgtgccctggtgcataaa
			tagagactcagctgtgctggcacactcagaagcttggaccgcatcctagccgccgac
			tcacacaaggcaggtgggtgaggaaatccaggtaaggctcctgacagcagctttaga
			agggtacttgctggagtgaattcgggcctctgattagctagcctcgaggatatcaag
			atctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
76	PL1	PL-	ggcctaactggccggtaccactagtgacgtcctgagcgacagtatagtgcacagtga
	089	Twist_v1	cattacagatgtttacgacgaattacagatgtttctcatcgattacagatgtttcag
		8.2-	ctcaattacagatgtttgctgctgattacagatgtttaccagagattacagatgttt
		coreCEA	gacgtctacgtaacccacgtgatgctgagaagtactcctgccctaggaagagactca
		CAM	gggcagagggaggaaggacagcagaccagacagtcacagcagccttgacaaaacgtt
			cctggaactaccggtgctagcctcgaggatatcaagatctggcctcggggccaagc
			ttggcaatccggtactgttggtaaagccacc
77	PL1	PL-	ggcctaactggccggtaccactagtgacgtcctgagcgacagtatagtgcacagtga
	090	Twist_v1	cattacagatgtttacgacgaattacagatgtttctcatcgattacagatgtttcag
		8.2-	ctcaattacagatgtttgctgctgattacagatgtttaccagagattacagatgttt
		coreFA	gacgtctacgtacgggaaaagttcagctgagagatataaaagagcagtctttccagc
		M111B	acctgcaaatccagagcggcgggcactgacgggcacttgcaccgtgtggacagactc
			tccggttctgtgagtggtttttcttttcccgggtcggacctggagttcttaggggga
			tggctgaaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagctt
			ggcaatccggtactgttggtaaagccacc
78	PL1	PL-	ggcctaactggccggtaccactagtgacgtcctgagcgacagtatagtgcacagtga
	091	Twist_v1	cattacagatgtttacgacgaattacagatgtttctcatcgattacagatgtttcag
		8-	ctcaattacagatgtttgctgctgattacagatgtttaccagagattacagatgttt
		HOXA1_	gacgtctacgtactgatcagcgatgctcatctcgacctgatcggtacaacttctcac
		v10-	ggaggcttctaagtcattacatacgtagtcattactatacgtgtcattacagatgct
		coreKIF	gtcattacacgaactgtcattacgtactcagtcattactacgtaggcccgccccctt
			tccttacgcggattggtagctgcaggcttccctatctgattggccgaacgaacgcag
			cgcgtaatttaaaatattgtatctgtaacaaagctgcacctcgtgggcggagttgtg
			ctctgcggctgcgaaagtccagcttcggcgactaggtgtgagtaagccagtatccca
			ggaggagcaagtggcacgtcttcgggtgagtgtgcggctgtgctggagcccgggtta
			ccagctctttaccggtgctagcctcgaggatatcaagatctggcctcggcggccaag
			cttggcaatccggtactgttggtaaagccacc
79	PL1	PL-	ggcctaactggccggtaccacactagtgacgtcctgagcgacagtatagtgcacagt
	092	Twist_v1	gacattacagatgtttacgacgaattacagatgtttctcatcgattacagatgtttc
		8-	agctcaattacagatgtttgctgctgattacagatgtttaccagagattacagatgt
		HOXA1_	ttgacgtctacgtactgatcagcgatgctcatctcgacctgatcggtacaacttctc
		v10-	acggaggcttctaagtcattacatacgtagtcattactatacgtgtcattacagatg
		coreCST	ctgtcattacacgaactgtcattacgtactcagtcattactacgtacatactgaaaa
			gcatacttttgcaatgttatttttaaaaacaaggaactctttaacccagggaagata
			atcacttggggaaaggaaggttcgtttctgagttagcaacaagtaaatgcagcacta
			gtgggtgggattgaggtgtgccctggttaagtggtgggggagtgaaaagagagatgg
			agaaagaggggatgggcagaaagaggaggaggagtcaggggcagggcatggaggtgg
			gtggggctgggctgccaaagcaggataaatgcacacctgcctgctggtctgggctcc
			ctgcctcgggctctcaccctcctctcctgcagctccagctttgtgctctaccggtgc
			tagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactg
			ttggtaaagccacc
80	PL1	PL-	ggcctaactggccggtacaactagtgactcctttgatgtacgcaactcctttgatgt
	093	Twist_v1	ctatgcgtcctttgatgttaaggattcctttgatgtaggtacatcctttgatgtccg
		8-	taaatcctttgatgtggtaccgtctactacctgatcaaacatgcccggacatgtcgt
		HOXA1_	aagacataaacatgcccggacatgtcctcgcaatctaacatgcccggacatgtcctc
		v10-	gcaatctaacatgcccggacatgtctgcaagctacaacatgcccggacatgtcgtac
		coreAGR	tcagtcattactacgtacatactgaaaagcatacttttgcaatgttatttttaaaaa
		2	caaggaactctttaacccagggaagataatcacttggggaaaggaaggttcgtttct
			gagttagcaacaagtaaatgcagcactagtgggtgggattgaggtgtgccctggtgc
			ataaatagagactcagctgtgctggcacactcagaagcttggaccgcatcctagccg
			ccgactcacacaaggcaggtgggtgaggaaatccaggtaaggctcctgacagcagct
			ttagaagggtacttgctggagtgaattcgggcctctgattactagcctcgaggatat
			caagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
81	PL1	PL-	ggcctaactggccggtaccactagtgacgtcctgagcgacagtatagtgcacagtga
	094	Twist_v1	cattacagatgtttacgacgaattacagatgtttctcatcgattacagatgtttcag
		8-	ctcaattacagatgtttgctgctgattacagatgtttaccagagattacagatgttt
		HOXA1_	gacgtctacgtactgatcagcgatgctcatctcgacctgatcggtacaacttctcac
		v10-	ggaggcttctaagtcattacatacgtagtcattactatacgtgtcattacagatgct
		coreCEA	gtcattacacgaactgtcattacgtactcagtcattactacgtaacccacgtgatgc
		CAM	tgagaagtactcctgccctaggaagagactcagggcagagggaggaaggacagcaga
			ccagacagtcacagcagccttgacaaaacgttcctggaactaccggtgctagcctcg
			aggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaa
			gccacc
82	PL1	PL-	ggcctaactggccggtaccactagtgacgtcctgagcgacagtatagtgcacagtga
	095	Twist_v1	cattacagatgtttacgacgaattacagatgtttctcatcgattacagatgtttcag
		8-	ctcaattacagatgtttgctgctgattacagatgtttaccagagattacagatgttt
		HOXA1_	gacgtctacgtactgatcagcgatgctcatctcgacctgatcggtacaacttctcac
		v10-	ggaggcttctaagtcattacatacgtagtcattactatacgtgtcattacagatgct
		coreFA	gtcattacacgaactgtcattacgtactcagtcattactacgtacgggaaaagttca
		M111B	gctgagagatataaaagagcagtctttccagcacctgcaaatccagagcggcgggca
			ctgacgggcacttgcaccgtgtggacagactctccggttctgtgagtggtttttctt
			ttcccgggtcggacctggagttcttagggggatggctgaaccggtgctagcctcgag
			gatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagc
			cacc
83	PL1	PL-	ggcctaactggccggtaccactagtgacgtctgtagctgagcgacagtatagtgcac
	096	HOXC10_	agtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcg
		v14-	taaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaatt
		coreKIF	gacgtctacgtaggcccgccccctttccttacgcggattggtagctgcaggcttccc
			tatctgattggccgaacgaacgcagcgcgtaatttaaaatattgtatctgtaacaaa
			gctgcacctcgtgggcggagttgtgctctgcggctgcgaaagtccagcttcggcgac
			taggtgtgagtaagccagtatcccaggaggagcaagtggcacgtcttcgggtgagtg
			tgcggctgtgctggagcccgggttaccagctctttaccggtctagcctcgaggatat
			caagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
84	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgatcagcgatgctcatct
	097	HOXA1_	cgacctgatcggtacaacttctcacggaggcttctaagtcattacatacgtagtcat
		v10-	tactatacgtgtcattacagatgctgtcattacacgaactgtcattacgtactcagt
		coreCST	cattactacgtaagtggtgggggagtgaaaagagagatggagaaagaggggatgggc
			agaaagaggaggaggagtcaggggcagggcatggaggtgggtggggctgggctgcca
			aagcaggataaatgcacacctgcctgctggtctgggctccctgcctcgggctctcac
			cctcctctcctgcagctccagctttgtgctctaccggtgctagcctcgaggatatca
			agatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
85	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgatcagcgatgctcatct
	098	HOXA1_	cgacctgatcggtacaacttctcacggaggcttctaagtcattacatacgtagtcat
		v10-	tactatacgtgtcattacagatgctgtcattacacgaactgtcattacgtactcagt
		coreKIF	cattactacgtaggcccgccccctttccttacgcggattggtagctgcaggcttccc
			tatctgattggccgaacgaacgcagcgcgtaatttaaaatattgtatctgtaacaaa
			gctgcacctcgtgggcggagttgtgctctgcggctgcgaaagtccagcttcggcgac
			taggtgtgagtaagccagtatcccaggaggagcaagtggcacgtcttcgggtgagtg
			tgcggctgtgctggagcccgggttaccagctctttaccggtgctagcctcgaggata
			tcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
86	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgatcagcgatgctcatct
	099	HOXA1_	cgacctgatcggtacaacttctcacggaggcttctaagtcattacatacgtagtcat
		v10-	tactatacgtgtcattacagatgctgtcattacacgaactgtcattacgtactcagt
		coreCEA	cattactacgtaacccacgtgatgctgagaagtactcctgccctaggaagagactca
		CAM	gggcagagggaggaaggacagcagaccagacagtcacagcagccttgacaaaacgtt
			cctggaactaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
87	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgatcagcgatgctcatct
	100	HOXA1_	cgacctgatcggtacaacttctcacggaggcttctaagtcattacatacgtagtcat
		v10-	tactatacgtgtcattacagatgctgtcattacacgaactgtcattacgtactcagt
		coreAGR	cattactacgtacatactgaaaagcatacttttgcaatgttatttttaaaaacaagg
		2	aactctttaacccagggaagataatcacttggggaaaggaaggttcgtttctgagtt
			agcaacaagtaaatgcagcactagtgggtgggattgaggtgtgccctggtgcataaa
			tagagactcagctgtgctggcacactcagaagcttggaccgcatcctagccgccgac
			tcacacaaggcaggtgggtgaggaaatccaggtaaggctcctgacagcagctttaga
			agggtacttgctggagtgaattcgggcctctgattagctagcctcgaggatatcaag
			atctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
88	PL1	PL-	ggcctaactggccggtaccactagtgacgtctgtagctgagcgacagtatagtgcac
	101	HOXC10_	agtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcg
		v14-	taaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaatt
		coreCST	gacgtctacgtaagtggtgggggagtgaaaagagagatggagaaagaggggatgggc
			agaaagaggaggaggagtcaggggcagggcatggaggtgggtggggctgggctgcca
			aagcaggataaatgcacacctgcctgctggtctgggctccctgcctcgggctctcac
			cctcctctcctgcagctccagctttgtgctctaccggtgctagcctcgaggatatca
			agatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
89	PL1	PL-	ggcctaactggccggtaccactagtgacgtctgtagctgagcgacagtatagtgcac
	102	HOXC10_	agtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcg
		v14-	taaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaatt
		coreFA	gacgtctacgtacgggaaaagttcagctgagagatataaaagagcagtctttccagc
		M111B	acctgcaaatccagagcggcgggcactgacgggcacttgcaccgtgtggacagactc
			tccggttctgtgagtggtttttcttttcccgggtcggacctggagttcttaggggga
			tggctgaaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagctt
			ggcaatccggtactgttggtaaagccacc
90	PL1	PL-	ggcctaactggccggtacaactagtgacgtctgtagctgagcgacagtatagtgcac
	103	HOXC10_	agtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcg
		v14-	taaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaatt
		coreAGR	gacgtctacgtacatactgaaaagcatacttttgcaatgttatttttaaaaacaagg
		2	aactctttaacccagggaagataatcacttggggaaaggaaggttcgtttctgagtt
			agcaacaagtaaatgcagcactagtgggtgggattgaggtgtgccctggtgcataaa
			tagagactcagctgtgctggcacactcagaagcttggaccgcatcctagccgccgac
			tcacacaaggcaggtgggtgaggaaatccaggtaaggctcctgacagcagctttaga
			agggtacttgctggagtgaattcgggcctctgattactagcctcgaggatatcaaga
			tctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
91	PL1	PL-	ggcctaactggccggtaccactagtgacgtctgtagctgagcgacagtatagtgcac
	104	HOXC10_	agtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcg
		v14-	taaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaatt
		coreCEA	gacgtctacgtaacccacgtgatgctgagaagtactcctgccctaggaagagactca
		CAM	gggcagagggaggaaggacagcagaccagacagtcacagcagccttgacaaaacgtt
			cctggaactaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
92	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtactgatcagcgatgctcatct
	105	HOXA1_	cgacctgatcggtacaacttctcacggaggcttctaagtcattacatacgtagtcat
		v10-	tactatacgtgtcattacagatgctgtcattacacgaactgtcattacgtactcagt
		coreFA	cattactacgtacgggaaaagttcagctgagagatataaaagagcagtctttccagc
		M111B	acctgcaaatccagagcggcgggcactgacgggcacttgcaccgtgtggacagactc
			tccggttctgtgagtggtttttcttttcccgggtcggacctggagttcttaggggga
			tggctgaaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagctt
			ggcaatccggtactgttggtaaagccacc
93	PL1	PL-	ggcctaactggccggtaccactagtgacgtctgtagctgagcgacagtatagtgcac
	106	HOXC10_	agtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcg
		v14-	taaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaatt
		CREB V	gacgtctacgtaacatcggctatgctgctgctaatgccacgtcaccacatcgacatg
		6-	ccacgtcaccatcatgccatgccacgtcaccactgcaagatgccacgtcaccacagt
		coreCST	ataatgccacgtcaccaagttactatgccacgtcaccaggtacctacgtaagtggtg
			ggggagtgaaaagagagatggagaaagaggggatgggcagaaagaggaggaggagtc
			aggggcagggcatggaggtgggtggggctgggctgccaaagcaggataaatgcacac
			ctgcctgctggtctgggctccctgcctcgggctctcaccctcctctcctgcagctcc
			agctttgtgctctaccggtgctagcctcgaggatatcaagatctggcctcggcggcc
			aagcttggcaatccggtactgttggtaaagccacc
94	PL1	PL-	ggcctaactggccggtacactagtgacgtctgtagctgagcgacagtatagtgcaca
	107	HOXC10_	gtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcgt
		v14-	aaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaattg
		CREB_v	acgtctacgtaacatcggctatgctgctgctaatgccacgtcaccacatcgacatgc
		6-	cacgtcaccatcatgccatgccacgtcaccactgcaagatgccacgtcaccacagta
		coreKIF	taatgccacgtcaccaagttactatgccacgtcaccaggtacctacgtaggcccgcc
			ccctttccttacgcggattggtagctgcaggcttccctatctgattggccgaacgaa
			cgcagcgcgtaatttaaaatattgtatctgtaacaaagctgcacctcgtgggcggag
			ttgtgctctgcggctgcgaaagtccagcttcggcgactaggtgtgagtaagccagta
			tcccaggaggagcaagtggcacgtcttcgggtgagtgtgcggctgtgctggagcccg
			ggttaccagctctttaccggtctagcctcgaggatatcaagatctggcctcggcggc
			caagcttggcaatccggtactgttggtaaagccacc
95	PL1	PL-	ggcctaactggccggtacaactagtgacgtctgtagctgagcgacagtatagtgcac
	108	HOXC10_	agtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcg
		v14-	taaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaatt
		CREB_	gacgtctacgtaacatcggctatgctgctgctaatgccacgtcaccacatcgacatg
		6-	ccacgtcaccatcatgccatgccacgtcaccactgcaagatgccacgtcaccacagt
		coreAGR	ataatgccacgtcaccaagttactatgccacgtcaccaggtacctacgtacatactg
		2	aaaagcatacttttgcaatgttatttttaaaaacaaggaactctttaacccagggaa
			gataatcacttggggaaaggaaggttcgtttctgagttagcaacaagtaaatgcagc
			actagtggggggattgaggtgtgccctggtgcataaatagagactcagctgtgctg
			gcacactcagaagcttggaccgcatcctagccgccgactcacacaaggcaggtgggt
			gaggaaatccaggtaaggctcctgacagcagctttagaagggtacttgctggagtga
			attcgggcctctgattactagcctcgaggatatcaagatctggcctcggcggccaag
			cttggcaatccggtactgttggtaaagccacc
96	PL1	PL-	ggcctaactggccggtaccactagtgacgtctgtagctgagcgacagtatagtgcac
	109	HOXC10_	agtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcg
		v14-	taaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaatt
		CREB_v	gacgtctacgtaacatcggctatgctgctgctaatgccacgtcaccacatcgacatg
		6-	ccacgtcaccatcatgccatgccacgtcaccactgcaagatgccacgtcaccacagt
		coreCEA	ataatgccacgtcaccaagttactatgccacgtcaccaggtacctacgtaacccacg
		CAM	tgatgctgagaagtactcctgccctaggaagagactcagggcagagggaggaaggac
			agcagaccagacagtcacagcagccttgacaaaacgttcctggaactaccggtgcta
			gcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgtt
			ggtaaagccacc
97	PL1	PL-	ggcctaactggccggtaccactagtgacgtctgtagctgagcgacagtatagtgcac
	110	HOXC10_	agtgactgcagcagtcattgtcgtaaattgagtatcgtcgtaaattgacgaacgtcg
		v14-	taaattagcgacagtcgtaaattagtacctgtcgtaaattactctgcgtcgtaaatt
		CREB_v	gacgtctacgtaacatcggctatgctgctgctaatgccacgtcaccacatcgacatg
		6-	ccacgtcaccatcatgccatgccacgtcaccactgcaagatgccacgtcaccacagt
		coreFA	ataatgccacgtcaccaagttactatgccacgtcaccaggtacctacgtacgggaaa
		M111B	agttcagctgagagatataaaagagcagtctttccagcacctgcaaatccagagcgg
			cgggcactgacgggcacttgcaccgtgtggacagactctccggttctgtgagtggtt
			tttcttttcccgggtcggacctggagttcttagggggatggctgaaccggtgctagc
			ctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttgg
			taaagccacc
98	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtaacatcggctatgctgctgct
	111	CREB_v	aatgccacgtcaccacatcgacatgccacgtcaccatcatgccatgccacgtcacca
		6-	ctgcaagatgccacgtcaccacagtataatgccacgtcaccaagttactatgccacg
		coreCST	tcaccaggtacctacgtaagtggtgggggagtgaaaagagagatggagaaagagggg
			atgggcagaaagaggaggaggagtcaggggcagggcatggaggtgggtggggctggg
			ctgccaaagcaggataaatgcacacctgcctgctggtctgggctccctgcctcgggc
			tctcaccctcctctcctgcagctccagctttgtgctctaccggtgctagcctcgagg
			atatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagcc
			acc
99	PL1	PL-	ggcctaactggccggtacaactagtgacgtctacgtaacatcggctatgctgctgct
	112	CREB_v	aatgccacgtcaccacatcgacatgccacgtcaccatcatgccatgccacgtcacca
		6-	ctgcaagatgccacgtcaccacagtataatgccacgtcaccaagttactatgccacg
		coreAGR	tcaccaggtacctacgtacatactgaaaagcatacttttgcaatgttatttttaaaa
		2	acaaggaactctttaacccagggaagataatcacttggggaaaggaaggttcgtttc
			tgagttagcaacaagtaaatgcagcactagtggggggattgaggtgtgccctggtg
			cataaatagagactcagctgtgctggcacactcagaagcttggaccgcatcctagcc
			gccgactcacacaaggcaggtgggtgaggaaatccaggtaaggctcctgacagcagc
			tttagaagggtacttgctggagtgaattcgggcctctgattactagcctcgaggata
			tcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
100	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtaacatcggctatgctgctgct
	113	CREB_v	aatgccacgtcaccacatcgacatgccacgtcaccatcatgccatgccacgtcacca
		6-	ctgcaagatgccacgtcaccacagtataatgccacgtcaccaagttactatgccacg
		coreKIF	tcaccaggtacctacgtaggcccgccccctttccttacgcggattggtagctgcagg
			cttccctatctgattggccgaacgaacgcagcgcgtaatttaaaatattgtatctgt
			aacaaagctgcacctcgtgggcggagttgtgctctgcggctgcgaaagtccagcttc
			ggcgactaggtgtgagtaagccagtatcccaggaggagcaagtggcacgtcttcggg
			tgagtgtgcggctgtgctggagcccgggttaccagctctttaccggtctagcctcga
			ggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaag
			ccacc
101	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtaacatcggctatgctgctgct
	114	CREB_v	aatgccacgtcaccacatcgacatgccacgtcaccatcatgccatgccacgtcacca
		6-	ctgcaagatgccacgtcaccacagtataatgccacgtcaccaagttactatgccacg
		coreCEA	tcaccaggtacctacgtaacccacgtgatgctgagaagtactcctgccctaggaaga
		CAM	gactcagggcagagggaggaaggacagcagaccagacagtcacagcagccttgacaa
			aacgttcctggaactaccggtgctagcctcgaggatatcaagatctggcctcggcgg
			ccaagcttggcaatccggtactgttggtaaagccacc
102	PL1	PL-	ggcctaactggccggtaccactagtgacgtctacgtaacatcggctatgctgctgct
	115	CREB_v	aatgccacgtcaccacatcgacatgccacgtcaccatcatgccatgccacgtcacca
		6-	ctgcaagatgccacgtcaccacagtataatgccacgtcaccaagttactatgccacg
		coreFA	tcaccaggtacctacgtacgggaaaagttcagctgagagatataaaagagcagtctt
		M111B	tccagcacctgcaaatccagagcggcgggcactgacgggcacttgcaccgtgtggac
			agactctccggttctgtgagtggtttttcttttcccgggtcggacctggagttctta
			gggggatggctgaaccggtgctagcctcgaggatatcaagatctggcctcggcggcc
			aagcttggcaatccggtactgttggtaaagccacc
103	PL1	HES6_v	GAATTCaagaCtgcaagCGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCATTA
	144	11-	TACGTCGCCTAAATCGAGATGCTGTAGGCACGTGTATCTGGCACGTGTACTCGGCAC
		coreBIR	GTGTACTAGGCACGTGTAAGAGGCACGTGTACGCGGCACGTGTAGGTACCTGCGCTC
		C5	CCGACATGCCCCGCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGG
			CAGAGGTGGGCTAGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCA
			ATCCGGTACTGTTGGTAAAGCCACCATGGAAG
104	PL1	HES6_v	GAATTCaagaCtgcaagCGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCATTA
	145	11-	TACGTCGCCTAAATCGAGATGCTGTAGGCACGTGTATCTGGCACGTGTACTCGGCAC
		TATA-	GTGTACTAGGCACGTGTAAGAGGCACGTGTACGCGGCACGTGTAGGTACCTATAAAA
		TSS	GGCCAGCAGCAGCCTGACCACATCTCATCCGCTAGCCTCGAGGATATCAAGATCTGG
			CCTCGGCGGCCAAGCTTGGCAATCCGGTACTGTTGGTAAAGCCACC
105	PL1	NPAS2_	GAATTCaagaCtgcaagCCTGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCAT
	146	v11-	TATACGTCGCCTAAATCGAGATGCTGGACACGTGTCCGAGACACGTGTCTGTGACAC
		coreBIR	GTGTCCGGGACACGTGTCGCAGACACGTGTCGTGGACACGTGTCGGTACCTGCGCTC
		C5	CCGACATGCCCCGCGGCGCGCCATTAACCGCCAGATTTGAGTCGCGGGACCCGTTGG
			CAGAGGTGGGCTAGCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAAGCTTGGCA
			ATCCGGTACTGTTGGTAAAGCCACC
106	PL1	NPAS2_	GAATTCaagaCtgcaagCCTGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCAT
	147	v11-	TATACGTCGCCTAAATCGAGATGCTGGACACGTGTCCGAGACACGTGTCTGTGACAC
		TATA-	GTGTCCGGGACACGTGTCGCAGACACGTGTCGTGGACACGTGTCGGTACCTATAAAA
		TSS	GGCCAGCAGCAGCCTGACCACATCTCATCCGCTAGCCTCGAGGATATCAAGATCTGG
			CCTCGGCGGCCAAGCTTGGCAATCCGGTACTGTTGGTAAAGCCACC
107	PL1	pGL4.10-	ggcctaactggccggtaccactagtatcgatccttcatagggcagggaggggtgggc
	15	FAM83	acttgggtgtgaccaaggagaggaggcgcgcctggtcaacagctctccctggcccgt
		A-43	gtccagctccctcctcacacagagaggggggcgcatctcagggatggcatctttccc
			ccccacagggaaattcttatctttgaaacagcatgggaatcgaggcacccaggaggg
			gagcagaggcaggcaggcctccttcaggcccatcctccagctgggctggtggtgcca
			gggaggctccctgcttggtaacaaaggcctgagggagagttgcgaaacccagcagga
			aagccggctcaccttcgcctccccctgcggctgggaggagaggaaatatcccatggc
			tgactgtgccaaggaggtgtctgagccagccctcccggcccgagggcagggcaggtg
			gccctgagagataagccaatcccgcagctgcagatgaggagttctgagaagcattgc
			tcaggacagcggtaaatcacttcttggaggtgccctgcacgccggtcctgggagcag
			gcggcctcccgggggtgcgggagccccactcctccgtggtgtgttccatttgcttcc
			cacatctggaggagctgacgtgccagcctcccccagcaccacccagggacgggaggc
			aaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaat
			ccggtactgttggtaaagccacc
108	PL1	PL-	ggcctaactggccggtaccgacgtctacctgatcaaacatgcccggacatgtcgtaa
	156	TP53_v5-	gacataaacatgcccggacatgtcctcgcaatctaacatgcccggacatgtcctcgc
		TATA-	aatctaacatgcccggacatgtctgcaagctacaacatgcccggacatgtctacgta
		TSS	gctagctataaaaggccagcagcagcctgaccacatctcatcctcctcgaggatatc
		FLUC	aagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
109	PL1	PL-	ggcctaactggccggtaccgacgtccctgatcggtacaacttctcacaacatgcctg
	157	TP53_v2	ggcatgtcgctatgcaacatgcctgggcatgtcagatgcaaacatgcctgggcatgt
		2-TATA-	cctgctataacatgcctgggcatgtcctgctataacatgcctgggcatgtctacgta
		TSS	gctagctataaaaggccagcagcagcctgaccacatctcatcctcctcgaggatatc
		FLUC	aagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
110	PL1	PL-TP53	ggcctaactggccggtaccgacgtctcgggcaagcgctcccgacatgcccgggcaag
	158	SURV_v	cgctcccgacatgcccgggcaagcgctcccgacatgcccgggcaagcgctcccgaca
		3-TATA-	tgcccgggcaagcgctcccgacatgcccgggcaagcgctcccgacatgccctacgta
		TSS	gctagctataaaaggccagcagcagcctgaccacatctcatcctcctcgaggatatc
		FLUC	aagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
111	PL1	PL-	ggcctaactggccggtaccttttgataaaaatcattaggtacggccgcggtgccagg
	159	TCF7_v2-	gcgtgcccttgggctccccgggcgcgaaactagtgacgtcctgagcgacagtatagt
		FOS-	gcacagtgactgcagcagtcattcctttgatgtacgcaactcctttgatgtctatgc
		coreBIR	gtcctttgatgttaaggattcctttgatgtaggtacatcctttgatgtccgtaaatc
		C5	ctttgatgtgacgtctacgtaggtgactcatgggtgactcatgtacgtaacgcgtcc
			cgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggc
			agaggtgggaattcaccggtgctagcctcgaggatatcaagatctggcctcggcggc
			caagcttggcaatccggtactgttggtaaagccacc
112	PL1	PL-FOS-	ggcctaactggccggtaccttttgataaaaatcattaggtacggccgcggtgccagg
	160	TCF_v2-	gcgtgcccttgggctccccgggcgcgaaactagtgacgtcggtgactcatgggtgac
		coreBIR	tcatgacgtctacgtactgagcgacagtatagtgcacagtgactgcagcagtcattc
		C5	ctttgatgtacgcaactcctttgatgtctatgcgtcctttgatgttaaggattcctt
			tgatgtaggtacatcctttgatgtccgtaaatcctttgatgttacgtaacgcgtccc
			gacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggca
			gaggtgggaattcaccggtgctagcctcgaggatatcaagatctggcctcggcggcc
			aagcttggcaatccggtactgttggtaaagccacc
113	PL1	PL-	ggcctaactggccggtaccaactagtgacgtcctgagcgacagtatagtgcacagtg
	161	TCF7_v2-	actgcagcagtcattcctttgatgtacgcaactcctttgatgtctatgcgtcctttg
		FOS-	atgttaaggattcctttgatgtaggtacatcctttgatgtccgtaaatcctttgatg
		coreAGR	tgacgtctacgtaggtgactcatgggtgactcatgtacgtacatactgaaaagcata
		2	cttttgcaatgttatttttaaaaacaaggaactctttaacccagggaagataatcac
			ttggggaaaggaaggttcgtttctgagttagcaacaagtaaatgcagcactagtggg
			tgggattgaggtgtgccctggtgcataaatagagactcagctgtgctggcacactca
			gaagcttggaccgcatcctagccgccgactcacacaaggcaggtgggtgaggaaatc
			caggtaaggctcctgacagcagctttagaagggtacttgctggagtgaattcgggcc
			tctgattagctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaa
			tccggtactgttggtaaagccacc
114	PL1	PL-FOS-	ggcctaactggccggtaccaactagtgacgtcggtgactcatgggtgactcatggac
	162	TCF7_v2-	gtctacgtactgagcgacagtatagtgcacagtgactgcagcagtcattcctttgat
		coreAGR	gtacgcaactcctttgatgtctatgcgtcctttgatgttaaggattcctttgatgta
		2	ggtacatcctttgatgtccgtaaatcctttgatgttacgtacatactgaaaagcata
			cttttgcaatgttatttttaaaaacaaggaactctttaacccagggaagataatcac
			ttggggaaaggaaggttcgtttctgagttagcaacaagtaaatgcagcactagtggg
			tgggattgaggtgtgccctggtgcataaatagagactcagctgtgctggcacactca
			gaagcttggaccgcatcctagccgccgactcacacaaggcaggtgggtgaggaaatc
			caggtaaggctcctgacagcagctttagaagggtacttgctggagtgaattcgggcc
			tctgattagctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaa
			tccggtactgttggtaaagccacc
115	PL1	PL-	ggcctaactggccggtaccaactagtgacgtcctgagcgacagtatagtgcacagtg
	163	TCF7_v2	actgcagcagtcattcctttgatgtacgcaactcctttgatgtctatgcgtcctttg
		coreAGR	atgttaaggattcctttgatgtaggtacatcctttgatgtccgtaaatcctttgatg
		2	tgacgtctacgtacatactgaaaagcatacttttgcaatgttatttttaaaaacaag
			gaactctttaacccagggaagataatcacttggggaaaggaaggttcgtttctgagt
			tagcaacaagtaaatgcagcactagtgggtgggattgaggtgtgccctggtgcataa
			atagagactcagctgtgctggcacactcagaagcttggaccgcatcctagccgccga
			ctcacacaaggcaggtgggtgaggaaatccaggtaaggctcctgacagcagctttag
			aagggtacttgctggagtgaattcgggcctctgattagctagcctcgaggatatcaa
			gatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
116	PL1	PL-	CAACTAGTGACGTCCTGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCATTCCT
	164	TCF7_v2-	TTGATGTACGCAACTCCTTTGATGTCTATGCGTCCTTTGATGTTAAGGATTCCTTTG
		FOS-	ATGTAGGTACATCCTTTGATGTCCGTAAATCCTTTGATGTGACGTCTACGTAGGTGA
		coreCEA	CTCATGGGTGACTCATGTACGTAACCCACGTGATGCTGAGAAGTACTCCTGCCCTAG
		CAM5	GAAGAGACTCAGGGCAGAGGGAGGAAGGACAGCAGACCAGACAGTCACAGCAGCCTT
			GACAAAACGTTCCTGGAACTACCGGT
117	PL1	PL-	ggcctaactggccggtaccaactagtgacgtcctgagcgacagtatagtgcacagtg
	165	TCF7_v2	actgcagcagtcattcctttgatgtacgcaactcctttgatgtctatgcgtcctttg
		coreCEA	atgttaaggattcctttgatgtaggtacatcctttgatgtccgtaaatcctttgatg
		CAM5	tgacgtctacgtaacccacgtgatgctgagaagtactcctgccctaggaagagactc
			agggcagagggaggaaggacagcagaccagacagtcacagcagccttgacaaaacgt
			tcctggaactaccggtgctagcctcgaggatatcaagatctggcctcggcggccaag
			cttggcaatccggtactgttggtaaagccacc
118	PL1	PL-	AACTAGTGACGTCCTGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCATTCCTT
	166	TCF7_v2-	TGATGTACGCAACTCCTTTGATGTCTATGCGTCCTTTGATGTTAAGGATTCCTTTGA
		coreFA	TGTAGGTACATCCTTTGATGTCCGTAAATCCTTTGATGTGACGTCTACGTATACGTA
		M111B	CGGGAAAAGTTCAGCTGAGAGATATAAAAGAGCAGTCTTTCCAGCACCTGCAAATCC
			AGAGCGGCGGGCACTGACGGGCACTTGCACCGTGTGGACAGACTCTCCGGTTCTGTG
			AGTGGTTTTTCTTTTCCCGGGTCGGACCTGGAGTTCTTAGGGGGATGGCTGaaccgg
			t
119	PL1	PL-	CTAGTGACGTCCTGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCATTCCTTTG
	167	TCF7_v2	ATGTACGCAACTCCTTTGATGTCTATGCGTCCTTTGATGTTAAGGATTCCTTTGATG
		coreCST	TAGGTACATCCTTTGATGTCCGTAAATCCTTTGATGTGACGTCTACGTATACGTAAG
			TGGTGGGGGAGTGAAAAGAGAGATGGAGAAAGAGGGGATGGGCAGAAAGAGGAGGAG
			GAGTCAGGGGCAGGGCATGGAGGTGGGTGGGGCTGGGCTGCCAAAGCAGGATAAATG
			CACACCTGCCTGCTGGTCTGGGCTCCCTGCCTCGGGCTCTCACCCTCCTCTCCTGCA
			GCTCCAGCTTTGTGCTCTa
120	PL1	PL-	CTAGTGACGTCCTGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCATTCCTTTG
	168	TCF7_v2	ATGTACGCAACTCCTTTGATGTCTATGCGTCCTTTGATGTTAAGGATTCCTTTGATG
		coreKIF2	TAGGTACATCCTTTGATGTCCGTAAATCCTTTGATGTGACGTCTACGTATACGTAGG
		0A	CCCGCCCCCTTTCCTTACGCGGATTGGTAGCTGCAGGCTTCCCTATCTGATTGGCCG
			AACGAACGCAGCGCGTAATTTAAAATATTGTATCTGTAACAAAGCTGCACCTCGTGG
			GCGGAGTTGTGCTCTGCGGCTGCGAAAGTCCAGCTTCGGCGACTAGGTGTGAGTAAG
			CCAGTATCCCAGGAGGAGCAAGTGGCACGTCTTCGGGTGAGTGTGCGGCTGTGCTGG
			AGCCCGGGTTACCAGCTCTTTA
121	PL1	pGL4.10-	ggcctaactggccggtaccaccatggggaaggtggggtgatcacaggacagtcagcc
	17	CEACA	tcgcagaggacagagaccacccaggactgtcagggagaacatggacaggccctgagc
		M5	cgcagctcagccaacagacacggagagggagggtccccctggagccttccccaagga
			cagcagagcccagagtcacccacctccctccaccacagtcctctctttccaggacac
			acaagacacctccccctccacatgcaggatctggggactcctgagacctctgggcct
			gggtctccatccctgggtcagtggggggttggtggtactggagacagagggctggt
			ccctccccagccaccacccagtgagcctttttctagcccccagagccacctctgtca
			ccttcctgttgggcatcatcccaccttcccagagccctggagagcatggggagaccc
			gggaccctgctgggtttctctgtcacaaaggaaaataatccccctggtgtgacagac
			ccaaggacagaacacagcagaggtcagcactggggaagacaggttgtcctcccaggg
			gatgggggtccatccaccttgccgaaaagatttgtctgaggaactgaaaatagaagg
			gaaaaaagaggagggacaaaagaggcagaaatgagaggggaggggacagaggacacc
			tgaataaagaccacacccatgacccacgtgatgctgagaagtactcctgccctagga
			agagactcagggcagagggaggaaggacagcagaccagacagtcacagcagccttga
			caaaacgttcctggaactaccggtgctagcctcgaggatatcaagatctggcctcgg
			cggccaagcttggcaatccggtactgttggtaaagccacc
122	PL1	PL-	ggcctaactggccggtaccttttgataaaaatcattaggtacggccgcggtgccagg
	183	TP53_v5-	gcgtgcccttgggctccccgggcgcgaaactagtgacgtctacctgatcaaacatgc
		coreBIR	ccggacatgtcgtaagacataaacatgcccggacatgtcctcgcaatctaacatgcc
		C5	cggacatgtcctcgcaatctaacatgcccggacatgtctgcaagctacaacatgccc
			ggacatgtctacgtaacgcgtcccgacatgccccgcggcgcgccattaaccgccaga
			tttgagtcgcgggacccgttggcagaggtgggaattcaccggtgctagcctcgagga
			tatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagcca
			CC
123	PL1	PL-	ggcctaactggccggtaccaactagtgacgtctacctgatcaaacatgcccggacat
	184	TP53_v5-	gtcgtaagacataaacatgcccggacatgtcctcgcaatctaacatgcccggacatg
		coreAGR	tcctcgcaatctaacatgcccggacatgtctgcaagctacaacatgcccggacatgt
		2	ctacgtacatactgaaaagcatacttttgcaatgttatttttaaaaacaaggaactc
			tttaacccagggaagataatcacttggggaaaggaaggttcgtttctgagttagcaa
			caagtaaatgcagcactagtgggtgggattgaggtgtgccctggtgcataaatagag
			actcagctgtgctggcacactcagaagcttggaccgcatcctagccgccgactcaca
			caaggcaggtgggtgaggaaatccaggtaaggctcctgacagcagctttagaagggt
			acttgctggagtgaattcgggcctctgattagctagcctcgaggatatcaagatctg
			gcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
124	PL1	PL-	ggcctaactggccggtaccaactagtgacgtctacctgatcaaacatgcccggacat
	185	TP53_v5-	gtcgtaagacataaacatgcccggacatgtcctcgcaatctaacatgcccggacatg
		coreFA	tcctcgcaatctaacatgcccggacatgtctgcaagctacaacatgcccggacatgt
		M111B	ctacgtacgggaaaagttcagctgagagatataaaagagcagtctttccagcacctg
			caaatccagagcggcgggcactgacgggcacttgcaccgtgtggacagactctccgg
			ttctgtgagtggtttttcttttcccgggtcggacctggagttcttagggggatggct
			gaaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaa
			tccggtactgttggtaaagccacc
125	PL1	PL-	ggcctaactggccggtaccaactagtgacgtctacctgatcaaacatgcccggacat
	186	TP53_v5-	gtcgtaagacataaacatgcccggacatgtcctcgcaatctaacatgcccggacatg
		coreCST	tcctcgcaatctaacatgcccggacatgtctgcaagctacaacatgcccggacatgt
			ctacccgttcgacaagcccggacatgctaagacataaacatgcccggacatgtcctc
			gcaatctaaccatgcccggacatgtcctcgcaatctaacatgcccggacatgtctgc
			aagctacaacatgcccggacatgtctacgtaagtggtgggggagtgaaaagagagat
			ggagaaagaggggatgggcagaaagaggaggaggagtcaggggcagggcatggaggt
			gggtggggctgggctgccaaagcaggataaatgcacacctgcctgctggtctgggct
			ccctgcctcgggctctcaccctcctctcctgcagctccagctttgtgctctaccggt
			gctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtac
			tgttggtaaagccacc
126	PL1	PL-	ggcctaactggccggtaccttttgataaaaatcattaggtacggccgcggtgccagg
	187	TCF7_v2	gcgtgcccttgggctccccgggcgcgaaactagtgacgtcctgagcgacagtatagt
		TP53_v5	gcacagtgactgcagcagtcattcctttgatgtacgcaactcctttgatgtctatgc
		coreBIR	gtcctttgatgttaaggattcctttgatgtaggtacatcctttgatgtccgtaaatc
		C5	ctttgatgtgacgtctacgtatctacctgatcaaacatgcccggacatgtcgtaaga
			cataaacatgcccggacatgtcctcgcaatctaacatgcccggacatgtcctcgcaa
			tctaacatgcccggacatgtctgcaagctacaacatgcccggacatgtctacgtaac
			gcgtcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggaccc
			gttggcagaggtgggaattcaccggtgctagcctcgaggatatcaagatctggcctc
			ggcggccaagcttggcaatccggtactgttggtaaagccacc
127	PL1	PL-	ggcctaactggccggtaccaactagtgacgtcctgagcgacagtatagtgcacagtg
	188	TCF7_v2-	actgcagcagtcattcctttgatgtacgcaactcctttgatgtctatgcgtcctttg
		TP53_v5-	atgttaaggattcctttgatgtaggtacatcctttgatgtccgtaaatcctttgatg
		coreAGR	tgacgtctacgtatctacctgatcaaacatgcccggacatgtcgtaagacataaaca
		2	tgcccggacatgtcctcgcaatctaacatgcccggacatgtcctcgcaatctaacat
			gcccggacatgtctgcaagctacaacatgcccggacatgtctacaatatacgtatct
			acctgatcaaacatgcccggacatgtcgtaagacataaacatgcccggacatgtcct
			cgcaatctaacatgcccggacatgtcctcgcaatctaacatgcccggacatgtctgc
			aagctacaacatgcccggacatgtctacgtacatactgaaaagcatacttttgcaat
			gttatttttaaaaacaaggaactctttaacccagggaagataatcacttggggaaag
			gaaggttcgtttctgagttagcaacaagtaaatgcagcactagtgggtgggattgag
			gtgtgccctggtgcataaatagagactcagctgtgctggcacactcagaagcttgga
			ccgcatcctagccgccgactcacacaaggcaggtgggtgaggaaatccaggtaaggc
			tcctgacagcagctttagaagggtacttgctggagtgaattcgggcctctgattagc
			tagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactg
			ttggtaaagccacc
130	PL1	pGL4.10-	ggcctaactggccggtaccactagtaagcctcaagatttcctttaggctcttaggta
	21	KIF20A	agaaatgtctaaggttcaaggaaaaaggttaagttggaagaatcccaggcaaaataa
			gtgcgaatccacgacagttggtaacccggacccacattagaactcagaggtcaagca
			gaagcgaacgactggaattccagtcaggcccgccccctttccttacgcggattggta
			gctgcaggcttccctatctgattggccgaacgaacgcagcgcgtaatttaaaatatt
			gtatctgtaacaaagctgcacctcgtgggcggagttgtgctctgcggctgcgaaagt
			ccagcttcggcgactaggtgtgagtaagccagtatcccaggaggagcaagtggcacg
			tcttcgggtgagtgtgcggctgtgctggagcccgggttaccagctcttaccggtgct
			agcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgt
			tggtaaagccacc
145	PL1	PL-	ggcctaactggccggtaccactagtggggcggggtgatgacacagcaattcgggact
	236	HIGH-	ttccacgcttgcgtgagaagagaccggaagtgaatgacacagcaattcgcttgcgtg
		coreFA	agaagctgggactttcctaggggcggggttgggactttccacatgacacagcaatac
		M111B-	actagtaacatttctctggcctaactggccggtaccgggaaaagttcagctgagaga
		FLUC-	tataaaagagcagtctttccagcacctgcaaatccagagcgggggcactgacgggc
		HA	acttgcaccgtgtggacagactctccggttctgtgagtggtttttcttttcccgggt
			cggacctggagttcttagggggatggctgaagaattcaccggtcgacgctagc
147	PL1	PL-	ggcctaactggccggtaccactagtgtcatctctttgaatattctgtagtttgagga
	238	AFP3-	gaatatttgttatattgcacaataaaataagtttgcaagttttttttttctgcccca
		FLUC-	aagagctctgtgtccttgaacataaaatacaaataaccgctatgctgttaattatta
		HA	acaaatgtcccattttcaacctaaggaaataccataaagtaacagatataccaacaa
			aaggttaataattaacaggcattgcctgaaaagagtataaaaggctttcagcatgat
			tttccatattgtgcttccaccactgccaataacaaaccggtgaattcaccggtcgac
			gctagc
148	PL1	FOSL1-	GAATTCACTAGTGACAGTATAGTGCACAGTGACTGCAGCAGGGTGACTCATGATGCC
	239	v1-	ACGTCACCAGGTGACTCATGATGCCACGTCACCAGGTGACTCATGATGCCACGTCAC
		CREB3L	CAGGTGACTCATGATGCCACGTCACCAGGTGACTCATGGGTACCTATAAAAGGCCAG
		1-v6-	CAGCAGCCTGACCACATCTCATCCA
		1x1_v1
149	PL1	FOSL1-	GAATTCACTAGTAGTATAGTGCACAGTGACTGCAGCAGGGTGACTCATGATGATGCC
	240	v1-	ACGTCACCAATGCCACGTCACCAGGTGACTCATGGGTGACTCATGATGCCACGTCAC
		CREB3L	CAATGCCACGTCACCAGGTGACTCATGGGTGACTCATGGGTACCTATAAAAGGCCAG
		1-v6-	CAGCAGCCTGACCACATCTCATCCA
		2×2_v1
150	PL1	FOXO1 ::	GAATTCACTAGTCTCAAGTATAAGGTAAGACATAGTTACTGCGACATCGGCTAGTAA
	241	ELK3_v	ACCGGAAGTGTCTGTAAACCGGAAGTGATCGTAAACCGGAAGTGAGCGTAAACCGGA
		6	AGTGCTAGTAAACCGGAAGTGGAAGTAAACCGGAAGTGGGTACCTATAAAAGGCCAG
			CAGCAGCCTGACCACATCTCATCCA
151	PL1	MTF1_v	GAATTCACTAGTGTACTCAAGTATAAGGTAAGATTTGCACACGGTACGTACTCATTT
	242	9	GCACACGGTACATGCGAGTTTGCACACGGTACAGCTCAGTTTGCACACGGTACGTCA
			GCTTTTGCACACGGTACATCAGAATTTGCACACGGTACGGTACCTATAAAAGGCCAG
			CAGCAGCCTGACCACATCTCATCCACCGGTG
152	PL1	NFE2L2_	GAATTCACTAGTTAATTGCTGAGTCATTGCTGCTATGTAATTGCTGAGTCATATGCC
	243	v14	TATCCTAATTGCTGAGTCATAATCGAGATGTAATTGCTGAGTCATGTCCGACGCATA
			ATTGCTGAGTCATTCTAACTCGCTAATTGCTGAGTCATGGTACCTATAAAAGGCCAG
			CAGCAGCCTGACCACATCTCATCCA
153	PL1	NFKB1_	GAATTCACTAGTGCTGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCATTATAC
	244	v3	GTAGGGGAATCCCCTCGAAGGGGAATCCCCTTTAAGGGGAATCCCCTCGCAGGGGAA
			TCCCCTCTCAGGGGAATCCCCTAACAGGGGAATCCCCTGGTACCTATAAAAGGCCAG
			CAGCAGCCTGACCACATCTCATCCA
154	PL1	TP53-v5-	GAATTCACTAGTGCATCCTTTGATGTTACCTGATCAAACATGCCCGGACATGTCGTA
	245	TCF7-	AGACATATCCTTTGATGTCTCGCAATCTAACATGCCCGGACATGTCCTCGCAATCTT
		v2-	CCTTTGATGTTGCAAGCTACAACATGCCCGGACATGTCGGTACCTATAAAAGGCCAG
		1x1_v1	CAGCAGCCTGACCACATCTCATCCA
155	PL1	XBP1_v	GAATTCACTAGTGCACCATTAGTACTTGATCAGTATGCCACGTCATCACTACTCTAT
	246	19	GCCACGTCATCTCCTAGATATGCCACGTCATCGTAAGACTATGCCACGTCATCTACA
			GCTTATGCCACGTCATCACGTACTTATGCCACGTCATCGGTACCTATAAAAGGCCAG
			CAGCAGCCTGACCACATCTCATCCA
156	PL5	Cancript-	ggcctaactggccggtaccactagtgtccccacccacacattcctgtccccacccac
	50	coreBIR	acattcctgtccccacccacacattcctgtccccacccacacattcctgtccccacc
		C5-	cacacattcctgtccccacccacacattcctgtgcgctcccgacatgccccgcggcg
		FLUC	cgccattaaccgccagatttgagtcgcgggacccgttggcagaggtgggctagcctc
			gaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaa
			agccacc
157	PL5	UAS-	ggcctaactggccggtaccagcttgcatgcctgcaggtcggagtactgtcctccgag
	51	minB-	cggagtactgtcctccgagcggagtactgtcctccgagcggagtactgtcctccgag
		FLUC_n	cggagtactgtcctccgagcggtgcgctcccgacatgccccgcggcgcgccattaac
		o KPNI	cgccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatca
			agatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
158	PL5	TTF-	ggcctaactggccggtaccactagtggttttgtggggttttgtggggttttgtgggg
	73	1_1_no	ttttgtggggttttgtggggttttgtggggttttgtggggttttgtggggttttgtg
		space_mi	gggttttgtggtgcgctcccgacatgccccgcggcgcgccattaaccgccagatttg
		nBIRC5	agtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcct
			cggcggccaagcttggcaatccggtactgttggtaaagccacc
159	PL5	TTF-	ggcctaactggccggtaccactagtagccacttgaaattagccacttgaaattagcc
	74	1_2_no	acttgaaattagccacttgaaattagccacttgaaattagccacttgaaattagcca
		space_mi	cttgaaatttgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgag
		nBIRC5	tcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcg
			gcggccaagcttggcaatccggtactgttggtaaagccacc
160	PL5	TTF-	ggcctaactggccggtaccactagtctgggaacaagtgctgggaacaagtgctggga
	75	1_3_no	acaagtgctgggaacaagtgctgggaacaagtgctgggaacaagtgctgggaacaag
		space_mi	tgctgggaacaagtgtgcgctcccgacatgccccgcggcgcgccattaaccgccaga
		nBIRC5	tttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctg
			gcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
161	PL5	TTF-	ggcctaactggccggtaccactagtgactcctcaaggggactcctcaaggggactcc
	76	1_4_no	tcaaggggactcctcaaggggactcctcaaggggactcctcaaggggactcctcaag
		space_mi	gggactcctcaagggtgcgctcccgacatgccccgcggcgcgccattaaccgccaga
		nBIRC5	tttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctg
			gcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
162	PL5	TCF7_no	ggcctaactggccggtaccactagtcgggctttgatctttcgggctttgatctttcg
	77	space_mi	ggctttgatctttcgggctttgatctttcgggctttgatctttcgggctttgatctt
		nBIRC5	tcgggctttgatcttttgcgctcccgacatgccccgcggcgcgccattaaccgccag
			atttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatct
			ggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
163	PL5	TCF7:L2_	ggcctaactggccggtaccactagtgcgctttgatgtgcggggcggccctttgaagt
	78	no	tggcgctttgatgtgcggggcggccctttgaagttggcgctttgatgtgcggggcgg
		space_mi	ccctttgaagttgtgcgctcccgacatgccccgcggcgcgccattaaccgccagatt
		nBIRC5	tgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggc
			ctcggcggccaagcttggcaatccggtactgttggtaaagccacc
164	PL5	MSC_no	ggcctaactggccggtaccactagtaacagctgttaacagctgttaacagctgttaa
	79	space_mi	cagctgttaacagctgttaacagctgttaacagctgttaacagctgttaacagctgt
		nBIRC5	ttgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcggga
			cccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaa
			gcttggcaatccggtactgttggtaaagccacc
165	PL5	ZEB1_no	ggcctaactggccggtaccactagtcacctgcacctgcacctgcacctgcacctgca
	80	space_mi	cctgcacctgcacctgcacctgcacctgcacctgcacctgtgcgctcccgacatgcc
		nBIRC5	ccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcagaggtggg
			ctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtact
			gttggtaaagccacc
166	PL5	MAX_M	ggcctaactggccggtaccactagtagttcaacacgtggtctgggagttcaacacgt
	81	YC_no	ggtctgggagttcaacacgtggtctgggagttcaacacgtggtctgggagttcaaca
		space_mi	cgtggtctgggtgcgctcccgacatgccccgcggcgcgccattaaccgccagatttg
		nBIRC5	agtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcct
			cggcggccaagcttggcaatccggtactgttggtaaagccacc
167	PL5	GATA6	ggcctaactggccggtaccactagtgacagataagaaagacagataagaaagacaga
	82	no	taagaaagacagataagaaagacagataagaaagacagataagaaagacagataaga
		space_mi	aagacagataagaaatgcgctcccgacatgccccgcggcgcgccattaaccgccaga
		nBIRC5	tttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctg
			gcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
168	PL5	GATA1-	ggcctaactggccggtaccactagtttctaatctatttctaatctatttctaatcta
	83	BIRC5co	tttctaatctatttctaatctatttctaatctatttctaatctatttctaatctatt
		re	tctaatctattgcgctcccgacatgccccgcggcgcgccattaaccgccagatttga
			gtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctc
			ggcggccaagcttggcaatccggtactgttggtaaagccacc
169	PL5	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	84	no	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		space_mi	gtgactcatgtgcgctcccgacatgccccgcggcgcgccattaaccgccagatttga
		nBIRC5	gtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctc
			ggcggccaagcttggcaatccggtactgttggtaaagccacc
170	PL5	STAT3_	ggcctaactggccggtaccactagtcttctgggaaacttctgggaaacttctgggaa
	85	no	acttctgggaaacttctgggaaacttctgggaaacttctgggaaacttctgggaaac
		space_mi	ttctgggaaatgcgctcccgacatgccccgcggcgcgccattaaccgccagatttga
		nBIRC5	gtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctc
			ggcggccaagcttggcaatccggtactgttggtaaagccacc
171	PL5	STAT:S	ggcctaactggccggtaccactagtaattcttagaaataaattcttagaaataaatt
	86	TAT_no	cttagaaataaattcttagaaataaattcttagaaataaattcttagaaataaattc
		space_mi	ttagaaatatgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgag
		nBIRC5	tcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcg
			gcggccaagcttggcaatccggtactgttggtaaagccacc
172	PL5	SOX9_no	ggcctaactggccggtaccactagtaaaacaaaggatcctttgttttaaaacaaagg
	87	space_mi	atcctttgttttaaaacaaaggatcctttgttttaaaacaaaggatcctttgtttta
		nBIRC5	aaacaaaggatcctttgttttctgcgctcccgacatgccccgcggcgcgccattaac
			cgccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatca
			agatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
173	PL5	HNF4_no	ggcctaactggccggtaccactagtaaagtccaagtccaaaagtccaagtccaaaag
	88	space_mi	tccaagtccaaaagtccaagtccaaaagtccaagtccaaaagtccaagtccaaaagt
		nBIRC5	ccaagtccatgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgag
			tcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcg
			gcggccaagcttggcaatccggtactgttggtaaagccacc
174	PL5	TTF-	ggcctaactggccggtaccactagtggttttgtggagaggttttgtggtcgggtttt
	89	1_1_3bp	gtgggacggttttgtggctaggttttgtggactggttttgtggtgcggttttgtggg
		space_mi	taggttttgtggtgcgctcccgacatgccccgcggcgcgccattaaccgccagattt
		nBIRC5	gagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcc
			tcggcggccaagcttggcaatccggtactgttggtaaagccacc
175	PL5	TTF-	ggcctaactggccggtaccactagtagccacttgaaattagaagccacttgaaattt
	90	1_2_3bp	cgagccacttgaaattgacagccacttgaaattctaagccacttgaaattactagcc
		space_mi	acttgaaatttgcgctcccgacatgccccgcggcgcgccattaaccgccagatttga
		nBIRC5	gtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctc
			ggcggccaagcttggcaatccggtactgttggtaaagccacc
176	PL5	TTF-	ggcctaactggccggtaccactagtctgggaacaagtgagactgggaacaagtgtcg
	91	1_3_3bp	ctgggaacaagtggacctgggaacaagtgctactgggaacaagtgactctgggaaca
		space_mi	agtgtgcctgggaacaagtgtgcgctcccgacatgccccgcggcgcgccattaaccg
		nBIRC5	ccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaag
			atctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
177	PL5	TTF-	ggcctaactggccggtaccactagtgactcctcaagggagagactcctcaagggtcg
	92	1_4_3bp	gactcctcaaggggacgactcctcaagggctagactcctcaagggactgactcctca
		space_mi	agggtgcgactcctcaagggtgcgctcccgacatgccccgcggcgcgccattaaccg
		nBIRC5	ccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaag
			atctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
178	PL5	TCF7_3bp	ggcctaactggccggtaccactagtccggctttgatctttagacgggctttgatctt
	93	space_mi	ttcgcgggctttgatctttgaccgggctttgatctttctacgggctttgatctttac
		nBIRC5	tcgggctttgatcttttgcgctcccgacatgccccgcggcgcgccattaaccgccag
			atttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatct
			ggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
179	PL5	TCF7:L2_	ggcctaactggccggtaccactagtgcgctttgatgtgcggggcggccctttgaagt
	94	3bp	tgagagcgctttgatgtgcggggcggccctttgaagttgtcggcgctttgatgtgcg
		space_mi	gggcggccctttgaagttgtgcgctcccgacatgccccgcggcgcgccattaaccgc
		nBIRC5	cagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaaga
			tctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
180	PL5	MSC_3bp	ggcctaactggccggtaccactagtaacagctgttagaaacagctgtttcgaacagc
	95	space_mi	tgttgacaacagctgttctaaacagctgttactaacagctgtttgcaacagctgttg
		nBIRC5	taaacagctgtttgcgctcccgacatgccccgcggcgcgccattaaccgccagattt
			gagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcc
			tcggcggccaagcttggcaatccggtactgttggtaaagccacc
181	PL5	ZEB1_3	ggcctaactggccggtaccactagtcacctgagacacctgtcgcacctggaccacct
	96	bp	gctacacctgactcacctgtgccacctgagacacctgtcgcacctggaccacctgtg
		space_mi	cgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggaccc
		nBIRC5	gttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagct
			tggcaatccggtactgttggtaaagccacc
182	PL5	MAX_M	ggcctaactggccggtaccactagtagttcaacacgtggtctgggagaagttcaaca
	97	YC_3bp	cgtggtctgggtcgagttcaacacgtggtctggggacagttcaacacgtggtctggg
		space_mi	ctaagttcaacacgtggtctgggtgcgctcccgacatgccccgcggcgcgccattaa
		nBIRC5	ccgccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatc
			aagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
183	PL5	GATA6_	ggcctaactggccggtaccactagtgacagataagaaaagagacagataagaaatcg
	98	3bp	gacagataagaaagacgacagataagaaactagacagataagaaaactgacagataa
		space_mi	gaaatgcgacagataagaaatgcgctcccgacatgccccgcggcgcgccattaaccg
		nBIRC5	ccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaag
			atctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
184	PL5	GATA1_	ggcctaactggccggtaccactagtttctaatctatagattctaatctattcgttct
	99	3bp	aatctatgacttctaatctatctattctaatctatactttctaatctattgcttcta
		space_mi	atctattgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcg
		nBIRC5	cgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcg
			gccaagcttggcaatccggtactgttggtaaagccacc
185	PL6	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgagaggtgactcatgtcgggtg
	00	3bp	actcatggacggtgactcatgctaggtgactcatgactggtgactcatgtgcggtga
		space_mi	ctcatgctgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtc
		nBIRC5	gcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggc
			ggccaagcttggcaatccggtactgttggtaaagccacc
186	PL6	STAT3_	ggcctaactggccggtaccactagtcttctgggaaaagacttctgggaaatcgcttc
	01	3bp	tgggaaagaccttctgggaaactacttctgggaaaactcttctgggaaatgccttct
		space_mi	gggaaatgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcg
		nBIRC5	cgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcg
			gccaagcttggcaatccggtactgttggtaaagccacc
187	PL6	STAT:S	ggcctaactggccggtaccactagtaattcttagaaataagaaattcttagaaatat
	02	TAT_3b	cgaattcttagaaatagacaattcttagaaatactaaattcttagaaataactaatt
		p	cttagaaatatgcgctcccgacatgccccgcggcgcgccattaaccgccagatttga
		space_mi	gtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctc
		nBIRC5	ggcggccaagcttggcaatccggtactgttggtaaagccacc
188	PL6	SOX9_3	ggcctaactggccggtaccactagtaaaacaaaggatcctttgttttagaaaaacaa
	03	bp	aggatcctttgtttttcgaaaacaaaggatcctttgttttgacaaaacaaaggatcc
		space_mi	tttgtttttgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagt
		nBIRC5	cgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcgg
			cggccaagcttggcaatccggtactgttggtaaagccacc
189	PL6	HNF4_3	ggcctaactggccggtaccactagtaaagtccaagtccaagaaaagtccaagtccat
	04	bp	cgaaagtccaagtccagacaaagtccaagtccactaaaagtccaagtccaactaaag
		space_mi	tccaagtccatgcgctcccgacatgccccgcggcgcgccattaaccgccagatttga
		nBIRC5	gtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctc
			ggcggccaagcttggcaatccggtactgttggtaaagccacc
190	PL6	STAT:S	ggcctaactggccggtaccactagtaattcttagaaataaattcttagaaataaatt
	05	TAT_no	cttagaaataaattcttagaaataaattcttagaaataaattcttagaaataaattc
		space_mi	ttagaaatatgcgctcccgacatgtcccgcggcgcgccattaaccgccagatttgag
		nBIRC5	tcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcg
		2 w extra	gcggccaagcttggcaatccggtactgttggtaaagccaccatcctcgaggatatca
		insert	agatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
191	PL6	HOXA1	ggcctaactggccggtaccactagtccaataaaaaccaataaaaaccaataaaaacc
	16	3_no	aataaaaaccaataaaaaccaataaaaaccaataaaaaccaataaaaaccaataaaa
		space_mi	atgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcggga
		nB	cccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaa
			gcttggcaatccggtactgttggtaaagccacc
193	PL6	FOXM1_	ggcctaactggccggtaccactagttgtttacttatgtttacttatgtttacttatg
	35	no	tttacttatgtttacttatgtttacttatgtttacttatgtttacttatgtttactt
		space_co	atgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcggga
		reBIRC5	cccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaa
			gcttggcaatccggtactgttggtaaagccacc
194	PL6	E2F2_no	ggcctaactggccggtaccactagtaaaatggcgccattttaaaatggcgccatttt
	36	space_co	aaaatggcgccattttaaaatggcgccattttaaaatggcgccattttaaaatggcg
		reBIRC5	ccatttttgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtc
			gcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggc
			ggccaagcttggcaatccggtactgttggtaaagccacc
195	PL6	RUNX1_	ggcctaactggccggtaccactagttattgtggttatattgtggttatattgtggtt
	37	no	atattgtggttatattgtggttatattgtggttatattgtggttatattgtggttat
		space_co	gcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacc
		reBIRC5	cgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
196	PL6	SOX4_no	ggcctaactggccggtaccactagtgaacaattgcagtgttgaacaattgcagtgtt
	38	space_co	gaacaattgcagtgttgaacaattgcagtgttgaacaattgcagtgttgaacaattg
		reBIRC5	cagtgttgaacaattgcagtgtttgcgctcccgacatgccccgcggcgcgccattaa
			ccgccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatc
			aagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
197	PL6	RREB1_	ggcctaactggccggtaccactagtccccaaaccaccccccccccccccaaaccacc
	39	no	ccccccccccccaaaccaccccccccccccccaaaccaccccccccccccccaaacc
		space_co	acccccccccctgcgctcccgacatgccccgcggcgcgccattaaccgccagatttg
		reBIRC5	agtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcct
			cggcggccaagcttggcaatccggtactgttggtaaagccacc
198	PL6	ETV4_no	CACTAGTACCGGAAGTAACCGGAAGTAACCGGAAGTAACCGGAAGTAACCGGAAGTA
	40	space_co	ACCGGAAGTAACCGGAAGTAACCGGAAGTAACCGGAAGTAtgcgctcccgacatgcc
		reBIRC5	ccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcagaggtggg
			ctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtact
			gttggtaaagccacc
199	PL6	HES6_no	ggcctaactggccggtaccactagtggcacgtgttggcacgtgttggcacgtgttgg
	41	space_co	cacgtgttggcacgtgttggcacgtgttggcacgtgttggcacgtgttggcacgtgt
		reBIRC5	ttgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcggga
			cccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaa
			gcttggcaatccggtactgttggtaaagccacc
200	PL6	ASCL1_	ggcctaactggccggtaccactagtcgagcagctggtgcgagcagctggtgcgagca
	42	no	gctggtgcgagcagctggtgcgagcagctggtgcgagcagctggtgcgagcagctgg
		space_co	tgtgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcggg
		reBIRC5	acccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggcca
			agcttggcaatccggtactgttggtaaagccacc
201	PL6	TWIST1_	ggcctaactggccggtaccactagttccagatgtttccagatgtttccagatgtttc
	43	no	cagatgtttccagatgtttccagatgtttccagatgtttccagatgtttgcgctccc
		space_co	gacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggca
		reBIRC5	gaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaat
			ccggtactgttggtaaagccacc
202	PL6	FOXA3_	ggcctaactggccggtaccactagtatagtaaacaatagtaaacaatagtaaacaat
	44	no	agtaaacaatagtaaacaatagtaaacaatagtaaacaatagtaaacatgcgctccc
		space_co	gacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggca
		reBIRC5	gaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaat
			ccggtactgttggtaaagccacc
203	PL6	PITX2_no	ggcctaactggccggtaccactagttaatccctaatccctaatccctaatccctaat
	45	space_co	ccctaatccctaatccctaatccctaatccctaatccctaatccctgcgctcccgac
		reBIRC5	atgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcagag
			gtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccg
			gtactgttggtaaagccacc
204	PL6	HOXB2_	ggcctaactggccggtaccactagtctaattaactaattaactaattaactaattaa
	46	no	ctaattaactaattaactaattaactaattaactaattaactaattaatgcgctccc
		space_co	gacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggca
		reBIRC5	gaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaat
			ccggtactgttggtaaagccacc
205	PL6	EN2_no	ggcctaactggccggtaccactagtcccaattagccccaattagccccaattagccc
	47	space_co	caattagccccaattagccccaattagccccaattagccccaattagctgcgctccc
		reBIRC5	gacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggca
			gaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaat
			ccggtactgttggtaaagccacc
206	PL6	DLX4_no	ggcctaactggccggtaccactagtcaattacaattacaattacaattacaattaca
	48	space_co	attacaattacaattacaattacaattacaattacaattatgcgctcccgacatgcc
		reBIRC5	ccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcagaggtggg
			ctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtact
			gttggtaaagccacc
207	PL6	GRHL1_	ggcctaactggccggtaccactagtaaaaccggttttaaaaccggttttaaaaccgg
	49	no	ttttaaaaccggttttaaaaccggttttaaaaccggttttaaaaccggttttaaaac
		space_co	cggtttttgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtc
		reBIRC5	gcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggc
			ggccaagcttggcaatccggtactgttggtaaagccacc
208	PL6	FOXM1_	ggcctaactggccggtaccactagttgtttacttaagatgtttacttatcgtgttta
	50	3bp	cttagactgtttacttactatgtttacttaacttgtttacttatgctgtttacttat
		space_co	gcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacc
		reBIRC5	cgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
209	PL6	E2F2_3b	ggcctaactggccggtaccactagtaaaatggcgccatttttcgaaaatggcgccat
	51	p	tttgacaaaatggcgccattttctaaaaatggcgccattttactaaaatggcgccat
		space_co	ttttgcaaaatggcgccatttttgcgctcccgacatgccccgcggcgcgccattaac
		reBIRC5	cgccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatca
			agatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
210	PL6	RUNX1_	ggcctaactggccggtaccactagttattgtggttatcgtattgtggttagactatt
	52	3bp	gtggttactatattgtggttaacttattgtggttatgctattgtggttatgcgctcc
		space_co	cgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggc
		reBIRC5	agaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaa
			tccggtactgttggtaaagccacc
211	PL6	SOX4_3	ggcctaactggccggtaccactagtgaacaattgcagtgttgacgaacaattgcagt
	53	bp	gttctagaacaattgcagtgttactgaacaattgcagtgtttgcgaacaattgcagt
		space_co	gtttgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgg
		reBIRC5	gacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggcc
			aagcttggcaatccggtactgttggtaaagccacc
212	PL6	RREB1_	ggcctaactggccggtaccactagtccccaaaccaccccccccccgacccccaaacc
	54	3bp	accccccccccctaccccaaaccaccccccccccactccccaaaccacccccccccc
		space_co	tgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggac
		reBIRC5	ccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaag
			cttggcaatccggtactgttggtaaagccacc
213	PL6	ETV4_3	ggcctaactggccggtaccactagtaccggaagtaagaaccggaagtatcgaccgga
	55	bp	agtagacaccggaagtactaaccggaagtaactaccggaagtatgcaccggaagtat
		space_co	gcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacc
		reBIRC5	cgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
214	PL6	HES6_3	ggcctaactggccggtaccactagtggcacgtgttagaggcacgtgtttcgggcacg
	56	bp	tgttgacggcacgtgttctaggcacgtgttactggcacgtgtttgcggcacgtgttt
		space_co	gcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacc
		reBIRC5	cgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
215	PL6	ASCL1_	ggcctaactggccggtaccactagtcgagcagctggtgagacgagcagctggtgtcg
	57	3bp	cgagcagctggtggaccgagcagctggtgctacgagcagctggtgactcgagcagct
		space_co	ggtgtgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcg
		reBIRC5	ggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggc
			caagcttggcaatccggtactgttggtaaagccacc
216	PL6	TWIST1_	ggcctaactggccggtaccactagttccagatgttagatccagatgtttcgtccaga
	58	3bp	tgttgactccagatgttctatccagatgttacttccagatgtttgctccagatgttt
		space_co	gcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacc
		reBIRC5	cgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
217	PLE	FOXA3_	ggcctaactggccggtaccactagtatagtaaacaagaatagtaaacatcgatagta
	59	3bp	aacagacatagtaaacactaatagtaaacaactatagtaaacatgcatagtaaacat
		space_co	gcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacc
		reBIRC5	cgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
218	PL6	PITX2_3	ggcctaactggccggtaccactagttaatcccagataatccctcgtaatcccgacta
	60	bp	atcccctataatcccacttaatccctgctaatcccacttaatccctgctaatccctg
		space_co	cgctcccgacatgccccgcggcgcgtcattaaccgccagatttgagtcgcgggaccc
		reBIRC5	gttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagct
			tggcaatccggtactgttggtaaagccacc
219	PLE	HOXB2_	ggcctaactggccggtaccactagtctaattaaagactaattaatcgctaattaaga
	61	3bp	cctaattaactactaattaaactctaattaatgcctaattaaactctaattaatgcg
		space_co	ctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgt
		reBIRC5	tggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttg
			gcaatccggtactgttggtaaagccacc
220	PL6	EN2_3bp	ggcctaactggccggtaccactagtcccaattagcagacccaattagctcgcccaat
	62	space_co	tagcgaccccaattagcctacccaattagcactcccaattagctgccccaattagct
		reBIRC5	gcgctcccgacatgccctgcggcgcgccattaaccgccagatttgagtcgcgggacc
			cgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagc
			ttggcaatccggtactgttggtaaagccacc
221	PL6	DLX4_3	ggcctaactggccggtaccactagtcaattaagacaattatcgcaattagaccaatt
	63	bp	actacaattaactcaattatgccaattaactcaattatgccaattaagacaattatg
		space_co	cgctcccgacatgccccgcggcgtgccattaaccgccagatttgagtcgcgggaccc
		reBIRC5	gttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagct
			tggcaatccggtactgttggtaaagccacc
222	PL6	GRHL1_	ggcctaactggccggtaccactagtaaaaccggttttagaaaaaccggtttttcgaa
	64	3bp	aaccggttttgacaaaaccggttttctaaaaaccggttttactaaaaccggtttttg
		space_co	caaaaccggtttttgcgctcccgacatgccccgcggcgcgccattaaccgccagatt
		reBIRC5	tgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggc
			ctcggcggccaagcttggcaatccggtactgttggtaaagccacc
223	PL6	FOSL1-	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	69	5X_BIR	gggtgactcatgggtgactcatgtgcgctcccgacatgccccgcggcgcgccattaa
		C5core	ccgccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggatatc
			aagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
224	PL6	FOSL1-	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	72	11X_BI	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		RC5core	gtgactcatgggtgactcatgggtgactcatgtgcgctcccgacatgccccgcggcg
			cgccattaaccgccagatttgagtcgcgggacccgttggcagaggtgggctagcctc
			gaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaa
			agccacc
225	PL6	FOSL1-	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	73	7X_BIR	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgtgcgctcccgac
		C5core	atgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcagag
			gtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccg
			gtactgttggtaaagccacc
226	PL6	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	74	no	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		space_no	gtgactcatgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcag
		p53_BIR	aggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatc
		C5core	cggtactgttggtaaagccacc
227	PL6	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	75	TATATS	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		S_10bp	gtgactcatgcggtgctagctataaaaggccagcagcagcctgaccacatctcatcc
		spacing	tcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgtt
			ggtaaagccacc
228	PL6	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	76	TATATS	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		S_no	gtgactcatgtataaaaggccagcagcagcctgaccacatctcatcctcctcgagga
		spacing	tatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagcca
			CC
229	PL6	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	85	TATATS	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		S_25bp	gtgactcatgacatctttcagggaccggtgctagctataaaaggccagcagcagcct
		spacing	gaccacatctcatcctcctcgaggatatcaagatctggcctcggcggccaagcttgg
			caatccggtactgttggtaaagccacc
230	PL6	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	86	TATATS	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		S_50bp	gtgactcatgtggctattagcagtaccgcttagacacatctttcagggaccggtgct
		spacing	agctataaaaggccagcagcagcctgaccacatctcatcctcctcgaggatatcaag
			atctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
231	PL6	Forkhead_	ggcctaactggccggtaccactagtctgtttacctgtttacctgtttacctgtttac
	89	7XFOS	ctgtttacggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtga
		L1_BIR	ctcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgtgcgctc
		C5core	ccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttgg
			cagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggca
			atccggtactgttggtaaagccacc
232	PL6	Forkhead_	ggcctaactggccggtaccactagtctgtttacagactgtttactcgctgtttacga
	90	7XFOS	cctgtttacctactgtttacggtgactcatgggtgactcatgggtgactcatgggtg
		L1_BIR	actcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgac
		C5core	tcatgtgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgc
		3bp	gggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcgg
			ccaagcttggcaatccggtactgttggtaaagccacc
233	PL8	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	25	10bp	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		spacer_c	gtgactcatgcataggcctctgaacaacgcgtcccgacatgccccgcggcgcgccat
		oreBIRC	taaccgccagatttgagtcgcgggacccgttggcagaggtgggctagcctcgaggat
		5	atcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccac
			C
234	PL8	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	26	30bp	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		spacer_c	gtgactcatgcataggcctctgatagagctgcgatagaccaagacaacgcgtcccga
		oreBIRC	catgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcaga
		5	ggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatcc
			ggtactgttggtaaagccacc
235	PL8	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	27	88bp	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		spacer_c	gtgactcatgcatagaaacgacgcaatatctccatagggttaacggcggaacttgac
		oreBIRC	ggcgtccattagccacttggtcatgggacagggggggaaaacggacaacgcgtcccg
		5	acatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcag
			aggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatc
			cggtactgttggtaaagccacc
236	PL8	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	28	Low_cor	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		eBIRC5	gtgactcatgcataccggaagtacttgcgcaatgaccggaagtacaacgcgtcccga
			catgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcaga
			ggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatcc
			ggtactgttggtaaagccacc
237	PL8	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	29	Medium	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		coreBI	gtgactcatgcatttgcgcaacaggggcggggtgatgacacagcaattcgcttgcgt
		RC5	gagaagagaccggaagtgagggactttccacatgacacagcaatacaacgcgtcccg
			acatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcag
			aggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatc
			cggtactgttggtaaagccacc
238	PL8	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	30	High_cor	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		eBIRC5	gtgactcatgcatggggggggtgatgacacagcaattcgggactttccacgcttgc
			gtgagaagagaccggaagtgaatgacacagcaattcgcttgcgtgagaagctgggac
			tttcctaggggcggggttgggactttccacatgacacagcaatacaacgcgtcccga
			catgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcaga
			ggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatcc
			ggtactgttggtaaagccacc
239	PL8	Low_cor	ggcctaactggccggtaccactagtaccggaagtacttgcgcaatgaccggaagtac
	31	eBIRC5	aacgcgtcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcggga
			cccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaa
			gcttggcaatccggtactgttggtaaagccacc
240	PL8	Medium_	ggcctaactggccggtaccactagtttgcgcaacaggggggggtgatgacacagca
	32	coreBI	attcgcttgcgtgagaagagaccggaagtgagggactttccacatgacacagcaata
		RC5	caacgcgtcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcggg
			acccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggcca
			agcttggcaatccggtactgttggtaaagccacc
241	PL8	High_cor	ggcctaactggccggtaccactagtggggcggggtgatgacacagcaattcgggact
	33	eBIRC5	ttccacgcttgcgtgagaagagaccggaagtgaatgacacagcaattcgcttgcgtg
			agaagctgggactttcctaggggcggggttgggactttccacatgacacagcaatac
			aacgcgtcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcggga
			cccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaa
			gcttggcaatccggtactgttggtaaagccacc
242	PL8	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	34	Tetramer	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		p53_core	gtgactcatgcatacaacgcgtcccgacatgccccgacatgcccatcgacatgcccc
		BIRC5	gacatgcccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcag
			aggtgggctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatc
			cggtactgttggtaaagccacc
243	PL8	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	35	p53RE_c	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		oreBIRC	gtgactcatgcatgaattcggacatgcccgggcatgtccccagggacatgcccgggc
		5	atgtccccagagacatgtccagacatgtccccaggaacatgtcccaacatgttgtcc
			aggagacatgtccagacatgtccccaggaacatgtcccaacatgttgtactagtaca
			acgcgtcccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggac
			ccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggcggccaag
			cttggcaatccggtactgttggtaaagccacc
244	PL8	EN7R_F	ggcctaactggccggtacctgccactcaaagtggcacactccctgctcaggaggccg
	36	OSL1_co	ggagggaggacacagccctggcaactcctctgccccggggggtcaggaaggggtcac
		reBIRC5	cccacactccagaaccctacagaatgtggccttggcttttcccatcaagagctgggg
			aaagccaggccccgacttcattaccccctgcccccgtcccatgctcagtgggcccca
			tcgtgggtccatgccacactcccaactgagcagccccgcagccccgcgtgtcacaga
			catggggcctcctaattgctgctgaggtcccaatccctggctggacgtgcctg
245	PL8	FOSL1_	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	58	CS6X-	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatga
		BIRC5co	ctagtgtccccacccacacattcctgtccccacccacacattcctgtccccacccac
		re	acattcctgtccccacccacacattcctgtccccacccacacattcctgtccccacc
			cacacattcctgtgcgctcccgacatgccccgcggcgcgccattaaccgccagattt
			gagtcgcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcc
			tcggcggccaagcttggcaatccggtactgttggtaaagccacc
246	PL8	pGL4.10-	ggcctaactggccggtaccaagacaggttgtcctcccaggggatgggggtccatcca
	80	coreCEA	ccttgccgaaaagatttgtctgaggaactgaaaatagaagggaaaaaagaggaggga
		CAM5_1	caaaagaggcagaaatgagaggggaggggacagaggacacctgaataaagaccacac
			ccatgacccacgtgatgctgagaagtactcctgccctaggaagagactcagggcaga
			gggaggaaggacagcagaccagacagtcacagcagccttgacaaaacgttcctggaa
			ctaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaa
			tccggtactgttggtaaagccacc
247	PL8	pGL4.10-	ggcctaactggccggtaccatgacccacgtgatgctgagaagtactcctgccctagg
	81	coreCEA	aagagactcagggcagagggaggaaggacagcagaccagacagtcacagcagccttg
		CAM5_2	acaaaacgttcctggaactaccggtgctagcctcgaggatatcaagatctggcctcg
			gcggccaagcttggcaatccggtactgttggtaaagccacc
248	PL8	pGL4.10-	ggcctaactggccggtaccctggatgctcatcccgccaccgtcgcccaccccgccgc
	82	coreFA	tgcagaaaggcagcaactgccacacacctaagcaacttggcgggctattcgccctgc
		M111B_	agctgccgccagcgcgcggctcccgccagcgcgctggcaatcaaaagtcggagaaag
		1	cgcgaaacctccaggcacctcccactccgcccagctaccgcgcagctcctccctagc
			ctccactgggagacaggggacgcccatgagcgggaaagagcagggcggtgattgctt
			agtttatcctgggacacgggaactggccgtggactgagtggtgccggggaggggatc
			actgagaccgggaagggtcatccagacaaatagggagggtgggcgggttggcgcgca
			gtaccctcggcccggccttcagacccacctgcgcgcgctgcgcgctcatccggtcct
			tcccttcaatcactgtctggagtgatgataattggcttccacagtggatgagagatg
			agtcatttacatccaatgagagaaaaacagcctccagagactcttcgtccattggcc
			agcgagagtgtcagttcccaggctcctgccgcgcacgggcgagcccttctaggcggg
			aaaagttcagctgagagatataaaagagcagtctttccagcacctgcaaatccagag
			cggcgggcactgacgggcacttgcaccgtgtggacagactctccggttctgtgagtg
			gtttttcttttcccgggtcggacctggagttcttagggggatggctgaaccggtgct
			agcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgt
			tggtaaagccacc
249	PL8	pGL4.10-	ggcctaactggccggtacctgagaccgggaagggtcatccagacaaatagggagggt
	83	coreFA	gggcgggttggcgcgcagtaccctcggcccggccttcagacccacctgcgcgcgctg
		M111B_	cgcgctcatccggtccttcccttcaatcactgtctggagtgatgataattggcttcc
		2	acagtggatgagagatgagtcatttacatccaatgagagaaaaacagcctccagaga
			ctcttcgtccattggccagcgagagtgtcagttcccaggctcctgccgcgcacgggc
			gagcccttctaggcgggaaaagttcagctgagagatataaaagagcagtctttccag
			cacctgcaaatccagagcggcgggcactgacgggcacttgcaccgtgtggacagact
			ctccggttctgtgagtggtttttcttttcccgggtcggacctggagttcttaggggg
			atggctgaaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagct
			tggcaatccggtactgttggtaaagccacc
250	PL8	pGL4.10-	ggcctaactggccggtaccgggaaaagttcagctgagagatataaaagagcagtctt
	84	coreFA	tccagcacctgcaaatccagagcggcgggcactgacgggcacttgcaccgtgtggac
		M111B_	agactctccggttctgtgagtggtttttcttttcccgggtcggacctggagttctta
		3	gggggatggctgaaccggtgctagcctcgaggatatcaagatctggcctcggcggcc
			aagcttggcaatccggtactgttggtaaagccacc
251	PL8	pGL4.10-	ggcctaactggccggtaccctgctcctccttcttgcgggccgcgccctgccggcagt
	85	coreCEP	gacgtgccccgccctgcagccgcgggattcaaactcccggaagcggcatccacacct
		55	gatggtgtgactcggccgacgcgagcgccgcgcttcgcttcagctgctaaccggtgc
			tagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactg
			ttggtaaagccacc
252	PL8	pGL4.10-	ggcctaactggccggtaccggcccgccccctttccttacgcggattggtagctgcag
	86	coreKIF2	gcttccctatctgattggccgaacgaacgcagcgcgtaatttaaaatattgtatctg
		0A	taacaaagctgcacctcgtgggcggagttgtgctctgcggctgcgaaagtccagctt
			cggcgactaggtgtgagtaagccagtatcccaggaggagcaagtggcacgtcttcgg
			gtgagtgtgcggctgtgctggagcccgggttaccagctcttaccggtgctagcctcg
			aggatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaa
			gccacc
253	PL8	pGL4.10-	ggcctaactggccggtaccttgttttgacaggagcagggaagtattgtagaaaataa
	87	coreAGR	tttttatcataatggagtatggcaggttatatgactgcgaggatcagaattgtgaat
		2_1	catctcttgtgtgtcttcaagtaaataaaggcaatctgcccacggagcagaaaaaaa
			atctacaaactacaaactctgtccaatcatgtaaagacaaatcagccttcaggcaaa
			tcaaatgtcttcattcaaagtctacctggatttggcactctgcccatcgtttcaaaa
			cctcttaacaatacgtttcacaaatagttaaaaacatgcatactgaaaagcatactt
			ttgcaatgttatttttaaaaacaaggaactctttaacccagggaagataatcacttg
			gggaaaggaaggttcgtttctgagttagcaacaagtaaatgcagcactagtgggtgg
			gattgaggtgtgccctggtgcataaatagagactcagctgtgctggcacactcagaa
			gcttggaccgcatcctagccgccgactcacacaaggcaggtgggtgaggaaatccag
			gtaaggctcctgacagcagctttagaagggtacttgctggagtgaattcgggcctct
			gattaccggtgctagcctcgaggatatcaagatctggcctcggcggccaagcttggc
			aatccggtactgttggtaaagccacc
254	PL8	pGL4.10-	ggcctaactggccggtaccacctcttaacaatacgtttcacaaatagttaaaaacat
	88	coreAGR	gcatactgaaaagcatacttttgcaatgttatttttaaaaacaaggaactctttaac
		2_2	ccagggaagataatcacttggggaaaggaaggttcgtttctgagttagcaacaagta
			aatgcagcactagtgggtgggattgaggtgtgccctggtgcataaatagagactcag
			ctgtgctggcacactcagaagcttggaccgcatcctagccgccgactcacacaaggc
			aggtgggtgaggaaatccaggtaaggctcctgacagcagctttagaagggtacttgc
			tggagtgaattcgggcctctgattaccggtgctagcctcgaggatatcaagatctgg
			cctcggcggccaagcttggcaatccggtactgttggtaaagccacc
255	PL8	pGL4.10-	ggcctaactggccggtacccagtgggtaggtctagcagtggcgcagcaatagagcgc
	89	coreUBE	tccggagcgtctcattggctggatcaaacccaagcgagccattgattggtcgacgcc
		2C	cccagagggttacaattcaaacgcgggcgggcgggcccgcagtcctgcagttgcagt
			cgtgttctccgagttcctgtctctctgccgagctagcctcgaggatatcaagatctg
			gcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
256	PL8	pGL4.10-	ggcctaactggccggtaccagtggtgggggagtgaaaagagagatggagaaagaggg
	90	coreCST1	gatgggcagaaagaggaggaggagtcaggggcagggcatggaggtgggtggggctgg
			gctgccaaagcaggataaatgcacacctgcctgctggtctgggctccctgcctcggg
			ctctcaccctcctctcctgcagctccagctttgtgctctaccggtgctagcctcgag
			gatatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagc
			cacc
257	PL8	hTERT-	ggcctaactggccggtaccactagtcgggttaccccacagcctaggccgattcgacc
	93	FLUC	tctctccgctggggccctcgctggcgtccctgcaccctgggagcgcgagcggcgcgc
			gggcggggaagcgcggcccagacccccgggtccgcccggagcagctgcgctgtcggg
			gccaggccgggctcccagtggattcgcgggcacagacgcccaggaccgcgcttccca
			cgtggcggagggactggggacccgggcacccgtcctgccccttcaccttccagctcc
			gcctcctccgcgcggaccccgccccgtcccgacccctcccgggtccccggcccagcc
			ccctccgggccctcccagcccctccccttcctttccgcggccccgccctctcctcgc
			ggcgcgagtttcaggcagcgctgcgtcctgctgcgcacgtgggaagccctggccccg
			gccacccccgcgatgccgcgcgctcctagctatcctcgaggatatcaagatctggcc
			tcggcggccaagcttggcaatccggtactgttggtaaagccacc
258	PL8	pGL4.10-	ggcctaactggccggtaccctggcaggaagcctactgagatttattgaaaaggaaac
	94	murine	cgaattatcagggcactcgtttgcaacgccaacctgggctgtgttcggggcatgccc
		BIRC5-	agcctgctgtctgcagtgtgaagctctttagaagccactgcaaccacaggccgcccg
		FLUC	acaggaacagagacactgaaaacgggcccgcagcaaggcaggctcagcagccaacag
			tcacacccaggaagcagtatttttcttctgctcctggactctcttgcggtgtatggc
			tgcttccctttggtctgagccaggccgatggtctcagaaatagacacccattgactt
			tcttttccagcgctgggacatacagaccccgcctccatcccagggtgtctataggaa
			ggatggcggctgctgcagggaggagggtctcctgtcttcctaagggcgcccctccac
			cagcctgtgggtgggtccgaggcacttccattccgatatctagctggccaaatcctg
			caaaccttgaggcaggaagaacctgcagagcacatgggacttgcagcggacatgctt
			taaagaggtgccccaggcccgtccaccgccctcggccaccctccgtgtcctctgggg
			agcagctgcggaagattcgagtcagaatagcaagaaggaaccgcagcagaaggtaca
			actcccagcatgccctgcgcccgccacgcccacaaggccaggcgcagatgggcgtgg
			ggcgggactttcccggctcgcctcgcgccgtccactcccagaaggcagcgggcgagg
			gcgtggggccggggctctcccggcatgctctgcggcgcgcctccgcccgcgcgattt
			gaatcctgcgtttgagtcgtcttggcggaggttgtggtgacgcgctagcctcgagga
			tatcaagatctggcctcggcggccaagcttggcaatccggtactgttggtaaagcca
			CC
259	PL8	pGL4.10-	ggcctaactggccggtaccactcccagaaggcagcgggcgagggcgtggggccgggg
	95	murine	ctctcccggcatgctctgcggcgcgcctccgcccgcgcgatttgaatcctgcgtttg
		coreBIR	agtcgtcttggcggaggttgtggtgacgcgctagctattctagcctcgaggatatca
		C5-	agatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
		FLUC
260	PL9	PL-	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	88	FOSL1-	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		coreCEA	gtgactcatggtgatcatgctagcctcgaggatatcaagatcggtaccatgacccac
		CAM5_2	gtgatgctgagaagtactcctgccctaggaagagactcagggcagagggaggaagga
			cagcagaccagacagtcacagcagccttgacaaaacgttcctggaactaccggtgct
			agcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggtactgt
			tggtaaagccacc
261	PL9	PL-	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	89	FOSL1-	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		coreFA	gtgactcatggtgatcatcgggaaaagttcagctgagagatataaaagagcagtctt
		M111B_	tccagcacctgcaaatccagagcggcgggcactgacgggcacttgcaccgtgtggac
		3	agactctccggttctgtgagtggtttttcttttcccgggtcggacctggagttctta
			gggggatggctgaaccggtgctagcctcgaggatatcaagatctggcctcggcggcc
			aagcttggcaatccggtactgttggtaaagccacc
262	PL9	PL-	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	90	FOSL1-	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		coreKIF2	gtgactcatggtgatcatgctagcctcgaggatatcaagatcggtaccggcccgccc
		0A	cctttccttacgcggattggtagctgcaggcttccctatctgattggccgaacgaac
			gcagcgcgtaatttaaaatattgtatctgtaacaaagctgcacctcgtgggcggagt
			tgtgctctgcggctgcgaaagtccagcttcggcgactaggtgtgagtaagccagtat
			cccaggaggagcaagtggcacgtcttcgggtgagtgtgcggctgtgctggagcccgg
			gttaccagctcttaccggtgctagcctcgaggatatcaagatctggcctcggcggcc
			aagcttggcaatccggtactgttggtaaagccacc
263	PL9	PL-	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	91	FOSL1-	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		coreCST	gtgactcatggtgatcatgctagcctcgaggatatcaagatcggtaccagtggtggg
		1	ggagtgaaaagagagatggagaaagaggggatgggcagaaagaggaggaggagtcag
			gggcagggcatggaggtgggtggggctgggctgccaaagcaggataaatgcacacct
			gcctgctggtctgggctccctgcctcgggctctcaccctcctctcctgcagctccag
			ctttgtgctctaccggtgctagcctcgaggatatcaagatctggcctcggcggccaa
			gcttggcaatccggtactgttggtaaagccacc
264	PL9	PL-	ggcctaactggccggtaccactagtgtccccacccacacattcctgtccccacccac
	92	Canscript-	acattcctgtccccacccacacattcctgtccccacccacacattcctgtccccacc
		coreCEA	cacacattcctgtccccacccacacattcctgaccggtgctagcctcgaggatatca
		CAM5_2	agatcggtaccatgacccacgtgatgctgagaagtactcctgccctaggaagagact
			cagggcagagggaggaaggacagcagaccagacagtcacagcagccttgacaaaacg
			ttcctggaactaccggtgctagcctcgaggatatcaagatctggcctcggcggccaa
			gcttggcaatccggtactgttggtaaagccacc
265	PL9	PL-	ggcctaactggccggtaccactagtgtccccacccacacattcctgtccccacccac
	93	Canscript-	acattcctgtccccacccacacattcctgtccccacccacacattcctgtccccacc
		coreFA	cacacattcctgtccccacccacacattcctgcgggaaaagttcagctgagagatat
		M111B_	aaaagagcagtctttccagcacctgcaaatccagagcggcgggcactgacgggcact
		3	tgcaccgtgtggacagactctccggttctgtgagtggtttttcttttcccgggtcgg
			acctggagttcttagggggatggctgaaccggtgctagcctcgaggatatcaagatc
			tggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
266	PL9	PL-	ggcctaactggccggtaccactagtgtccccacccacacattcctgtccccacccac
	94	Canscript-	acattcctgtccccacccacacattcctgtccccacccacacattcctgtccccacc
		coreKIF2	cacacattcctgtccccacccacacattcctgcggcccgccccctttccttacgcgg
		0A	attggtagctgcaggcttccctatctgattggccgaacgaacgcagcgcgtaattta
			aaatattgtatctgtaacaaagctgcacctcgtgggcggagttgtgctctgcggctg
			cgaaagtccagcttcggcgactaggtgtgagtaagccagtatcccaggaggagcaag
			tggcacgtcttcgggtgagtgtgcggctgtgctggagcccgggttaccagctcttac
			cggtgctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccg
			gtactgttggtaaagccacc
267	PL9	PL-	ggcctaactggccggtaccactagtgtccccacccacacattcctgtccccacccac
	95	Canscript-	acattcctgtccccacccacacattcctgtccccacccacacattcctgtccccacc
		coreAGR	cacacattcctgtccccacccacacattcctgaccggtgctagcctcgaggatatca
		2_2	agatcggtaccacctcttaacaatacgtttcacaaatagttaaaaacatgcatactg
			aaaagcatacttttgcaatgttatttttaaaaacaaggaactctttaacccagggaa
			gataatcacttggggaaaggaaggttcgtttctgagttagcaacaagtaaatgcagc
			actagtgggtgggattgaggtgtgccctggtgcataaatagagactcagctgtgctg
			gcacactcagaagcttggaccgcatcctagccgccgactcacacaaggcaggtgggt
			gaggaaatccaggtaaggctcctgacagcagctttagaagggtacttgctggagtga
			attcgggcctctgattaccggtgctagcctcgaggatatcaagatctggcctcggcg
			gccaagcttggcaatccggtactgttggtaaagccacc
268	PL9	PL-	ggcctaactggccggtaccactagtgtccccacccacacattcctgtccccacccac
	96	Canscript-	acattcctgtccccacccacacattcctgtccccacccacacattcctgtccccacc
		coreCST	cacacattcctgtccccacccacacattcctgaccggtgctagcctcgaggatatca
		1	agatcggtaccagtggtgggggagtgaaaagagagatggagaaagaggggatgggca
			gaaagaggaggaggagtcaggggcagggcatggaggtgggtggggctgggctgccaa
			agcaggataaatgcacacctgcctgctggtctgggctccctgcctcgggctctcacc
			ctcctctcctgcagctccagctttgtgctctaccggtgctagcctcgaggatatcaa
			gatctggcctcggcggccaagcttggcaatccggtactgttggtaaagccacc
269	PL9	PL-	ggcctaactggccggtaccactagtggtgactcatgggtgactcatgggtgactcat
	99	FOSL1-	gggtgactcatgggtgactcatgggtgactcatgggtgactcatgggtgactcatgg
		coreAGR	gtgactcatggtgatcatgctagcctcgaggatatcaagatcggtaccacctcttaa
		2_2	caatacgtttcacaaatagttaaaaacatgcatactgaaaagcatacttttgcaatg
			ttatttttaaaaacaaggaactctttaacccagggaagataatcacttggggaaagg
			aaggttcgtttctgagttagcaacaagtaaatgcagcactagtgggtgggattgagg
			tgtgccctggtgcataaatagagactcagctgtgctggcacactcagaagcttggac
			cgcatcctagccgccgactcacacaaggcaggtgggtgaggaaatccaggtaaggct
			cctgacagcagctttagaagggtacttgctggagtgaattcgggcctctgattaccg
			gtgctagcctcgaggatatcaagatctggcctcggcggccaagcttggcaatccggt
			actgttggtaaagccacc
271	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	30	5XFOSL	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		1-	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		coreBIR	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
		C5-	ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
		FLUC	accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTGGTGACTCATGGGTGACTCATGGGTGACT
			CATGGGTGACTCATGGGTGACTCATGtgcgctcccgacatgccccgcggcgcgccat
			taaccgccagatttgagtcgcgggacccgttggcagaggtgggaattcaccggtcga
			cgctagc
273	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	31	7XFOSL	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		1-	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		coreBIR	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
		C5-	ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
		FLUC	accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTGGTGACTCATGGGTGACTCATGGGTGACT
			CATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGtgcgctccc
			gacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggca
			gaggtgggaattcaccggtcgacgctagc
274	NP1	NP-	TCTGTAGTTTGAGGAGAATATTTGTTATATTGCACAATAAAATAAGTTTGCAAGTTT
	03	AFP3-	TTTTTTTCTGCCCCAAAGAGCTCTGTGTCCTTGAACATAAAATACAAATAACCGCTA
		FLUC	TGCTGTTAATTATTAACAAATGTCCCATTTTCAACCTAAGGAAATACCATAAAGTAA
			CAGATATACCAACAAAAGGTTAATAATTAACAGGCATTGCCTGAAAAGAGTATAAAA
			GGCTTTCAGCATGATTTTCCATATTGTGCTTCCACCACTGCCAATAACAAAccggtc
			gacgctagc
278	NP1	NP-AFP-	gcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcct
	02	FLUC	aataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggg
			gtggggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctg
			gggatgcggtgggctctatggcccgggacggccgctagcccgcctaatgagcgggct
			tttttttggcttgttgtccacaaccgttaaaccttaaaagctttaaaagccttatat
			attcttttttttcttataaaacttaaaaccttagaggctatttaagttgctgattta
			tattaattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagta
			cgttagccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgag
			agcttagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctg
			atccacgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacat
			cttgttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgt
			atctaccttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagg
			gcgtgcccttgggctccccgggcgcgaCTAGTCTCGAGTCTTGTGTGCCTGGCATAT
			GATAGGCATTTAATAGTTTTAAAGAATTAATGTATTTAGATGAATTGCATACCAAAT
			CTGCTGTCTTTTCTTTATGGCTTCATTAACTTAATTTGAGAGAAATTAATTATTCTG
			CAACTTAGGGACAAGTCATCTCTTTGAATATTCTGTAGTTTGAGGAGAATATTTGTT
			ATATTTGCAAAATAAAATAAGTTTGCAAGTTTTTTTTTTCTGCCCCAAAGAGCTCTG
			TGTCCTTGAACATAAAATACAAATAACCGCTATGCTGTTAATTATTGGCAAATGTCC
			CATTTTCAACCTAAGGAAATACCATAAAGTAACAGATATACCAACAAAAGGTTACTA
			GTTAACAGGCATTGCCTGAAAAGAGTATAAAAGAATTTCAGCATGATTTTCCATATT
			GTGCTTCCACCACTGCCAATAACAAAATAACTAGCAGAGCTAGCCtcgaggctagc
279	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	88	coreAGR	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		2-FLUC	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
			acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgAATGCATACTAGTaacatttctctggcctaactgg
			ccggtacCACCTCTTAACAATACGTTTCACAAATAGTTAAAAACATGCATACTGAAA
			AGCATACTTTTGCAATGTTATTTTTAAAAACAAGGAACTCTTTAACCCAGGGAAGAT
			AATCACTTGGGGAAAGGAAGGTTCGTTTCTGAGTTAGCAACAAGTAAATGCAGCACT
			AGTGGGTGGGATTGAGGTqTGCCCTGGTGCATAAATAGAGACTCAGCTGTGCTGGCA
			CACTCAGAAGCTTGGACCGCATCCTAGCCGCCGACTCACACAAGGCAGGTGGGTGAG
			GAAATCCAGGTAAGGCTCCTGACAGCAGCTTTAGAAGGGTACTTGCTGGAGTGAATT
			CGGGCCTCTGATTAccggtcgacgctagc
281	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	85	coreCEA	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		CAM5-	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		FLUC	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgAATGCATACTAGTaacatttctctggcctaactgg
			ccggtaccatgACCCACGTGATGCTGAGAAGTACTCCTGCCCTAGGAAGAGACTCAG
			GGCAGAGGGAGGAAGGACAGCAGACCAGACAGTCACAGCAGCCTTGACAAAACGTTC
			CTGGAACTaccggtcgacgctagc
282	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	89	coreCST-	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		FLUC	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
			acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgAATGCATACTAGTaacatttctctggcctaactgg
			ccggtaccAGTGGTGGGGGAGTGAAAAGAGAGATGGAGAAAGAGGGGATGGGCAGAA
			AGAGGAGGAGGAGTCAGGGGCAGGGCATGGAGGTGGGTGGGGCTGGGCTGCCAAAGC
			AGGATAAATGCACACCTGCCTGCTGGTCTGGGCTCCCTGCCTCGGGCTCTCACCCTC
			CTCTCCTGCAGCTCCAGCTTTGTGCTCTccggtcgacgctagc
283	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	86	coreFA	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		M111B-	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		FLUC	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgAATGCATACTAGTaacatttctctggcctaactgg
			ccggtacCGGGAAAAGTTCAGCTGAGAGATATAAAAGAGCAGTCTTTCCAGCACCTG
			CAAATCCAGAGCGGCGGGCACTGACGGGCACTTGCACCGTGTGGACAGACTCTCCGG
			TTCTGTGAGTGGTTTTTCTTTTCCCGGGTCGGACCTGGAGTTCTTAGGGGGATGGCT
			Gaaccggtcgacgctagc
284	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	87	coreKIF2	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		0A-	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		FLUC	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcAATGCATACTAGTaacatttctctggcctaactggc
			cggtacCGGCCCGCCCCCTTTCCTTACGCGGATTGGTAGCTGCAGGCTTCCCTATCT
			GATTGGCCGAACGAACGCAGCGCGTAATTTAAAATATTGTATCTGTAACAAAGCTGC
			ACCTCGTGGGCGGAGTTGTGCTCTGCGGCTGCGAAAGTCCAGCTTCGGCGACTAGGT
			GTGAGTAAGCCAGTATCCCAGGAGGAGCAAGTGGCACGTCTTCGGGTGAGTGTGCGG
			CTGTGCTGGAGCCCGGGTTACCAGCTCTTAAccggtcgacgctagc
285	NP4	NP-	gagagcaactgcataaggctatgaagagatacgccctggttcctggaacaattgctt
	00	CREB3L	ttacagatgcacatatcgaggtggacatcacttacgctgagtacttcgaaatgtccg
		1_v6-	ttcggttggcagaagctatgaaacgatatgggctgaatacaaatcacagaatcgtcg
		coreBIR	tatgcagtgaaaactctcttcaattctttatgccggtgttgggcgcgttatttatcg
		C5-	gagttgcagttgcgcccgcgaacgacatttataatgaacgtgaattgctcaacagta
		FLUC	tgggcatttcgcagcctaccgtggtgttcgtttccaaaaaggggttgcaaaaaattt
			tgaacgtgcaaaaaaagctcccaatcatccaaaaaattattatcatggattctaaaa
			cggattaccagggatttcagtcgatgtacacgttcgtcacatctcatctacctcccg
			gttttaatgaatacgattttgtgccagagtccttcgatagggacaagacaattgcac
			tgatcatgaactcctctggatctactggtctgcctaaaggtgtcgctctgcctcata
			gaactgcctgcgtgagattctcgcatgccagagatcctatttttggcaatcaaatca
			ttccggatactgcgattttaagtgttgttccattccatcacggttttggaatgttta
			ctacactcggatatttgatatgtggatttcgagtcgtcttaatgtatagatttgaag
			aagagctgtttctgaggagccttcaggattacaagattcaaagtgcgctgctggtgc
			caaccctattctccttcttcgccaaaagcactctgattgacaaatacgatttatcta
			atttacacgaaattgcttctggtggcgctcccctctctaaggaagtcggggaagcgg
			ttgccaagaggttccatctgccaggtatcaggcaaggatatgggctcactgagacta
			catcagctattctgattacacccgagggggatgataaaccgggcgcggtcggtaaag
			ttgttccattttttgaagcgaaggttgtggatctggataccgggaaaacgctgggcg
			ttaatcaaagaggcgaactgtgtgtgagaggtcctatgattatgtccggttatgtaa
			acaatccggaagcgaccaacgccttgattgacaaggatggatggctacattctggag
			acatagcttactgggacgaagacgaacacttcttcatcgttgaccgcctgaagtctc
			tgattaagtacaaaggctatcaggtggctcccgctgaattggaatccatcttgctcc
			aacaccccaacatcttcgacgcaggtgtcgcaggtcttcccgacgatgacgccggtg
			aacttcccgccgccgttgttgttttggagcacggaaagacgatgacggaaaaagaga
			tcgtggattacgtcgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttg
			tgtttgtggacgaagtaccgaaaggtcttaccggaaaactcgacgcaagaaaaatca
			gagagatcctcataaaggccaagaagggcggaaagatcgccgtgtaatgaatgcatg
			aattcctgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttc
			cttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgc
			atcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacag
			caagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctat
			ggcccgggacggccgctagcccgcctaatgagcgggcttttttttggcttgttgtcc
			acaaccgttaaaccttaaaagctttaaaagccttatatattcttttttttcttataa
			aacttaaaaccttagaggctatttaagttgctgatttatattaattttattgttcaa
			acatgagagcttagtacgtgaaacatgagagcttagtacgttagccatgagagctta
			gtacgttagccatgagggtttagttcgttaaacatgagagcttagtacgttaaacat
			gagagcttagtacgtactatcaacaggttgaactgctgatccacgttgtggtagaat
			tggtaaagagagtcgtgtaaaatatcgagttcgcacatcttgttgtctgattattga
			tttttggcgaaaccatttgatcatatgacaagatgtgtatctaccttaacttaatga
			ttttgataaaaatcattaggtacggccgcggtgccagggcgtgcccttgggctcccc
			gggcgcgaCTAGTAACATTTCTCTGGCCTAACTGGCCGGTACCACATCGGCTATGCT
			GCTGCTAATGCCACGTCACCACATCGACATGCCACGTCACCATCATGCCATGCCACG
			TCACCACTGCAAGATGCCACGTCACCACAGTATAATGCCACGTCACCAAGTTACTAT
			GCCACGTCACCAggtacctgcgctcccgacatgccccgcggcgcgccattaaccgcc
			agatttgagtcgcgggacccgttggcagaggtggaccggtcgacgctagc
289	NP4	NP-	cgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttgt
	03	E4AD-	tgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatcta
		AFP3-	ccttaacttaatgattttgataaaaatcattaggtacCACTAGTTATTAATAGTAAT
		FLUC	CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTA
			CGGTAAATGGCCCGCCTTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGA
			CGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGT
			ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGC
			CCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGA
			CCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCA
			TGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGG
			GATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATC
			AACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATGGATCTCAGATTGAATTA
			TTTGCCTGTCATACAGCTAATAATTGACCATAAGACAATTAGATTTAAATTAGTTTT
			GAATCTTTCTAATACCAAAGTTCAGTTTACTGTTCCATGTTGCTTCTGAGTGGCTTC
			ACAGACTTATGAAAAAGTAAACGGAATCAGAATTACATCAATGCAAAAGCATTGCTG
			TGAACTCTGTACTTAGGACTAAACTTTGAGCAATAACACATATAGATTGAGGATTGT
			TTGCTGTTAGTATACAAACTCTGGTTCAAAGCTCCTCTTTATTGCTTGTCTTGGAAA
			ATTTGCTGTTCTTCATGGTTTCTCTTTTCACTGCTATCTATTTTTCTCAACCACTCA
			CATGGCTACAATAACTGTCTGCAAGCTTATGATTCCCAAATATCTATCTCTAGCCTC
			AATCTTGTTCCAGAAGATAAAAAGTAGTATTCAAATGCACATCAACGTCTCCACTTG
			GAGGGCTTAAAGACGTTTCAACATACAAACCGGGGAGTTTTGCCTGGAATGTTTCCT
			AAAATGTGTCCTGTAGCACATAGGGTCCTCTTGTTCCTTAAAATCTAATTACTTTTA
			GCCCAGTGCTCATCCCACCTATGGGGAGATGAGAGTGAAAAGGGAGCCTGATTAATA
			ATTACACTAAGTCAATAGGCATAGAGCCAGGACTGTTTGGGTAAACTGGTCACTTTA
			TCTTAAACTAAATATATCCAAAACTGAACATGTACTTAGTTACTAAGTCTTTGACTT
			TATCTCATTCATACCACTCAGCTTTATCCAGGCCACTTATTTGACAGTATTATTGCG
			AAAACTTCCTACTAGTGTCATCTCTTTGAATATTCTGTAGTTTGAGGAGAATATTTG
			TTATATTGCACAATAAAATAAGTTTGCAAGTTTTTTTTTTCTGCCCCAAAGAGCTCT
			GTGTCCTTGAACATAAAATACAAATAACCGCTATGCTGTTAATTATTAACAAATGTC
			CCATTTTCAACCTAAGGAAATACCATAAAGTAACAGATATACCAACAAAAGGTTAAT
			AATTAACAGGCATTGCCTGAAAAGAGTATAAAAGGCTTTCAGCATGATTTTCCATAT
			TGTGCTTCCACCACTGCCAATAACAAAccggtcgacgctagc
290	NP3	NP-	actggtctgcctaaaggtgtcgctctgcctcatagaactgcctgcgtgagattctcg
	71	EN7R-	catgccagagatcctatttttggcaatcaaatcattccggatactgcgattttaagt
		FOS-	gttgttccattccatcacggttttggaatgtttactacactcggatatttgatatgt
		coreBIR	ggatttcgagtcgtcttaatgtatagatttgaagaagagctgtttctgaggagcctt
		C5-	caggattacaagattcaaagtgcgctgctggtgccaaccctattctccttcttcgcc
		FLUC	aaaagcactctgattgacaaatacgatttatctaatttacacgaaattgcttctggt
			ggcgctcccctctctaaggaagtcggggaagcggttgccaagaggttccatctgcca
			ggtatcaggcaaggatatgggctcactgagactacatcagctattctgattacaccc
			gagggggatgataaaccgggcgcggtcggtaaagttgttccattttttgaagcgaag
			gttgtggatctggataccgggaaaacgctgggcgttaatcaaagaggcgaactgtgt
			gtgagaggtcctatgattatgtccggttatgtaaacaatccggaagcgaccaacgcc
			ttgattgacaaggatggatggctacattctggagacatagcttactgggacgaagac
			gaacacttcttcatcgttgaccgcctgaagtctctgattaagtacaaaggctatcag
			gtggctcccgctgaattggaatccatcttgctccaacaccccaacatcttcgacgca
			ggtgtcgcaggtcttcccgacgatgacgccggtgaacttcccgccgccgttgttgtt
			ttggagcacggaaagacgatgacggaaaaagagatcgtggattacgtcgccagtcaa
			gtaacaaccgcgaaaaagttgcgcggaggagttgtgtttgtggacgaagtaccgaaa
			ggtcttaccggaaaactcgacgcaagaaaaatcagagagatcctcataaaggccaag
			aagggcggaaagatcgccgtgtaatgaatgcatgaattcctgtgccttctagttgcc
			agccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactc
			ccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtc
			attctattctggggggtggggtggggcaggacagcaagggggaggattgggaagaca
			atagcaggcatgctggggatgcggtgggctctatggcccgggacggccgctagcccg
			cctaatgagcgggcttttttttggcttgttgtccacaaccgttaaaccttaaaagct
			ttaaaagccttatatattcttttttttcttataaaacttaaaaccttagaggctatt
			taagttgctgatttatattaattttattgttcaaacatgagagcttagtacgtgaaa
			catgagagcttagtacgttagccatgagagcttagtacgttagccatgagggtttag
			ttcgttaaacatgagagcttagtacgttaaacatgagagcttagtacgtactatcaa
			caggttgaactgctgatccacgttgtggtagaattggtaaagagagtcgtgtaaaat
			atcgagttcgcacatcttgttgtctgattattgatttttggcgaaaccatttgatca
			tatgacaagatgtgtatctaccttaacttaatgattttgataaaaatcattaggtac
			ggccgcggtgccagggcgtgcccttgggctccccgggcgcgaCTAGTAACATTTCTC
			TGGCCTAACTGGCCGGTACCTGCCACTCAAAGTGGCACACTCCCTGCTCAGGAGGCC
			GGGAGGGAGGACACAGCCCTGGCAACTCCTCTGCCCCGGGGGGTCAGGAAGGGGTCA
			CCCCACACTCCAGAACCCTACAGAATGTGGCCTTGGCTTTTCCCATCAAGAGCTGGG
			GAAAGCCAGGCCCCGACTTCATTACCCCCTGCCCCCGTCCCATGCTCAGTGGGCCCC
			ATCGTGGGTCCATGCCACACTCCCAACTGAGCAGCCCCGCAGCCCCGCGTGTCACAG
			ACATGGGGCCTCCTAATTGCTGCTGAGGTCCCAATCCCTGGCTGGACGTGCCTGATG
291	NP3	NP-	GAAGAGCCAGCTCTGGTCTCAGGGGGCTGGTTTGCAGGAGTCTCCACAGACCTGGCT
	69	EN18-	CCAGCTTTGTGTCTTCAAATGAATACCCGGCCAAGATTGCAACTAAATTACCAGAAA
		Canscript-	CACTTAGGTTTCCTCACAGACTCCACAACAGGGATGGAGAAGGAAGTCAGCTGACGA
		FLUC	GGTTACGACGCTGTTCGAGGGAGTCTTTCTTGGGTCACAAGTGGTAAACTGTGTTCC
			CTGAACAAAACCAGGAAGCTTTCAGTGTTTATTGTATGTACTAAGTGGAGGGAGGGG
			CTTCAGATTCTGATAAAAATATCTCCCCATTCCCAGTGCCCAATGTGACATGAATAG
			GAGGGCCCCTCCCTGAATTCCCAAGCAGATCTCCAGAGACAGCTTCAGAGAGCAGGG
			AGCCCACGGTGGCTGGGGCTTTAGGGACTTTCTGGGTTGTGGGGAGGCTAGAGGCTG
			GGCAGTCCCAGCAGGATTTGGCCTCTAGGGACCGGGCACTGTAGGGCTCAGGAGAGC
			AGCTGCCGTCCCAGTATATAAGCATAGGTGGAATTATCTGGAAACATATTTCTGCGT
			TTCACAGGCAGAGAAATCAGTCTATCCCTAAAGAATGGAAGAGCTACAGTAGCAGAC
			CTACCACCCTCCACCCTCCCACAGGCAAAAGCCCCTGAGATTCAGGTTTGGGAAGAA
			AAAGAAAATATCCCAAATATGTCATTTGAGAAAGCAGCTGCTAACCACAGGCGGCCC
			CAGCTTTTCTCAAGATCCAGGATGTGGGTTCAGTGCCCTTACTAGGGCAGTGGGGGA
			GGACGGTCAGTACCAGGACCCCAGGCACAGGCCTGGAGGACTTGCTCCCCCAAGCAA
			CTCAGATCCACGCAGAACCCATGGTACCACTAGTGGTGACTCATGGGTGACTCATGG
			GTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGT
			GACTCATGGGTGACTCATGtgcgctcccgacatgccccgcggcgcgccattaaccgc
			cagatttgagtcgcgggacccgttggcagaggtggaccggtcgacgctagc
			cgattttgtgccagagtccttcgatagggacaagacaattgcactgatcatgaactc
			ctctggatctactggtctgcctaaaggtgtcgctctgcctcatagaactgcctgcgt
			gagattctcgcatgccagagatcctatttttggcaatcaaatcattccggatactgc
			gattttaagtgttgttccattccatcacggttttggaatgtttactacactcggata
			tttgatatgtggatttcgagtcgtcttaatgtatagatttgaagaagagctgtttct
			gaggagccttcaggattacaagattcaaagtgcgctgctggtgccaaccctattctc
			cttcttcgccaaaagcactctgattgacaaatacgatttatctaatttacacgaaat
			tgcttctggtggcgctcccctctctaaggaagtcggggaagcggttgccaagaggtt
			ccatctgccaggtatcaggcaaggatatgggctcactgagactacatcagctattct
			gattacacccgagggggatgataaaccgggcgcggtcggtaaagttgttccattttt
			tgaagcgaaggttgtggatctggataccgggaaaacgctgggcgttaatcaaagagg
			cgaactgtgtgtgagaggtcctatgattatgtccggttatgtaaacaatccggaagc
			gaccaacgccttgattgacaaggatggatggctacattctggagacatagcttactg
			ggacgaagacgaacacttcttcatcgttgaccgcctgaagtctctgattaagtacaa
			aggctatcaggtggctcccgctgaattggaatccatcttgctccaacaccccaacat
			cttcgacgcaggtgtcgcaggtcttcccgacgatgacgccggtgaacttcccgccgc
			cgttgttgttttggagcacggaaagacgatgacggaaaaagagatcgtggattacgt
			cgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttgtgtttgtggacga
			agtaccgaaaggtcttaccggaaaactcgacgcaagaaaaatcagagagatcctcat
			aaaggccaagaagggcggaaagatcgccgtgtaatgaatgcatgaattcctgtgcct
			tctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaa
			ggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctg
			agtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggat
			tgggaagacaatagcaggcatgctggggatgcggtgggctctatggcccgggacggc
			cgctagcccgcctaatgagcgggcttttttttggcttgttgtccacaaccgttaaac
			cttaaaagctttaaaagccttatatattcttttttttcttataaaacttaaaacctt
			agaggctatttaagttgctgatttatattaattttattgttcaaacatgagagctta
			gtacgtgaaacatgagagcttagtacgttagccatgagagcttagtacgttagccat
			gagggtttagttcgttaaacatgagagcttagtacgttaaacatgagagcttagtac
			gtactatcaacaggttgaactgctgatccacgttgtggtagaattggtaaagagagt
			cgtgtaaaatatcgagttcgcacatcttgttgtctgattattgatttttggcgaaac
			catttgatcatatgacaagatgtgtatctaccttaacttaatgattttgataaaaat
			cattaggtacggccgcggtgccagggcgtgcccttgggctccccgggcgcgACTAGT
			CTTCTGCCCTGAGAAAGACCTATGATTGCATGACACAAAAGAGACTGTTCAAAGGGA
			CACCATCATTCAGCAGGGCAAGCCTCCTTGCTGGGGGCAACCTGGTAGCTCCTGAGC
			CTCCCTCATCTTCACTGAGCCCCTCCAACTCTCTGAGTTCCCATGCCCCTCACTGAA
			CCTCCCTTCCCCCATGGCGAGCCTCCGCCAGCACCTTTGCACACACTCAGCCCCTTC
			CCCCTACTGAGCCCCAGCACAGTCACTGAACAGCTCTTCTTCCCCTCTGACTGAGTC
			ATCCTCCCAAGCCCTCCCCTTCCCCTCACTGAGTCTCCACCACCCCTGGTCACTGGG
			CACCCTGCTTCTGACCTCCTCCCTCCCCCAACCCCTCCACCCTTCCTCTTCACTGAG
			CCTGGCGCCTCTCACCCACCCGCCTTCCTCTCCCAGCCGCTTCTGAGCTGCCTCTTT
			GGAGCCCAACTGTCTCGCCCACGAGTCCCCATCACTCAGTCTCACTCACTCTAAGAC
			ACCTGAAAGCAGTTAGAGAACATGTGTTCATGGGGGGAGGATGAGGCTCTATCATCA
			TCCTGCAAACTAGTGTCCCCACCCACACATTCCTGTCCCCACCCACACATTCCTGTC
			CCCACCCACACATTCCTGTCCCCACCCACACATTCCTGTCCCCACCCACACATTCCT
			GTCCCCACCCACACATTCCTGAccggtcgacgctagc
292	NP3	NP-	cgattttgtgccagagtccttcgatagggacaagacaattgcactgatcatgaactc
	70	EN19-	ctctggatctactggtctgcctaaaggtgtcgctctgcctcatagaactgcctgcgt
		Canscript-	gagattctcgcatgccagagatcctatttttggcaatcaaatcattccggatactgc
		FLUC	gattttaagtgttgttccattccatcacggttttggaatgtttactacactcggata
			tttgatatgtggatttcgagtcgtcttaatgtatagatttgaagaagagctgtttct
			gaggagccttcaggattacaagattcaaagtgcgctgctggtgccaaccctattctc
			cttcttcgccaaaagcactctgattgacaaatacgatttatctaatttacacgaaat
			tgcttctggtggcgctcccctctctaaggaagtcggggaagcggttgccaagaggtt
			ccatctgccaggtatcaggcaaggatatgggctcactgagactacatcagctattct
			gattacacccgagggggatgataaaccgggcgcggtcggtaaagttgttccattttt
			tgaagcgaaggttgtggatctggataccgggaaaacgctgggcgttaatcaaagagg
			cgaactgtgtgtgagaggtcctatgattatgtccggttatgtaaacaatccggaagc
			gaccaacgccttgattgacaaggatggatggctacattctggagacatagcttactg
			ggacgaagacgaacacttcttcatcgttgaccgcctgaagtctctgattaagtacaa
			aggctatcaggtggctcccgctgaattggaatccatcttgctccaacaccccaacat
			cttcgacgcaggtgtcgcaggtcttcccgacgatgacgccggtgaacttcccgccgc
			cgttgttgttttggagcacggaaagacgatgacggaaaaagagatcgtggattacgt
			cgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttgtgtttgtggacga
			agtaccgaaaggtcttaccggaaaactcgacgcaagaaaaatcagagagatcctcat
			aaaggccaagaagggcggaaagatcgccgtgtaatgaatgcatgaattcctgtgcct
			tctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaa
			ggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctg
			agtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggat
			tgggaagacaatagcaggcatgctggggatgcggtgggctctatggcccgggacggc
			cgctagcccgcctaatgagcgggcttttttttggcttgttgtccacaaccgttaaac
			cttaaaagctttaaaagccttatatattcttttttttcttataaaacttaaaacctt
			agaggctatttaagttgctgatttatattaattttattgttcaaacatgagagctta
			gtacgtgaaacatgagagcttagtacgttagccatgagagcttagtacgttagccat
			gagggtttagttcgttaaacatgagagcttagtacgttaaacatgagagcttagtac
			gtactatcaacaggttgaactgctgatccacgttgtggtagaattggtaaagagagt
			cgtgtaaaatatcgagttcgcacatcttgttgtctgattattgatttttggcgaaac
			catttgatcatatgacaagatgtgtatctaccttaacttaatgattttgataaaaat
			cattaggtacggccgcggtgccagggcgtgcccttgggctccccgggcgcgACTAGT
			GAACATACACACCTGTGGGGGTGTCTAAGGGGCTCCCAGGGAGTTCTGGGGGGTCCT
			GGGGAGCAGGACCCTCTTCACTCCCTCCTCCAGGGGAAGTGGCCCTGGGGCACCCCA
			GGCTGTTCCCCCAGCTCTGTGGGGCCGAAGCCATCCACAGGGGGCTTTCCCCACCGG
			ATGTGGTGCGGGCCGTGGTTAATCTCACTTGAGTTAGTCACCCAGGACAAACAGCTA
			ACCGACACAATTCCTCCCAAGTCCAGGGGGCCGGAGGCGGGGTCAGCACCTGGCGGC
			AGGAGACAGTGCTGCCCTGGGATGTGGCCGGGCCTCCCTCCATTCCCAATCCTGTTG
			TCTCTGTGGCAATACCTGGCTGGGAGCTCCTATCAGGCCCGTGACCCCCGCCCTTTC
			TCCAGTGCCCTCCTGTCTGCATTCACCTGTCAGATCCCGgGGAGAGAGGGGCACTGG
			CGGCCGCCCAGGACCAGAGCTGTGGGGCCTCCCGCACCAGAGTGCAGTGAAGGTTTG
			TGGGCTGCTAGTGTCCCCACCCACACATTCCTGTCCCCACCCACACATTCCTGTCCC
			CACCCACACATTCCTGTCCCCACCCACACATTCCTGTCCCCACCCACACATTCCTGT
			CCCCACCCACACATTCCTGAccggtcgacgctagc
293	NP3	NP-	gagagcaactgcataaggctatgaagagatacgccctggttcctggaacaattgctt
	99	ETV4-	ttacagatgcacatatcgaggtggacatcacttacgctgagtacttcgaaatgtccg
		coreBIR	ttcggttggcagaagctatgaaacgatatgggctgaatacaaatcacagaatcgtcg
		C5-	tatgcagtgaaaactctcttcaattctttatgccggtgttgggcgcgttatttatcg
		FLUC	gagttgcagttgcgcccgcgaacgacatttataatgaacgtgaattgctcaacagta
			tgggcatttcgcagcctaccgtggtgttcgtttccaaaaaggggttgcaaaaaattt
			tgaacgtgcaaaaaaagctcccaatcatccaaaaaattattatcatggattctaaaa
			cggattaccagggatttcagtcgatgtacacgttcgtcacatctcatctacctcccg
			gttttaatgaatacgattttgtgccagagtccttcgatagggacaagacaattgcac
			tgatcatgaactcctctggatctactggtctgcctaaaggtgtcgctctgcctcata
			gaactgcctgcgtgagattctcgcatgccagagatcctatttttggcaatcaaatca
			ttccggatactgcgattttaagtgttgttccattccatcacggttttggaatgttta
			ctacactcggatatttgatatgtggatttcgagtcgtcttaatgtatagatttgaag
			aagagctgtttctgaggagccttcaggattacaagattcaaagtgcgctgctggtgc
			caaccctattctccttcttcgccaaaagcactctgattgacaaatacgatttatcta
			atttacacgaaattgcttctggtggcgctcccctctctaaggaagtcggggaagcgg
			ttgccaagaggttccatctgccaggtatcaggcaaggatatgggctcactgagacta
			catcagctattctgattacacccgagggggatgataaaccgggcgcggtcggtaaag
			ttgttccattttttgaagcgaaggttgtggatctggataccgggaaaacgctgggcg
			ttaatcaaagaggcgaactgtgtgtgagaggtcctatgattatgtccggttatgtaa
			acaatccggaagcgaccaacgccttgattgacaaggatggatggctacattctggag
			acatagcttactgggacgaagacgaacacttcttcatcgttgaccgcctgaagtctc
			tgattaagtacaaaggctatcaggtggctcccgctgaattggaatccatcttgctcc
			aacaccccaacatcttcgacgcaggtgtcgcaggtcttcccgacgatgacgccggtg
			aacttcccgccgccgttgttgttttggagcacggaaagacgatgacggaaaaagaga
			tcgtggattacgtcgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttg
			tgtttgtggacgaagtaccgaaaggtcttaccggaaaactcgacgcaagaaaaatca
			gagagatcctcataaaggccaagaagggcggaaagatcgccgtgtaatgaatgcatg
			aattcctgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttc
			cttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgc
			atcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacag
			caagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctat
			ggcccgggacggccgctagcccgcctaatgagcgggcttttttttggcttgttgtcc
			acaaccgttaaaccttaaaagctttaaaagccttatatattcttttttttcttataa
			aacttaaaaccttagaggctatttaagttgctgatttatattaattttattgttcAA
			ACATGAGAGCTTAGTACGTGaaacatgagagcttagtacgtgaaacatgagagctta
			gtacgttagccatgagagcttagtacgttagccatgagggtttagttcgttaaacat
			gagagcttagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactg
			ctgatccacgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgca
			catcttgttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatg
			tgtatctaccttaacttaatgattttgataaaaatcattaggtacggccgcggtgcc
			agggcgtgcccttgggctccccgggcgcgaCTAGTAACATTTCTCTGGCCTAACTGG
			CCGGTACCACTAGTACCGGAAGTAAGAACCGGAAGTATCGACCGGAAGTAGACACCG
			GAAGTACTAACCGGAAGTAACTACCGGAAGTATGCACCGGAAGTAtgcgctcccgac
			atgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcagag
			gtggaccggtcgacgctagc
301	NP3	NP-FOS-	tcaaacatgagagcttagtacgtgaaaCATGAGAGCTTAGTACGTTAGCcatgagag
	91	coreAGR	cttagtacgttagccatgagagcttagtacgttagccatgagggtttagttcgttaa
		2-FLUC	acatgagagcttagtacgttaaacatgagagcttagtacgtactatcaacaggttga
			actgctgatccacgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagtt
			cgcacatcttgttgtctgattattgatttttggcgaaaccatttgatcatatgacaa
			gatgtgtatctaccttaacttaatgattttgataaaaatcattaggtacggccgcgg
			tgccagggcgtgcccttgggctccccgggcgcgaATGCATACTAGTAACATTTCTCT
			GGCCTAACTGGCCGGTACCGATCTTGATATCCTCGAGGCTAGCATGATCACCATGAG
			TCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTC
			ACCCATGAGTCACCCATGAGTCACCCATGAGTCACCACTAGTGGTACCACCTCTTAA
			CAATACGTTTCACAAATAGTTAAAAACATGCATACTGAAAAGCATACTTTTGCAATG
			TTATTTTTAAAAACAAGGAACTCTTTAACCCAGGGAAGATAATCACTTGGGGAAAGG
			AAGGTTCGTTTCTGAGTTAGCAACAAGTAAATGCAGCACTAGTGGGTGGGATTGAGG
			TgTGCCCTGGTGCATAAATAGAGACTCAGCTGTGCTGGCACACTCAGAAGCTTGGAC
			CGCATCCTAGCCGCCGACTCACACAAGGCAGGTGGGTGAGGAAATCCAGGTAAGGCT
			CCTGACAGCAGCTTTAGAAGGGTACTTGCTGGAGTGAATTCGGGCCTCTGATTAccg
			gtcgacgctagc
302	NP4	NP-FOS-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	04	coreCEA	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		CAM-	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		FLUC	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgAATGCATaCTAGTGGTGACTCATGGGTGACTCATG
			GGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGG
			TGACTCATGGGTGACTCATGGTGATCATGCTAGCCTCGAGGATATCAAGATCGGTAC
			CATGACCCACGTGATGCTGAGAAGTACTCCTGCCCTAGGAAGAGACTCAGGGCAGAG
			GGAGGAAGGACAGCAGACCAGACAGTCACAGCAGCCTTGACAAAACGTTCCTGGAAC
			Taccggtcgacgctagc
303	NP3	NP-FOS-	aattttattgttcaaacatgagagcttagtacgtgaaaCATGAGAGCTTAGTACGTT
	92	coreCST-	AGCcatgagagcttagtacgttagccatgagagcttagtacgttagccatgagggtt
		FLUC	tagttcgttaaacatgagagcttagtacgttaaacatgagagcttagtacgtactat
			caacaggttgaactgctgatccacgttgtggtagaattggtaaagagagtcgtgtaa
			aatatcgagttcgcacatcttgttgtctgattattgatttttggcgaaaccatttga
			tcatatgacaagatgtgtatctaccttaacttaatgattttgataaaaatcattagg
			tacggccgcggtgccagggcgtgcccttgggctccccgggcgcgAATGCATACTAGT
			AACATTTCTCTGGCCTAACTGGCCGGTACCGATCTTGATATCCTCGAGGCTAGCATG
			ATCACCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTC
			ACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCACTAGTGGTA
			CCAGTGGTGGGGGAGTGAAAAGAGAGATGGAGAAAGAGGGGATGGGCAGAAAGAGGA
			GGAGGAGTCAGGGGCAGGGCATGGAGGTGGGTGGGGCTGGGCTGCCAAAGCAGGATA
			AATGCACACCTGCCTGCTGGTCTGGGCTCCCTGCCTCGGGCTCTCACCCTCCTCTCC
			TGCAGCTCCAGCTTTGTGCTCTaccggtcgacgctagc
304	NP3	NP-FOS-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	90	coreFA	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		M111B-	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		FLUC	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTAACATTTCTCTGGCCTAACTGGCCGGTAC
			CACTAGTGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGAC
			TCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGTGATCAT
			GCTAGCCTCGAGGATATCAAGATCGGTACCGGGAAAAGTTCAGCTGAGAGATATAAA
			AGAGCAGTCTTTCCAGCACCTGCAAATCCAGAGCGGCGGGCACTGACGGGCACTTGC
			ACCGTGTGGACAGACTCTCCGGTTCTGTGAGTGGTTTTTCTTTTCCCGGGTCGGACC
			TGGAGTTCTTAGGGGGATGGCTGaaccggtcgacgctagc
305	NP4	NP-FOS-	ataccgggaaaacgctgggcgttaatcaaagaggcgaactgtgtgtgagaggtccta
	05	coreKIF-	tgattatgtccggttatgtaaacaatccggaagcgaccaacgccttgattgacaagg
		FLUC	atggatggctacattctggagacatagcttactgggacgaagacgaacacttcttca
			tcgttgaccgcctgaagtctctgattaagtacaaaggctatcaggtggctcccgctg
			aattggaatccatcttgctccaacaccccaacatcttcgacgcaggtgtcgcaggtc
			ttcccgacgatgacgccggtgaacttcccgccgccgttgttgttttggagcacggaa
			agacgatgacggaaaaagagatcgtggattacgtcgccagtcaagtaacaaccgcga
			aaaagttgcgcggaggagttgtgtttgtggacgaagtaccgaaaggtcttaccggaa
			aactcgacgcaagaaaaatcagagagatcctcataaaggccaagaagggcggaaaga
			tcgccgtgtaatgaatgcatgaattcctgtgccttctagttgccagccatctgttgt
			ttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttc
			ctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggg
			gggtggggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgc
			tggggatgcggtgggctctatggcccgggacggccgctagcccgcctaatgagcggg
			cttttttttggcttgttgtccacaaccgttaaaccttaaaagctttaaaagccttat
			atattcttttttttcttataaaacttaaaaccttagaggctatttaagttgctgatt
			tatattaattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttag
			tacgttagccatgagagcttagtacgttagccatgagggtttagttcgttaaacatg
			agagcttagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgc
			tgatccacgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcac
			atcttgttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgt
			gtatctaccttaacttaatgattttgataaaaatcattaggtacggccgcggtgcca
			gggcgtgcccttgggctccccgggcgcgAATGCATaCTAGTGGTGACTCATGGGTGA
			CTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACT
			CATGGGTGACTCATGGGTGACTCATGGTGATCATGCTAGCCTCGAGGATATCAAGAT
			CGGTACCGGCCCGCCCCCTTTCCTTACGCGGATTGGTAGCTGCAGGCTTCCCTATCT
			GATTGGCCGAACGAACGCAGCGCGTAATTTAAAATATTGTATCTGTAACAAAGCTGC
			ACCTCGTGGGCGGAGTTGTGCTCTGCGGCTGCGAAAGTCCAGCTTCGGCGACTAGGT
			GTGAGTAAGCCAGTATCCCAGGAGGAGCAAGTGGCACGTCTTCGGGTGAGTGTGCGG
			CTGTGCTGGAGCCCGGGTTACCAGCTCTTccggtcgacgctagc
310	NP4	NP-FOS-	cttataaaacttaaaaccttagaggctatttaagttgctgatttatattaattttat
	64	FOS-	tgttcaaacatgagagcttagtacgtgaaaCATGAGAGCTTAGTACGTTAGCcatga
		coreAGR	gagcttagtacgttagccatgagagcttagtacgttagccatgagggtttagttcgt
		2-FLUC	taaacatgagagcttagtacgttaaacatgagagcttagtacgtactatcaacaggt
			tgaactgctgatccacgttgtggtagaattggtaaagagagtcgtgtaaaatatcga
			gttcgcacatcttgttgtctgattattgatttttggcgaaaccatttgatcatatga
			caagatgtgtatctaccttaacttaatgattttgataaaaatcattaggtacggccg
			cggtgccagggcgtgcccttgggctccccgggcgcgaATGCATACTAGTAACATTTC
			TCTGGCCTAACTGGCCGGTACCGATCTTGATATCCTCGAGGCTAGCATGATCACCAT
			GAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGA
			GTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCACTAGTGGTACCGATTCT
			TGATATCCTCGAGGCTAGCATGATCACCATGAGTCACCCATGAGTCACCCATGAGTC
			ACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCAC
			CCATGAGTCACCACTAGTGGTACCACCTCTTAACAATACGTTTCACAAATAGTTAAA
			AACATGCATACTGAAAAGCATACTTTTGCAATGTTATTTTTAAAAACAAGGAACTCT
			TTAACCCAGGGAAGATAATCACTTGGGGAAAGGAAGGTTCGTTTCTGAGTTAGCAAC
			AAGTAAATGCAGCACTAGTGGGTGGGATTGAGGTgTGCCCTGGTGCATAAATAGAGA
			CTCAGCTGTGCTGGCACACTCAGAAGCTTGGACCGCATCCTAGCCGCCGACTCACAC
			AAGGCAGGTGGGTGAGGAAATCCAGGTAAGGCTCCTGACAGCAGCTTTAGAAGGGTA
			CTTGCTGGAGTGAATTCGGGCCTCTGATTAccggtcgacgctagc
311	NP4	NP-FOS-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	06	FOS-	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		coreCEA	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		CAM-	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
		FLUC	ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgAATGCATaCTAGTAACATTTCTCTGGCCTAACTGG
			CCGGTACCACTAGTGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCAT
			GGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGG
			TGATCATGCTAGCCTCGAGGATATCAAGATCGGTACCACTAGTGGTGACTCATGGGT
			GACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGA
			CTCATGGGTGACTCATGGGTGACTCATGGTGATCATGCTAGCCTCGAGGATATCAAG
			ATCGGTACCATGACCCACGTGATGCTGAGAAGTACTCCTGCCCTAGGAAGAGACTCA
			GGGCAGAGGGAGGAAGGACAGCAGACCAGACAGTCACAGCAGCCTTGACAAAACGTT
			CCTGGAACTaccggtcgacgctagc
312	NP4	NP-FOS-	cttataaaacttaaaaccttagaggctatttaagttgctgatttatattaattttat
	63	FOS-	tgttcaaacatgagagcttagtacgtgaaaCATGAGAGCTTAGTACGTTAGCcatga
		FOS-	gagcttagtacgttagccatgagagcttagtacgttagccatgagggtttagttcgt
		coreAGR	taaacatgagagcttagtacgttaaacatgagagcttagtacgtactatcaacaggt
		2-FLUC	tgaactgctgatccacgttgtggtagaattggtaaagagagtcgtgtaaaatatcga
			gttcgcacatcttgttgtctgattattgatttttggcgaaaccatttgatcatatga
			caagatgtgtatctaccttaacttaatgattttgataaaaatcattaggtacggccg
			cggtgccagggcgtgcccttgggctccccgggcgcgaATGCATACTAGTAACATTTC
			TCTGGCCTAACTGGCCGGTACCGATCTTGATATCCTCGAGGCTAGCATGATCACCAT
			GAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCACTAGTGGTACCGATC
			TTGATATCCTCGAGGCTAGCATGATCACCATGAGTCACCCATGAGTCACCCATGAGT
			CACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCA
			CCCATGAGTCACCACTAGTGGTACCGATTCTTGATATCCTCGAGGCTAGCATGATCA
			CCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCC
			ATGAGTCACCCATGAGTCACCCATGAGTCACCCATGAGTCACCACTAGTGGTACCAC
			CTCTTAACAATACGTTTCACAAATAGTTAAAAACATGCATACTGAAAAGCATACTTT
			TGCAATGTTATTTTTAAAAACAAGGAACTCTTTAACCCAGGGAAGATAATCACTTGG
			GGAAAGGAAGGTTCGTTTCTGAGTTAGCAACAAGTAAATGCAGCACTAGTGGGTGGG
			ATTGAGGTgTGCCCTGGTGCATAAATAGAGACTCAGCTGTGCTGGCACACTCAGAAG
			CTTGGACCGCATCCTAGCCGCCGACTCACACAAGGCAGGTGGGTGAGGAAATCCAGG
			TAAGGCTCCTGACAGCAGCTTTAGAAGGGTACTTGCTGGAGTGAATTCGGGCCTCTG
			ATTAccggtcgacgctagc
315	NP4	NP-FOS-	ctgggacgaagacgaacacttcttcatcgttgaccgcctgaagtctctgattaagta
	59	TATA-	caaaggctatcaggtggctcccgctgaattggaatccatcttgctccaacaccccaa
		TSS-	catcttcgacgcaggtgtcgcaggtcttcccgacgatgacgccggtgaacttcccgc
		FLUC-	cgccgttgttgttttggagcacggaaagacgatgacggaaaaagagatcgtggatta
		3′OIPR	cgtcgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttgtgtttgtgga
			cgaagtaccgaaaggtcttaccggaaaactcgacgcaagaaaaatcagagagatcct
			cataaaggccaagaagggcggaaagatcgccgtgtaatgaattgggATCTTCacaca
			gcagGTaaggttgcGGGCCGGGCCTGGGCCGGGTCCGGGCCGGGgcccgcctaatga
			gcgggcttttttttggcttgttgtccacaaccgttaaaccttaaaagctttaaaagc
			cttatatattcttttttttcttataaaacttaaaaccttagaggctatttaagttgc
			tgatttatattaattttattgttcaaacatgagagcttagtacgtgaaacatgagag
			cttagtacgttagccatgagagcttagtacgttagccatgagggtttagttcgttaa
			acatgagagcttagtacgttaaacatgagagcttagtacgtactatcaacaggttga
			actgctgatccacgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagtt
			cgcacatcttgttgtctgattattgatttttggcgaaaccatttgatcatatgacaa
			gatgtgtatctaccttaacttaatgattttgataaaaatcattaccgcaCTGACccc
			tggtgttgcTTTTTTTTTTTAGgccgcaagCTGAAGcgtgtccctgtgccttctagt
			tgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgcc
			actcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtagg
			tgtcattctattctggggggtggggtggggcaggacagcaagggggaggattgggaa
			gacaatagcaggcatgctggggatgcggtgggctctatggggtaccatgcatactag
			tGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGG
			GTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGCGGTGCTAGCTATA
			AAAGGCCAGCAGCAGCCTGACCACATCTCATCCTCctcgaggatatcaagatctggc
			ctcggcggccagaattcaccggtcacc
318	NP3	NP-	ggccgctagcccgcctaatgagcgggcttttttttggcttgttgtccacaaccgtta
	14	FOSL1-	aaccttaaaagctttaaaagccttatatattcttttttttcttataaaacttaaaac
		Canscript-	cttagaggctatttaagttgctgatttatattaattttattgttcaaacatgagagc
		coreBIR	ttagtacgtgaaacatgagagcttagtacgttagccatgagagcttagtacgttagc
		C5-	catgagggtttagttcgttaaacatgagagcttagtacgttaaacatgagagcttag
		FLUC	tacgtactatcaacaggttgaactgctgatccacgttgtggtagaattggtaaagag
			agtcgtgtaaaatatcgagttcgcacatcttgttgtctgattattgatttttggcga
			aaccatttgatcatatgacaagatgtgtatctaccttaacttaatgattttgataaa
			aatcattaggtacCACTAGTGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTG
			ACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGACTAGT
			GTCCCCACCCACACATTCCTGTCCCCACCCACACATTCCTGTCCCCACCCACACATT
			CCTGTCCCCACCCACACATTCCTGTCCCCACCCACACATTCCTGTCCCCACCCACAC
			ATTCCTGtgcgctcccgacatgccccgcggcgcgccattaaccgccagatttgagtc
			gcgggacccgttggcagaggtgggctagcctcgaggatatcaagatctggcctcggc
			ggccaagcttgctagc
319	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	08	FOSL1-	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		coreBIR	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		C5-	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
		FLUC	ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTGGTGACTCATGGGTGACTCATGGGTGACT
			CATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCA
			TGGGTGACTCATGtgcgctcccgacatgccccgcggcgcgccattaaccgccagatt
			tgagtcgcgggacccgttggcagaggtggaccggtcgacgctagc
324	NP3	NP-	gacggccgctagcccgcctaatgagcgggcttttttttggcttgttgtccacaaccg
	34	FOSL1-	ttaaaccttaaaagctttaaaagccttatatattcttttttttcttataaaacttaa
		High-	aaccttagaggctatttaagttgctgatttatattaattttattgttcAAACATGAG
		FLUC	AGCTTAGTACGTGaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
			agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
			tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
			acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTGGTGACTCATGGGTGACTCATGGGTGACT
			CATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCA
			TGGGTGACTCATGcatGGGGGGGGGtgATGACACAGCAATtcGGGACTTTCCacGCT
			TGCGTGAGAAGagACCGGAAGTgaATGACACAGCAATtcGCTTGCGTGAGAAGctGG
			GACTTTCCtaGGGGCGGGGttGGGACTTTCCacATGACACAGCAATacaAcgcGtcc
			cgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggc
			agaggtgggaattcaccggtcgacgctagc
325	NP3	NP-	tttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgttagc
	32	FOSL1-	catgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagcttag
		Low-	tacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatccacg
		FLUC	ttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttgttg
			tctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatctacc
			ttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgtgcc
			cttgggctccccgggcgcgaCTAGTGGTGACTCATGGGTGACTCATGGGTGACTCAT
			GGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGG
			GTGACTCATGcatACCGGAAGTacTTGCGCAAtgACCGGAAGTacaAcgcGtcccga
			catgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcaga
			ggtgggaattcaccggtcgacgctagc
326	NP3	NP-	taattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgt
	33	FOSL1-	tagccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagc
		Med-	ttagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatc
		FLUC	cacgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatctt
			gttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatc
			taccttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcg
			tgcccttgggctccccgggcgcgaCTAGTGGTGACTCATGGGTGACTCATGGGTGAC
			TCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTC
			ATGGGTGACTCATGcatTTGCGCAAcaGGGGGGGGGtgATGACACAGCAATtcGCTT
			GCGTGAGAAGagACCGGAAGTgaGGGACTTTCCacATGACACAGCAATacaAcgcGt
			cccgacatgccccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttg
			gcagaggtgggaattcaccggtcgacgctagc
328	NP3	NP-	gcccgcctaatgagcgggcttttttttggcttgttgtccacaaccgttaaaccttaa
	15	FOSL1-	aagctttaaaagccttatatattcttttttttcttataaaacttaaaaccttagagg
		TATA-	ctatttaagttgctgatttatattaattttattgttcaaacatgagagcttagtacg
		TSS-	tgaaacatgagagcttagtacgttagccatgagagcttagtacgttagccatgaggg
		FLUC	tttagttcgttaaacatgagagcttagtacgttaaacatgagagcttagtacgtact
			atcaacaggttgaactgctgatccacgttgtggtagaattggtaaagagagtcgtgt
			aaaatatcgagttcgcacatcttgttgtctgattattgatttttggcgaaaccattt
			gatcatatgacaagatgtgtatctaccttaacttaatgattttgataaaaatcatta
			ggtacCACTAGTGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGG
			GTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGGGTGACTCATGCGG
			TGCTAGCTATAAAAGGCCAGCAGCAGCCTGACCACATCTCATCCTCctcgaggatat
			caagatctggcctcggcggccaagcttgctagc
329	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	96	HIGH-	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		coreAGR	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		2-FLUC	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTGGGGGGGGGtgATGACACAGCAATtcGGG
			ACTTTCCacGCTTGCGTGAGAAGagACCGGAAGTgaATGACACAGCAATtcGCTTGC
			GTGAGAAGctGGGACTTTCCtaGGGGCGGGGttGGGACTTTCCacATGACACAGCAA
			TacagtacCACCTCTTAACAATACGTTTCACAAATAGTTAAAAACATGCATACTGAA
			AAGCATACTTTTGCAATGTTATTTTTAAAAACAAGGAACTCTTTAACCCAGGGAAGA
			TAATCACTTGGGGAAAGGAAGGTTCGTTTCTGAGTTAGCAACAAGTAAATGCAGCAC
			TAGTGGGTGGGATTGAGGTgTGCCCTGGTGCATAAATAGAGACTCAGCTGTGCTGGC
			ACACTCAGAAGCTTGGACCGCATCCTAGCCGCCGACTCACACAAGGCAGGTGGGTGA
			GGAAATCCAGGTAAGGCTCCTGACAGCAGCTTTAGAAGGGTACTTGCTGGAGTGAAT
			TCGGGCCTCTGATTAccggtcgacgctagc
330	NP3	NP-	GGGGCGGGGtgATGACACAGCAATtcGGGACTTTCCacGCTTGCGTGAGAAGagACC
	35	HIGH-	GGAAGTgaATGACACAGCAATtcGCTTGCGTGAGAAGctGGGACTTTCCtaGGGGCG
		coreBIR	GGGttGGGACTTTCCacATGACACAGCAATacaAcgcGtcccgacatgccccgcggc
		C5-	gcgccattaaccgccagatttgagtcgcgggacccgttggcagaggtgggaattcac
		FLUC	cggtcgacgctagc
331	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	93	HIGH-	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		coreCEA	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		CAM-	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
		FLUC	ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTGGGGGGGGGtgATGACACAGCAATtcGGG
			ACTTTCCacGCTTGCGTGAGAAGagACCGGAAGTgaATGACACAGCAATtcGCTTGC
			GTGAGAAGctGGGACTTTCCtaGGGGCGGGGttGGGACTTTCCacATGACACAGCAA
			TacacTAGTAACATTTCTCTGGCCTAACTGGCCGGTACCATGACCCACGTGATGCTG
			AGAAGTACTCCTGCCCTAGGAAGAGACTCAGGGCAGAGGGAGGAAGGACAGCAGACC
			AGACAGTCACAGCAGCCTTGACAAAACGTTCCTGGAACtaccggtcgacgctagc
332	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	97	HIGH-	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		coreCST-	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		FLUC	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
			ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTGGGGGGGGGtgATGACACAGCAATtcGGG
			ACTTTCCacGCTTGCGTGAGAAGagACCGGAAGTgaATGACACAGCAATtcGCTTGC
			GTGAGAAGctGGGACTTTCCtaGGGGCGGGGttGGGACTTTCCacATGACACAGCAA
			TacactagtaacatttctctggcctaactggccggtaccAGTGGTGGGGGAGTGAAA
			AGAGAGATGGAGAAAGAGGGGATGGGCAGAAAGAGGAGGAGGAGTCAGGGGCAGGGC
			ATGGAGGTGGGTGGGGCTGGGCTGCCAAAGCAGGATAAATGCACACCTGCCTGCTGG
			TCTGGGCTCCCTGCCTCGGGCTCTCACCCTCCTCTCCTGCAGCTCCAGCTTTGTGCT
			CTaccggtcgacgctagc
333	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	94	HIGH-	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		coreFA	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		M111B-	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
		FLUC	ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTGGGGGGGGGtgATGACACAGCAATtcGGG
			ACTTTCCacGCTTGCGTGAGAAGagACCGGAAGTgaATGACACAGCAATtcGCTTGC
			GTGAGAAGctGGGACTTTCCtaGGGGGGGGGttGGGACTTTCCacATGACACAGCAA
			TacacTAGTAACATTTCTCTGGCCTAACTGGCCGGTACCGGGAAAAGTTCAGCTGAG
			AGATATAAAAGAGCAGTCTTTCCAGCACCTGCAAATCCAGAGCGGCGGGCACTGACG
			GGCACTTGCACCGTGTGGACAGACTCTCCGGTTCTGTGAGTGGTTTTTCTTTTCCCG
			GGTCGGACCTGGAGTTCTTAGGGGGATGGCTGAaccggtcgacgctagc
334	NP4	NP-	AGgccgcaagCTGAAGcgtgtccctgtgccttctagttgccagccatctgttgtttg
	65	High-	cccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttccta
		coreFA	ataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgggggg
		M111B-	tggggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctgg
		FLUC-	ggatgcggtgggctctatggggtaccatgcataCTAGTGGGGCGGGGtgATGACACA
		3′OIPR	GCAATtcGGGACTTTCCacGCTTGCGTGAGAAGagACCGGAAGTgaATGACACAGCA
			ATtcGCTTGCGTGAGAAGctGGGACTTTCCtaGGGGGGGGttGGGACTTTCCacAT
			GACACAGCAATacacTAGTAACATTTCTCTGGCCTAACTGGCCGGTACCGGGAAAAG
			TTCAGCTGAGAGATATAAAAGAGCAGTCTTTCCAGCACCTGCAAATCCAGAGCGGCG
			GGCACTGACGGGCACTTGCACCGTGTGGACAGACTCTCCGGTTCTGTGAGTGGTTTT
			TCTTTTCCCGGGTCGGACCTGGAGTTCTTAGGGGGATGGCTGAagaattcaccggtc
			acc
335	NP3	NP-	aattttattgttcaaacatgagagcttagtacgtgaaacatgagagcttagtacgtt
	95	HIGH-	agccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagct
		coreKIF2	tagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatcc
		0A-	acgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatcttg
		FLUC	ttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatct
			accttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcgt
			gcccttgggctccccgggcgcgaCTAGTGGGGGGGGGtgATGACACAGCAATtcGGG
			ACTTTCCacGCTTGCGTGAGAAGagACCGGAAGTgaATGACACAGCAATtcGCTTGC
			GTGAGAAGctGGGACTTTCCtaGGGGCGGGGttGGGACTTTCCacATGACACAGCAA
			TacactagtaacatttctctggcctaactggccggtacCGGCCCGCCCCCTTTCCTT
			ACGCGGATTGGTAGCTGCAGGCTTCCCTATCTGATTGGCCGAACGAACGCAGCGCGT
			AATTTAAAATATTGTATCTGTAACAAAGCTGCACCTCGTGGGCGGAGTTGTGCTCTG
			CGGCTGCGAAAGTCCAGCTTCGGCGACTAGGTGTGAGTAAGCCAGTATCCCAGGAGG
			AGCAAGTGGCACGTCTTCGGGTGAGTGTGCGGCTGTGCTGGAGCCCGGGTTACCAGC
			TCTTAaccggtcgacgctagc
342	NP4	NP-	gagagcaactgcataaggctatgaagagatacgccctggttcctggaacaattgctt
	01	HOXA1_	ttacagatgcacatatcgaggtggacatcacttacgctgagtacttcgaaatgtccg
		v8-	ttcggttggcagaagctatgaaacgatatgggctgaatacaaatcacagaatcgtcg
		coreBIR	tatgcagtgaaaactctcttcaattctttatgccggtgttgggcgcgttatttatcg
		C5-	gagttgcagttgcgcccgcgaacgacatttataatgaacgtgaattgctcaacagta
		FLUC	tgggcatttcgcagcctaccgtggtgttcgtttccaaaaaggggttgcaaaaaattt
			tgaacgtgcaaaaaaagctcccaatcatccaaaaaattattatcatggattctaaaa
			cggattaccagggatttcagtcgatgtacacgttcgtcacatctcatctacctcccg
			gttttaatgaatacgattttgtgccagagtccttcgatagggacaagacaattgcac
			tgatcatgaactcctctggatctactggtctgcctaaaggtgtcgctctgcctcata
			gaactgcctgcgtgagattctcgcatgccagagatcctatttttggcaatcaaatca
			ttccggatactgcgattttaagtgttgttccattccatcacggttttggaatgttta
			ctacactcggatatttgatatgtggatttcgagtcgtcttaatgtatagatttgaag
			aagagctgtttctgaggagccttcaggattacaagattcaaagtgcgctgctggtgc
			caaccctattctccttcttcgccaaaagcactctgattgacaaatacgatttatcta
			atttacacgaaattgcttctggtggcgctcccctctctaaggaagtcggggaagcgg
			ttgccaagaggttccatctgccaggtatcaggcaaggatatgggctcactgagacta
			catcagctattctgattacacccgagggggatgataaaccgggcgcggtcggtaaag
			ttgttccattttttgaagcgaaggttgtggatctggataccgggaaaacgctgggcg
			ttaatcaaagaggcgaactgtgtgtgagaggtcctatgattatgtccggttatgtaa
			acaatccggaagcgaccaacgccttgattgacaaggatggatggctacattctggag
			acatagcttactgggacgaagacgaacacttcttcatcgttgaccgcctgaagtctc
			tgattaagtacaaaggctatcaggtggctcccgctgaattggaatccatcttgctcc
			aacaccccaacatcttcgacgcaggtgtcgcaggtcttcccgacgatgacgccggtg
			aacttcccgccgccgttgttgttttggagcacggaaagacgatgacggaaaaagaga
			tcgtggattacgtcgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttg
			tgtttgtggacgaagtaccgaaaggtcttaccggaaaactcgacgcaagaaaaatca
			gagagatcctcataaaggccaagaagggcggaaagatcgccgtgtaatgaatgcatg
			aattcctgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttc
			cttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgc
			atcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacag
			caagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctat
			ggcccgggacggccgctagcccgcctaatgagcgggcttttttttggcttgttgtcc
			acaaccgttaaaccttaaaagctttaaaagccttatatattcttttttttcttataa
			aacttaaaaccttagaggctatttaagttgctgatttatattaattttattgttcAA
			ACATGAGAGCTTAGTACGTGaaacatgagagcttagtacgtgaaacatgagagctta
			gtacgttagccatgagagcttagtacgttagccatgagggtttagttcgttaaacat
			gagagcttagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactg
			ctgatccacgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgca
			catcttgttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatg
			tgtatctaccttaacttaatgattttgataaaaatcattaggtacggccgcggtgcc
			agggcgtgcccttgggctccccgggcgcgaCTAGTAACATTTCTCTGGCCTAACTGG
			CCggtaccCGATGTAGCTGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCATTA
			TACGTCGCCTAAATCGAGATGCTGTACTGATCTATAAGGATCGGTAATGACGTAATG
			ACGTAATGACGTAATGACGTAATGACGTAATGAcggtacctgcgctcccgacatgcc
			ccgcggcgcgccattaaccgccagatttgagtcgcgggacccgttggcagaggtgga
			ccggtcgacgctagc
343	NP4	NP-	aactgcataaggctatgaagagatacgccctggttcctggaacaattgcttttacag
	02	HOXC10_	atgcacatatcgaggtggacatcacttacgctgagtacttcgaaatgtccgttcggt
		v24-	tggcagaagctatgaaacgatatgggctgaatacaaatcacagaatcgtcgtatgca
		coreBIR	gtgaaaactctcttcaattctttatgccggtgttgggcgcgttatttatcggagttg
		C5-	cagttgcgcccgcgaacgacatttataatgaacgtgaattgctcaacagtatgggca
		FLUC	tttcgcagcctaccgtggtgttcgtttccaaaaaggggttgcaaaaaattttgaacg
			tgcaaaaaaagctcccaatcatccaaaaaattattatcatggattctaaaacggatt
			accagggatttcagtcgatgtacacgttcgtcacatctcatctacctcccggtttta
			atgaatacgattttgtgccagagtccttcgatagggacaagacaattgcactgatca
			tgaactcctctggatctactggtctgcctaaaggtgtcgctctgcctcatagaactg
			cctgcgtgagattctcgcatgccagagatcctatttttggcaatcaaatcattccgg
			atactgcgattttaagtgttgttccattccatcacggttttggaatgtttactacac
			tcggatatttgatatgtggatttcgagtcgtcttaatgtatagatttgaagaagagc
			tgtttctgaggagccttcaggattacaagattcaaagtgcgctgctggtgccaaccc
			tattctccttcttcgccaaaagcactctgattgacaaatacgatttatctaatttac
			acgaaattgcttctggtggcgctcccctctctaaggaagtcggggaagcggttgcca
			agaggttccatctgccaggtatcaggcaaggatatgggctcactgagactacatcag
			ctattctgattacacccgagggggatgataaaccgggcgcggtcggtaaagttgttc
			cattttttgaagcgaaggttgtggatctggataccgggaaaacgctgggcgttaatc
			aaagaggcgaactgtgtgtgagaggtcctatgattatgtccggttatgtaaacaatc
			cggaagcgaccaacgccttgattgacaaggatggatggctacattctggagacatag
			cttactgggacgaagacgaacacttcttcatcgttgaccgcctgaagtctctgatta
			agtacaaaggctatcaggtggctcccgctgaattggaatccatcttgctccaacacc
			ccaacatcttcgacgcaggtgtcgcaggtcttcccgacgatgacgccggtgaacttc
			ccgccgccgttgttgttttggagcacggaaagacgatgacggaaaaagagatcgtgg
			attacgtcgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttgtgtttg
			tggacgaagtaccgaaaggtcttaccggaaaactcgacgcaagaaaaatcagagaga
			tcctcataaaggccaagaagggcggaaagatcgccgtgtaatgaatgcatgaattcc
			tgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgac
			cctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgca
			ttgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaaggg
			ggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatggcccg
			ggacggccgctagcccgcctaatgagcgggcttttttttggcttgttgtccacaacc
			gttaaaccttaaaagctttaaaagccttatatattcttttttttcttataaaactta
			aaaccttagaggctatttaagttgctgatttatattaattttattgttcaaacatga
			gagcttagtacgtgaaaCATGAGAGCTTAGTACGTTAGCcatgagagcttagtacgt
			tagccatgagagcttagtacgttagccatgagggtttagttcgttaaacatgagagc
			ttagtacgttaaacatgagagcttagtacgtactatcaacaggttgaactgctgatc
			cacgttgtggtagaattggtaaagagagtcgtgtaaaatatcgagttcgcacatctt
			gttgtctgattattgatttttggcgaaaccatttgatcatatgacaagatgtgtatc
			taccttaacttaatgattttgataaaaatcattaggtacggccgcggtgccagggcg
			tgcccttgggctccccgggcgcgaCTAGTAACATTTCTCTGGCCTAACTGGCCggta
			ccAGCTGAGCGACAGTATAGTGCACAGTGACTGCAGCAGTCATTATACGTCGCCTAA
			ATCGAGATGCTGTACTGATCTATAAGTCGTAAACTGTCGTAAACTGTCGTAAACTGT
			CGTAAACTGTCGTAAACTGTCGTAAACTggtacctgcgctcccgacatgccccgcgg
			cgcgccattaaccgccagatttgagtcgcgggacccgttggcagaggtggaccggtc
			gacgctagc